Health Canada schválila léčivý přípravek MYQORZO od společnosti Cytokinetics pro dospělé pacienty se symptomatickou obstrukční hypertrofickou kardiomyopatií funkční třídy NYHA II–III.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
“This company milestone marks the fifth regulatory approval for MYQORZO in less than a year and lays the foundation for its future availability for patients in Canada,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “Cytokinetics is committed to the global HCM community, and we look forward to expanding access to MYQORZO to patients living with oHCM.”
The authorization in Canada, follows the approval of MYQORZO in December 2025 by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical Products Administration (NMPA) for the treatment of adults with NYHA class II-III oHCM, to improve exercise capacity and symptoms. Earlier in 2026, the European Commission (EC) approved MYQORZO, and the Medicines and Healthcare products Regulatory Agency (MHRA) authorized its use across the United Kingdom.
“Many patients with obstructive HCM have spent years living with breathlessness, fatigue and functional limitations in their everyday lives, with limited options for non-invasive therapy,” said Rafik Tadros, M.D., PhD., Director of the Cardiovascular Genetics Centre at the Montreal Heart Institute. “With improvements in exercise capacity and symptoms observed in SEQUOIA-HCM and a well-tolerated profile, this approval is a major step forward, and I look forward to having it as an option for our patients in Canada.”
The approval by Health Canada is supported by positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New England Journal of Medicine, which demonstrated statistically significant and clinically meaningful benefits across symptoms, exercise capacity, hemodynamics, and biomarker endpoints.1
The results from SEQUOIA-HCM showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake (pVO2) measured by cardiopulmonary exercise testing (CPET) by 1.76 mL/kg/min compared to baseline in patients treated with MYQORZO versus 0.0 mL/kg/min in patients treated with placebo (least square mean (LSM) difference [95% CI] of 1.74 mL/kg/min [1.04 - 2.44]; p=0.000002).1 The treatment effect of MYQORZO was consistent across all prespecified subgroups, including age, sex, patient baseline characteristics, and in patients receiving or not receiving background beta-blocker therapy.
MYQORZO was well-tolerated, with no instances of worsening heart failure or treatment interruptions due to low LVEF. Treatment emergent serious adverse events occurred in 5.6% of patients on MYQORZO and 9.3% of patients on placebo. Core laboratory echocardiographic LVEF was observed to be <50% in 5 patients (3.5%) on MYQORZO compared to 1 patient (0.7%) on placebo. Hypertension (8% vs 2%) was the only adverse reaction occurring in >5% of patients and more commonly on MYQORZO than on placebo. MYQORZO-associated increases in blood pressure are consistent with relief of LVOT obstruction and improved cardiac output.
The Product Monograph for MYQORZO includes a Boxed WARNING for the risk of heart failure. MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF and Valsalva left ventricular outflow tract gradient (LVOT-G) are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is ≥40% and <50%. Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences worsening heart failure due to systolic dysfunction.
For more information about MYQORZO, see the full Product Monograph.
About MYQORZO® (aficamten)
MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China and European Union, United Kingdom and Canada for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. MYQORZO was engineered to achieve a predictable exposure response, rapid onset of action and reversibility.1
Aficamten was studied in ACACIA-HCM, a completed Phase 3 clinical trial of aficamten in patients with nHCM. Aficamten is also under clinical investigation in CEDAR-HCM in a pediatric population with oHCM. Safety and efficacy of aficamten have not been established in a pediatric patient population. In addition, aficamten is being studied in FOREST-HCM, an open-label extension clinical study.
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. In obstructive HCM, the thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller, stiffer and less able to relax and fill with blood. Ultimately, HCM limits the heart’s pumping function, leading to reduced exercise capacity and a variety of symptoms.
HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately one out of 350 individuals worldwide.2
Approximately half of patients with HCM have obstructive HCM (oHCM) and half have non-obstructive HCM (nHCM).3
People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.4 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.5 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.
References
Maron, MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424Tsenov et al. Healthcare access, symptom burden, and psychological impact in hypertrophic cardiomyopathy: a multinational patient-driven survey. Int J Cardiol Cardiovasc Risk Prev2025 Aug 4;27:200485. doi:10.1016/j.ijcrp.2025.200485.Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552.Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic. Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
PacBio a Verily Health uzavřely víceleté strategické partnerství, které propojí sekvenování HiFi s datovou a AI platformou Verily Pre pro biomedicínský výzkum.
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows | Source: PacBio
MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.
The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration.
“This collaboration reflects a shared focus on making high-quality genomic data more accessible and useful across research and development, while creating a foundation for continued innovation in health,” said Stephen Gillett, Chairman and CEO of Verily Health. “Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need.”
“PacBio HiFi sequencing offers our customers the most complete and highest quality data available, which is ideal for training AI models where the input determines the success of the output” said Mark Van Oene, President and CEO of PacBio. “Through this collaboration with Verily Health, we are building a path to turn richer biological data into AI-ready data at scale to ultimately help researchers get more from both their sequencing and their models.”
Verily Pre provides the foundation to build, deploy and scale intelligent applications across healthcare and life sciences. Under the collaboration, Verily Health will configure Pre Workbench to connect PacBio sequencing workflows, acting as the secure governed research environment for the aggregation, analysis, and curation of HiFi genomic datasets. The companies also plan to use the Verily Pre trusted agentic environment (TAE) to run model training and inference, enabling researchers to explore deeper, longitudinal genomic datasets and support their workflows. Over the course of the multi-year collaboration, PacBio and Verily Health plan to expand the integration to support increasingly large and complex long-read programs across research organizations, biopharma and population genomics. The companies envision a common infrastructure that can scale with increasingly large and complex long-read programs, supporting multimodal research and AI development across biopharma, clinical institutions, population genomics and other areas of precision health.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.comand follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About Verily Health Inc.
At the intersection of technology, data science, and healthcare, Verily Health transforms complex health data into trusted intelligence, enabling health solutions that are more personal, predictive, and precise.
Verily’s flagship Governed Health Intelligence platform, Verily Pre, enables healthcare organizations to responsibly govern, model, and securely activate their protected health data at scale, deploying intelligence with the scientific rigor, oversight, and auditability needed for healthcare.
For more information about Verily Health, please visit verily.com
Disclaimer:
The Verily Pre platform is not a medical device and has not been evaluated by the FDA. Customers developing Software as a Medical Device (SaMD) are solely responsible for regulatory compliance.
Forward looking statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and Verily Health; plans to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform to create AI-ready clinic-genomic datasets; making genomic data more accessible and usable to power future biomedical AI application and create a foundation for continued innovation in health; impact in finding new answers for neurology, oncology, rare disease, and other areas of critical unmet need; building a path to turn richer biological data into AI-ready data; Verily Health configuring Pre Workbench as secure governed research environment; the use of TAEs to run model training and inference; developing a common infrastructure capable of supporting increasingly large and complex long-read programs; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using , and collaborating with third parties to develop, new technologies; potential product performance, interoperability and quality issues; potential regulatory issues relating to the development and use AI technologies; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
AST SpaceMobile podpoří záměr společností Deutsche Telekom, Orange, Telefónica a Vodafone prozkoumat potenciální společnou nabídku na spektrum pro mobilní satelitní služby (MSS) v Evropě.
Collaboration among Europe’s four largest mobile network operators expected to accelerate network integration, expand coverage and improve connectivity for the citizens of Europe
Dedicated European-operated ground infrastructure and BlueBird satellite capabilities support service readiness across more than 500 million mobile subscribers
MIDLAND, Texas--(BUSINESS WIRE)--AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, welcomes the Letter of Intent signed by its mobile network operator partners Deutsche Telekom, Orange, Telefónica and Vodafone to explore a potential joint bid for Mobile Satellite Services (MSS) spectrum as AST SpaceMobile continues to advance service readiness across Europe.
The collaboration among Europe’s four largest mobile network operators is expected to accelerate network integration, improve the customer experience and extend coverage into areas without reliable mobile connectivity. The initiative supports a coordinated approach to spectrum access and service deployment, strengthening European digital data sovereignty while enabling operators to deliver space-based cellular broadband through their existing mobile services.
“Europe’s mobile network operators are taking an important step toward extending connectivity to every subscriber, wherever they live, work and travel,” said Wayne Thorsen, Chief Commercial Officer of AST SpaceMobile. “Our role is to support our partners with the satellite technology, spectrum capabilities and ground infrastructure needed to deliver cellular broadband directly to the phones people already use. Together, we are building a third layer of connectivity that expands coverage and strengthens the resilience of Europe’s mobile networks.”
AST SpaceMobile’s existing European joint venture, Satellite Connect Europe, AST SpaceMobile is providing a dedicated network of European-operated ground infrastructure that link its BlueBird satellites with mobile operators’ core networks. This infrastructure is designed to support coverage across Europe, a market with over 500 million mobile subscribers, while keeping data handling and service control within European jurisdiction. Operators retain their customer relationships as satellite connectivity extends the reach of their terrestrial networks.
AST SpaceMobile’s BlueBird satellites feature the largest communication satellites ever deployed in low Earth orbit and connect directly to standard, unmodified smartphones, backed by 3,900 patent and patent pending claims. The company has demonstrated peak download speeds of 98.9 Mbps, with next-generation satellites expected to deliver peak data rates approaching 200 Mbps. These capabilities are designed to support voice, video and broadband services for consumers, businesses, first responders and governments.
The Company’s satellite technology can tune across approximately 1,150 MHz of mobile network operator partners’ low- and mid-band spectrum globally. Together with AST SpaceMobile’s S-band priority rights, this flexibility enables the Company to combine participating operators’ spectrum with satellite spectrum to support expanded coverage and capacity in European markets, subject to applicable authorizations.
About AST SpaceMobile
AST SpaceMobile is building the first and only global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on our extensive IP and patent portfolio, and designed for both commercial and government applications. Our engineers and space scientists are on a mission to enable 4G and 5G space-based cellular broadband to every device, everywhere, for today’s nearly 6 billion mobile subscribers globally. For more information, follow AST SpaceMobile on YouTube, X (Formerly Twitter), LinkedIn and Facebook. Watch this video for an overview of the SpaceMobile mission.
Forward-Looking Statements
This communication contains “forward-looking statements” that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “would,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside AST SpaceMobile’s control and are difficult to predict.
Factors that could cause such differences include, but are not limited to: (i) expectations regarding AST SpaceMobile’s strategies and future financial performance, including AST’s future business plans or objectives, expected functionality of the SpaceMobile Service, anticipated timing of the launch of the Block 2 BlueBird satellites, anticipated demand and acceptance of mobile satellite services, prospective performance and commercial opportunities and competitors, the timing of obtaining regulatory approvals, ability to finance its research and development activities, commercial partnership acquisition and retention, products and services, pricing, marketing plans, operating expenses, market trends, revenues, liquidity, cash flows and uses of cash, capital expenditures, and AST SpaceMobile’s ability to invest in growth initiatives; (ii) the negotiation of definitive agreements with mobile network operators relating to the SpaceMobile Service that would supersede preliminary agreements and memoranda of understanding and the ability to enter into commercial agreements with other parties or government entities; (iii) the ability of AST SpaceMobile to grow and manage growth profitably and retain its key employees and AST SpaceMobile’s responses to actions of its competitors and its ability to effectively compete; (iv) changes in applicable laws or regulations; (v) the possibility that AST SpaceMobile may be adversely affected by other economic, business, and/or competitive factors; (vi) the outcome of any legal proceedings that may be instituted against AST SpaceMobile; and (vii) other risks and uncertainties indicated in the Company’s filings with the Securities and Exchange Commission (SEC), including those in the Risk Factors section of AST SpaceMobile’s Form 10-K filed with the SEC on March 2, 2026, its Form 10-Q for the fiscal quarter ended March 31, 2026 filed with the SEC on May 11, 2026 and the future reports that it may file from time to time with the SEC.
AST SpaceMobile cautions that the foregoing list of factors is not exclusive. AST SpaceMobile cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors in AST SpaceMobile’s Form 10-K filed with the SEC on March 2, 2026, its Form 10-Q for the fiscal quarter ended March 31, 2026 filed with the SEC on May 11, 2026 and the future reports that it may file from time to time with the SEC. AST SpaceMobile’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, AST SpaceMobile disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Cleveland-Cliffs ve čtvrtletí končícím v září 2026 vykázal upravený zisk na akcii ve výši 0,28 USD a tržby ve výši 5,61 mld. USD, čímž překonal odhady analytiků.
Cleveland-Cliffs (CLF - Free Report) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to a loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +16.67%. A quarter ago, it was expected that this mining company would post a loss of $0.21 per share when it actually produced a loss of $0.2, delivering a surprise of +4.76%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Cleveland-Cliffs, which belongs to the Zacks Steel - Producers industry, posted revenues of $5.61 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 0.56%. This compares to year-ago revenues of $4.73 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Cleveland-Cliffs shares have lost about 8.7% since the beginning of the year versus the S&P 500's gain of 11.9%.
What's Next for Cleveland-Cliffs?While Cleveland-Cliffs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Cleveland-Cliffs was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.37 on $5.47 billion in revenues for the coming quarter and $0.10 on $21.13 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Steel - Producers is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, SSAB (SSAAY - Free Report) , has yet to report results for the quarter ended September 2026.
This company is expected to post quarterly earnings of $0.09 per share in its upcoming report, which represents a year-over-year change of +12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
SSAB's revenues are expected to be $2.91 billion, up 20.6% from the year-ago quarter.
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment
Two Oral Presentations to Showcase Deep, Durable Responses with TIL Cell Therapy in Frontline Melanoma and Previously Treated Soft Tissue Sarcomas
PHILADELPHIA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, will present five abstracts from its TIL platform at the European Society for Medical Oncology (ESMO) Congress 2026, including two oral presentations of new clinical data in previously untreated advanced melanoma and, for the first time, in two soft tissue sarcomas. The congress takes place October 23–27, 2026, in Madrid, Spain.
The oral presentation of results with lifileucel in two previously treated soft tissue sarcomas, undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), are from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance. Soft tissue sarcomas are rare and highly heterogeneous cancers comprising approximately 80 tumor subtypes, with an estimated incidence of 4–5 cases per 100,000 people annually in Europe and ~3.5 new diagnoses per 100,000 people in the United States each year.1, 2 For patients with advanced UPS and DDLPS who progress following standard therapies, treatment options remain limited and prognosis is often poor, highlighting the need for new approaches that can deliver meaningful and durable responses.
“This is our first congress presentation of TIL cell therapy in two soft tissue sarcomas with significant unmet need,” said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Iovance. “The efficacy and durability observed in this early cohort are what moved us quickly toward our ongoing SARATOGA registrational trial of lifileucel in UPS and DDLPS. This is the broadest look yet at how Iovance’s growing TIL platform performs across solid tumors.”
A second oral presentation, as a proffered paper, highlights the final Phase 2 results for lifileucel in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-naive advanced melanoma. Additional posters will highlight emerging translational and real-world evidence, including an indirect comparison suggesting that lifileucel may approximately double four-year overall survival rates compared with standard-of-care therapies in anti-PD-1-resistant advanced melanoma. Together, these data continue to expand the evidence base for Iovance’s TIL platform.
“Our Phase 2 results in frontline, advanced melanoma show deep, durable responses with a single treatment of lifileucel added to pembrolizumab,” Berkowitz continued. “These data reinforce the scientific rationale behind TILVANCE-301, our Phase 3 trial evaluating lifileucel earlier in the treatment of advanced melanoma, highlighting the opportunity this approach may offer patients who don’t achieve lasting benefit from today’s frontline treatments.”
Oral Presentations
Proffered Paper (Abstract #2072O): Efficacy and Safety of Lifileucel and Pembrolizumab in Patients with Immune Checkpoint Inhibitor-Naïve Advanced Melanoma: Final Results from IOV-COM-202 Study
Authors: Andrew J.S. Furness, et al.
Session: Friday, October 23, 2026, 16:15–17:45 CEST Rapid Oral (Abstract #3725RO): Lifileucel in Patients with Undifferentiated Pleomorphic Sarcoma (UPS) or Dedifferentiated Liposarcoma (DDLS)
Authors: Lauren Banks, et al.
Session: Monday, October 26, 2026, 08:30–10:00 CEST Poster Presentations
Poster (Abstract #4359P): Enrichment of Putative Tumor-Reactive Clones in NSCLC Patients Responding to Lifileucel: Temporal Single Cell Analysis from a Clinical Trial
Authors: Martin Wermke, et al.
Session: Friday, October 23, 2026, 15:15–16:00 CEST Poster (Abstract #2117P): Indirect Comparison of Overall Survival (OS) between Lifileucel versus Standard-of-Care (SoC) in US Real-World Settings in Anti-PD-1 Resistant Advanced Melanoma
Authors: Barbara Ma, et al.
Session: Saturday, October 24, 2026, 12:00–12:45 CEST Poster (Abstract #2125P): Lifileucel versus Nivolumab plus Relatlimab (NIVO+RELA) in Anti–PD-(L)1-Resistant Advanced Melanoma: A Match-Adjusted Indirect Comparison (MAIC) of Efficacy Outcomes
Authors: Gino K. In, et al.
Session: Saturday, October 24, 2026, 12:00–12:45 CEST The ESMO Congress 2026 scientific program and abstracts are available at https://www.esmo.org/meeting-calendar/esmo-congress-2026. Presentations will be available following the conclusion of each session on www.iovance.com and the ESMO Congress virtual platform.
About SARATOGA
SARATOGA (NCT07741877) is a registrational Phase 2 clinical trial evaluating the safety and efficacy of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy. UPS and DDLPS are high-grade, aggressive soft tissue sarcomas associated with poor prognosis and limited treatment options for patients who progress on chemotherapy.
About TILVANCE
TILVANCE-301 (NCT05727904) is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.
About the ESMO Congress
The ESMO Congress is organized by the European Society for Medical Oncology (ESMO) and is one of the world’s most influential annual oncology meetings, bringing together more than 37,000 clinicians, researchers, patient advocates, and industry representatives from around the world. The ESMO Congress 2026 takes place October 23–27, 2026, at IFEMA Madrid, Spain, and features presentations of practice-changing clinical data, translational science, and educational programming across all major tumor types. For more information, visit www.esmo.org.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
References
1. Gronchi A, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006.
2. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2026 Estimates. Cancer Stat Facts: Soft Tissue including Heart Cancer https://seer.cancer.gov/statfacts/html/soft.html . Accessed October 13, 2026.
Společnost Altimmune představí 48týdenní data ze studie fáze 2b: pemvidutide u pacientů s MASH oproti placebu snížil markery fibrózy, ztukovatění jater a ALT.
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability
Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide
GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that new clinical and preclinical data on pemvidutide will be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.
Data being presented will include results from 48-week IMPACT Phase 2b analyses in metabolic dysfunction-associated steatohepatitis (MASH) which showed that treatment with pemvidutide achieved concurrent reductions in two non-invasive markers of fibrosis, liver stiffness and ELF score, as well as liver fat and alanine aminotransferase (ALT) compared to placebo. These concordant changes across multiple non-invasive tests provide a more robust picture of treatment response than an individual measure. Separate IMPACT data showed that gastrointestinal adverse events were mild to moderate, with no severe gastrointestinal treatment-emergent adverse events reported. Treatment discontinuations due to adverse events were lower with pemvidutide than placebo, with a greater proportion of pemvidutide-treated patients completing study treatment despite no dose titration.
New preclinical data also showed a significant reduction in mean alcohol intake with pemvidutide in a hamster model, supporting further clinical investigation of pemvidutide in alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).
Altimmune will also have an Exhibit Booth at the meeting.
Details of the presentations are as follows:
Oral Presentations:
Abstract Title: Pemvidutide Treatment Reduces Alcohol Intake in a Lean Golden Syrian Hamster Model Session: Industry Review ShowcaseDate/Time: Saturday, November 7, 2026, 8:15 a.m. MTPresenter: John J. Suschak Abstract Title: Pemvidutide Treatment Results in Concurrent Reductions in Multiple Non-Invasive Tests for Hepatic Inflammation and Fibrosis: 48-Week Responder Analyses of the IMPACT Phase 2b Trial in Metabolic Dysfunction-Associated Steatohepatitis Session: Clinical Trial Pipeline for MASH 2026Date/Time: Sunday, November 8, 2026, 11:45 a.m. – 12:00 p.m. MTPresenter: Dr. Naim Alkhouri Poster Presentation:
Abstract Title: Gastrointestinal Tolerability of Pemvidutide Without Dose Titration in Patients with Metabolic Dysfunction-Associated Steatohepatitis from the Phase 2b IMPACT Trial Session: MASLD/MASH TherapeuticsDate/Time: Saturday, November 7, 2026, 1 p.m. - 2 p.m. MTPresenter: Dr. Mazen Noureddin A copy of the oral presentations and posters will be accessible on the Events section of the Altimmune website following the meeting.
Exhibit Booth
Altimmune will showcase its pipeline in a newly designed display in the exhibit hall at the Colorado Convention Center, open November 6, 2026, from 5:00 to 6:30 p.m. MT and November 7-8, 2026, from 9:30 a.m. to 5:00 p.m. MT.
The Booth will feature information on pemvidutide, along with information on the Company's actively enrolling PERFORMA Phase 3 trial of pemvidutide in patients with MASH. Altimmune medical affairs staff will be on-site throughout the meeting to engage with conference attendees.
About Pemvidutide
Pemvidutide is an investigational novel peptide with balanced 1:1 glucagon/GLP-1 dual receptor agonist activity that effects reductions in liver fat, inflammation, and fibrosis, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss and are involved in pathways related to craving and reward.
The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced topline 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the PERFORMA Phase 3 trial, a global, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH was initiated. In July 2026, the Company announced positive topline results from the RECLAIM Phase 2 trial in AUD. In August 2026, the Company announced completion of enrollment of the RESTORE Phase 2 trial in ALD.
About the IMPACT Phase 2b Study
The randomized, placebo-controlled, double-blind IMPACT Phase 2b trial (NCT05989711) enrolled 212 participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 or F3, with and without diabetes. Study participants were randomized 1:2:2 to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg or placebo for 48 weeks. The primary efficacy endpoints, measured at 24 weeks, were MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH. Secondary endpoints included non-invasive tests of fibrosis and weight loss measured at 24 and 48 weeks.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations [email protected]
OneMedNet uzavřel dvanáctou partnerskou distribuční dohodu; globální poskytovatel farmaceutických dat bude deidentifikovaná klinická data společnosti z USA nabízet farmaceutickým zákazníkům po celém světě.
MINNEAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced its 12th channel partner agreement, under which a leading global provider of pharmaceutical intelligence and data solutions will distribute OneMedNet’s U.S.-sourced, de-identified clinical data to its established base of pharmaceutical customers worldwide. The agreement broadens OneMedNet’s reach into one of the fastest-growing segments of life sciences data. The global Real-World Data market is estimated at approximately US$2.7 billion in 2026 and is projected to reach US$7.1 billion by 2033, according to Coherent Market Insights1, as pharmaceutical companies increasingly rely on Real-World Data to support drug development, regulatory submissions, and commercial decisions.
OneMedNet is witnessing data partners increasingly select its Real-World Data for the qualities pharmaceutical customers value most: first-party data sourced directly from healthcare providers rather than intermediaries or secondary markets, de-identified at the source, and delivered at regulatory-grade quality. By pairing OneMedNet’s multimodal clinical data with their own analytics and intelligence offerings, partners can support their pharmaceutical customers across clinical development, regulatory submissions, market access, and medical AI.
This agreement marks OneMedNet’s 12th channel partnership, reflecting a deliberate strategy to extend the Company’s commercial reach through established distribution channels while maintaining direct control of data sourcing, curation, and de-identification.
“We believe our channel partners choose OneMedNet for the same reason end customers do: data that comes straight from the source,” said Aaron Green, President & CEO of OneMedNet. “First-party, direct-from-source data gives our partners confidence in the quality, provenance, and compliance of what they deliver to their customers. This partnership expands our reach in the pharmaceutical market.”
About OneMedNet Corporation
OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.
Learn more at www.onemednet.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the benefits and expected scope of the channel partner agreement, our distribution strategy, and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
BitMine drží 6 041 481 ETH, tedy 4,9 % celkové nabídky, a hodnota jejích kryptoměnových, hotovostních a obchodovatelných aktiv dosahuje 15,1 miliardy USD.
Bitmine owns 4.9% of the total ETH coin supply of 122.1 million
Bitmine is 99% of the way to the 'Alchemy of 5%' in just 15 months
Bitmine released Chairman's Message on October 7 titled "Crypto Bull Underway — This Cycle Likely the Largest"
Bitmine was added to the Russell 1000 Large-cap index on June 26, 2026
Bitmine's Series A Preferred Stock is trading on the NYSE under the symbol BMNP
Bitmine has 5,067,309 staked ETH, representing $12 billion at $2,365 per ETH. MAVAN (Made in America VAlidator Network) is a premier Ethereum staking destination for BMNR and institutional investors
Bitmine owns $74 million of Eightco (NASDAQ: ORBS), now one of the only publicly listed equities in the world to provide investors indirect exposure to OpenAI
Bitmine Crypto + Total Cash Holdings & Marketable Securities + "Moonshots" total $15.1 billion, including 6.04 million ETH tokens, total cash & marketable securities of $582 million, and other crypto holdings
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETH
, /PRNewswire/ -- (NYSE: BMNR) Bitmine Immersion Technologies, Inc. ("Bitmine" or the "Company"), a Bitcoin and Ethereum Network company with a focus on the accumulation of crypto for long term investment, today announced Bitmine crypto + total cash & marketable securities + "moonshots" holdings totaling $15.1 billion.
BITMINE: Achievements in first year of operations
Chairman's Message: Crypto Bull Underway
STAKING: BMNR now staking over 5 million ETH as of Oct 18, 2026
"The risk appetite of investors contracted in the past few weeks fueled by the worrying combination of AI funding and AI model safety; escalating US-Iran war activity; anxiousness in front of US midterm elections and generally rising bond yields around the world. This has triggered a selloff in AI stocks including semis and memory stocks, and has further led to selloffs in the Korean and Taiwan markets, both of which are dominated by semis and memory stocks," stated Thomas "Tom" Lee, Chairman of Bitmine.
"Crypto is widely held in the US, Korea and Taiwan. So naturally, when investors in those regions de-risk, this creates spillover pressures in crypto markets. In the past, whenever fundamentals remain resilient and strong, while price declines, these have historically been attractive risk/reward opportunities. And given crypto's positive exposure to both modernizing global financial system rails and to agentic-AI, we believe this will again prove to be the case," continued Lee.
As of October 18, 2026 at 3:00pm ET, the Company's crypto holdings are comprised of 6,041,481 ETH at $2,365 per ETH (per CoinbaseNASDAQ: COIN), 215 Bitcoin (BTC), $180 million stake in Beast Industries, $74 million stake in Eightco Holdings (NASDAQ: ORBS) ("moonshots") and total cash & marketable securities of $582 million. Bitmine's ETH holdings are 4.9% of the ETH supply (of 122.1 million ETH).
"We believe Bitmine is positioned to outperform the crypto bull market that we expect to be coming, as the company has strengthened its competitive position over the past year in the midst of a crypto winter (bear market)," continued Lee.
"Over the past week, we acquired 12,535 ETH. Bitmine's track record of consistent buying of crypto is unmatched by any public company in the world. Bitmine has bought ETH each and every week since the inception of the ETH Treasury Strategy on June 30, 2025," stated Lee.
On October 7, Bitmine released its latest Chairman's message titled "Crypto Bull Underway — This Cycle Likely the Largest." The presentation is available at the Bitmine website (presentation link).
Earlier in 2026, Bitmine launched MAVAN (the Made in America VAlidator Network), the institutional-grade staking platform. While MAVAN was originally developed to support Bitmine's own Ethereum treasury, MAVAN has expanded to serve institutional investors, custodians, and ecosystem partners seeking best-in-class staking infrastructure. A portion of Bitmine's ETH is already staked on the MAVAN platform.
As of October 18, 2026, Bitmine total staked ETH stands at 5,067,309 ($12 billion at $2,365 per ETH). "Bitmine has staked more ETH than other entities in the world. At scale (assuming Bitmine's ETH is fully staked by MAVAN and its staking partners), the projected ETH staking reward would be $369 million on an annualized basis (using 2.58% 7-day BMNR yield). This compares to annualized staking revenues at $309 million based upon 5.1 million staked ETH (84% of the 6.04 million ETH held by Bitmine)," continued Lee.
Bitmine's crypto holdings reign as the #1 Ethereum treasury and #2 global treasury, behind Strategy Inc., which reportedly owns 848,250 BTC valued at approximately $74 billion. Bitmine remains the largest ETH treasury in the world.
Bitmine management believes the GENIUS Act and the Securities and Exchange Commission's (SEC) Project Crypto are as transformational to financial services in 2026 as the U.S. action on August 15, 1971, which ended the Bretton Woods system and took the U.S. dollar off the gold standard 55 years ago. This 1971 event was the catalyst for the modernization of Wall Street, creating the iconic Wall Street titans and financial and payment rails of today.
The Chairman's message can be found here:
https://www.Bitminetech.io/chairmans-message
The Fiscal Full Year 2025 Earnings presentation and corporate presentation can be found here: https://Bitminetech.io/investor-relations/
To stay informed, please sign up at: https://Bitminetech.io/contact-us/
About Bitmine
Bitmine Immersion Technologies, Inc. (NYSE: BMNR), together with its subsidiaries ("Bitmine" or the "Company"), is a blockchain technology infrastructure company operating across institutional digital asset staking and validation services, bitcoin mining, and strategic digital asset management. As the world's leading Ethereum Treasury company, it implements an innovative digital asset strategy for institutional investors and public market participants. The Company provides institutional-grade staking and validation infrastructure—through which it earns staking rewards and validation income—alongside bitcoin mining activities. Bitmine holds digital assets strategically, generating yield on those holdings to support liquidity and capital formation. Since 2025, the Company has expanded its blockchain infrastructure capabilities, including developing and deploying MAVAN, its institutional staking and validation platform. The Company's activities further include investments in early-stage blockchain opportunities ("moonshot" investments) and ancillary mining, hosting, and consulting services.
For additional details, follow on X:
https://x.com/bitmnr
https://x.com/fundstrat
Cautionary Note on Forward Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include all statements that are not purely historical and can generally be identified by terms such as "expects," "projects," "intends," "plans," "believes," "anticipates," "estimates," "may," "will," "would," "could," "should," "view," "likely," "positioned," or similar expressions. This press release specifically contains forward-looking statements regarding: (i) the Company's goal of acquiring 5% of the total ETH supply (the "Alchemy of 5%" initiative); (ii) the Company's digital asset accumulation and treasury strategy, including statements regarding continued weekly ETH acquisitions and the Company's status as the largest ETH treasury in the world; (iii) the Company's staking operations, including projected annualized ETH staking rewards of approximately $369 million at scale, assuming the Company's ETH is fully staked by MAVAN and its staking partners, and currently projected annualized staking revenues of approximately $309 million; (iv) MAVAN's expansion to serve institutional investors, custodians, and ecosystem partners; (v) management's beliefs regarding crypto market conditions, including expectations of a coming crypto bull market and that the current cycle is likely the largest, that recent price declines represent attractive risk/reward opportunities, and that the Company is positioned to outperform the crypto bull market; (vi) management's beliefs regarding the impact of investor risk appetite, AI funding and AI model safety, geopolitical events, U.S. midterm elections, bond yields, and Korean and Taiwanese market conditions on crypto markets, and crypto's exposure to modernizing global financial system rails and agentic-AI; (vii) management's belief that the GENIUS Act and SEC Project Crypto are transformational to financial services; and (viii) statements regarding the value of the Company's crypto, cash, marketable securities, and "moonshot" holdings, including the indirect exposure to OpenAI provided by the Company's investment in Eightco Holdings.
These forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: the extreme volatility and unpredictability of digital asset prices, including ETH and Bitcoin; the Company's reliance on third-party pricing sources and reported market values, which may fluctuate materially; changes in market conditions affecting the trading price and volume of the Company's securities; the Company's ability to successfully execute its digital asset acquisition strategy and achieve its ETH accumulation targets, including the "Alchemy of 5%" goal; the Company's ability to finance its business operations and MAVAN expansion; operational, security, and technological risks associated with the Company's staking and validation operations, including network failures, slashing events, cybersecurity breaches, and protocol changes; the risk that actual staking yields, rewards, and revenues differ materially from projected amounts, including if the Company's ETH is not fully staked; competition in the digital asset treasury, staking, and mining industries; the Company's dependence on key personnel; regulatory developments affecting digital assets, blockchain technology, and staking activities, including the ultimate enactment, implementation, and interpretation of the GENIUS Act and other pending legislation; actions by the SEC, CFTC, and other regulatory bodies; risks related to the Company's "moonshot" investments, including in Eightco Holdings and Beast Industries; macroeconomic and geopolitical factors, including inflation, interest rates, bond yields, military conflicts, elections, and general economic conditions; volatility in AI-related and semiconductor equities and in foreign markets, including Korea and Taiwan; changes to the Ethereum protocol; the performance of third-party service providers, exchanges, custodians, and staking partners; and the other risk factors described in the Company's filings with the SEC.
The forward-looking statements contained in this press release are based on information available to management as of the date of this release and reflect management's current expectations, estimates, and beliefs concerning future events. Actual results may vary materially from those expressed or implied based on the factors described above and in the Risk Factors section of the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025 filed with the SEC on November 21, 2025, the Company's Quarterly Reports on Form 10-Q, and the Company's other filings with the SEC, as amended or updated from time to time. Copies of these filings are available at www.sec.gov and at https://Bitminetech.io/investor-relations/. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Bitmine expressly disclaims any obligation to update or revise any forward-looking statements except as required by applicable law.
Společnost Fiserv globálně spustila Commerce Hub, platformu pro jednotnou správu přeshraničních plateb a služeb; objem zpracovaných plateb dosahuje několika miliard a meziročně roste o více než 100 %.
Single integration gives businesses access to local payment methods, acquiring capabilities and commerce services with unified settlement, reconciliation and reporting across markets | Source: Fiserv, Inc.
MILWAUKEE, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, today announced the global availability of Commerce Hub, a platform that enables enterprise merchants to orchestrate and simplify commerce through a single connection to Fiserv's commerce capabilities.
Commerce Hub currently supports more than several billions in processing and growing more than 100% YOY across multiple industries, payment methods and business models, supporting enterprises ranging spanning global marketplaces and platforms, to traditional brick-and-mortar and advanced, specialized sectors including grocery, petroleum and restaurants. Built to help businesses simplify and scale commerce operations, Commerce Hub brings together payment optimization, orchestration, and value-added services in a single platform, enabling clients to improve performance, streamline operations, and deliver consistent commerce experiences across markets.
As businesses pursue growth across borders, they often face a mix of payment providers, fragmented integration, local payment methods, and evolving regulatory considerations that create operational complexities and costs. Commerce Hub simplifies global commerce by providing access to market-specific payment options, acquiring services and value-added capabilities through a single platform, helping businesses scale more efficiently while maintaining a consistent operating model across markets. Combining Fiserv’s global reach with deep local market expertise, Commerce Hub enables businesses to launch faster, optimize performance and gain greater visibility across their commerce operations globally.
Through Commerce Hub, merchants can access:
One global connection: A single integration for onboarding, APIs, reporting, and operational controls for Fiserv merchant services.Local commerce capabilities at a global scale: Access to local payment methods, acquiring, settlement options, and regional expertise that help businesses meet customer expectations in every market.Scalable infrastructure: Cloud-native technology designed to streamline integrations and accelerate the delivery of new commerce capabilities.Integrated value-added services: Payment optimization, fraud protection, cross-border capabilities, and support for emerging payment methods from a unified platform. “Growth shouldn't be constrained by payment complexity,” said Lia Cao, Chief Revenue Officer, Enterprise and Platforms, at Fiserv. “Commerce Hub simplifies cross-border expansion by bringing together global scale, local expertise and value-added services on a single platform. We're helping clients expand faster, operate more efficiently, and deliver great customer experiences wherever they do business.”
Extending Global Commerce Strategy with Commerce Hub
Dell Technologies is among the global enterprises leveraging Commerce Hub to support a more unified approach to commerce. Dell's experience using Commerce Hub to introduce PIX in Brazil reflects how businesses can adapt to local customer preferences while keeping operations consistent at scale.
For more information on how Commerce Hub supports our clients in advancing global expansion, visit https://www.fiserv.com/en/who-we-serve/enterprise/commerce-hub-for-payment-orchestration/commerce-hub-grow-beyond-borders.html.
About Fiserv
Fiserv, Inc. (NASDAQ: FISV), a Fortune 500 company, is a global leader uniting commerce and finance. The company powers sustained growth and innovation at scale for financial institutions and businesses worldwide across payments, account processing, digital banking, merchant acquiring, network services, e-commerce, and Clover®, the all-in-one business management platform. Fiserv is a member of the S&P 500® Index and one of FORTUNE® America’s Most Innovative Companies. Visit fiserv.com and follow on social media for more information and the latest company news.
Media Relations:
Melissa Moritz
Vice President, External Communications
Fiserv, Inc. [email protected]
Centrus Energy (LEU) koupila dodavatele centrifug Westerman Holdings za zhruba 116 milionů USD, aby posílila dodavatelský řetězec a rozšířila výrobu mimo jaderný sektor.
Secures a key centrifuge component supplier and best-in-class manufacturer with an existing and growing business
Diversifies revenue base by expanding Centrus' addressable market with significant adjacent, non-nuclear manufacturing work
Drives continued growth for both organizations through commercial and operational synergies and cost savings
, /PRNewswire/ -- Centrus Energy Corp. (NYSE: LEU) ("Centrus"), a trusted supplier of nuclear fuel and services, today announced that it has acquired Westerman Holdings, LLC ("Westerman"), one of Centrus' largest and most diversified suppliers, for approximately $116 million, funded through a combination of approximately $95 million cash on hand and $21 million of equity. The transaction is expected to be accretive to adjusted earnings per share in the first year following closing.
The acquisition represents a significant milestone for Centrus as it builds supply chain resilience while diversifying its revenue base. Westerman's expertise strengthens and de-risks Centrus' supply chain by securing and bringing in-house its critical manufacturing capabilities. The acquisition simultaneously broadens Centrus' manufacturing platform, customer base, and future revenue opportunities through commercial and operational synergies.
The addition of Westerman supports Centrus' previously announced multi-billion-dollar expansion of uranium enrichment capacity. Westerman is an existing manufacturer for centrifuge casings and other major centrifuge components for Centrus. With the acquisition, Centrus intends to secure this key supplier while expanding Westerman's capabilities. Westerman currently services a number of non-nuclear customers across a variety of industries including oil and gas as well as other high-growth industrial sectors, diversifying Centrus' revenue base beyond its core nuclear business. The acquisition is expected to result in lower project costs for Centrus and greater efficiencies with an integrated supply chain.
"Westerman is a highly regarded, best-in-class supplier and fabricator for Centrus, the broader nuclear industry, and a number of other sectors," said Amir Vexler, President and CEO of Centrus. "Bringing Westerman in-house demonstrates our commitment to securing our supply chain to support our build-out while adding to our capabilities and expanding our customer base. We are committed to growing and expanding Westerman alongside our enrichment business, and are confident that this transaction will unlock significant value for our shareholders."
"Westerman has spent more than a century building advanced, differentiated manufacturing capabilities," said Jacob Garrett, CEO of Westerman, who will now transition to President of Westerman and also become a Vice President of Centrus Energy. "Joining with Centrus will allow us to accelerate that trajectory. Together, we can expand our production, deepen our nuclear manufacturing portfolio, and create new opportunities for our employees, our customers, and our communities. We are excited for the future we will build together."
Centrus acquired all of Westerman's business lines and Westerman has become a subsidiary within Centrus. Westerman will continue to operate under the Westerman name, leveraging its brand identity and customer relationships.
Founded in 1909, Westerman is an established, high-quality industrial fabrication manufacturer with specialized capabilities serving the nuclear, oil and gas, and broader high-growth industrial markets. With approximately 400 employees and four world-class facilities in Ohio, Oklahoma, and Wyoming, Westerman provides a broad portfolio of products that span upstream and midstream oil and gas production equipment, engineered industrial systems, and nuclear‑grade products including UF6 cylinders.
Barclays served as financial advisor to Centrus and Wachtell, Lipton, Rosen & Katz served as legal counsel to Centrus for this transaction.
About Centrus
Centrus Energy is a trusted American supplier of nuclear fuel and services for the nuclear power industry, helping meet the growing need for clean, affordable, carbon-free energy. Since 1998, the Company has provided its utility customers with more than 1,850 reactor years of fuel, which is equivalent to more than 7 billion tons of coal. With world-class technical and engineering capabilities, Centrus is pioneering production of High-Assay, Low-Enriched Uranium and is leading the effort to restore America's uranium enrichment capabilities at scale so that we can meet our clean energy, energy security, and national security needs. Find out more at www.centrusenergy.com or follow us on LinkedIn and X.
About Westerman
Westerman is a large equipment fabricator, focused on continuous improvements in design, engineering, and manufacturing. Our broad portfolio of equipment supports production, dehydration, stabilization, filtration, and custody transfer metering, setting new standards for performance and economics nationwide. We proudly serve other diverse end markets such as Nuclear, Marine, and Industrial.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "will", "should", "could", "would" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions with respect to future events and operational, economic and financial performance.
For Centrus Energy Corp., particular factors that involve uncertainty and could cause our actual future results to differ materially from those expressed in our forward-looking statements and which are, and may be, exacerbated by any worsening of the global business and economic environment include but are not limited to the following: the war in Ukraine and other geopolitical conflicts; our government contracts, including related to changes to the U.S. government's appropriated funding levels for HALEU and the government's inability to satisfy its obligations, and our lease to our facility in Piketon, Ohio; whether or when government demand for HALEU or LEU for government or commercial uses will materialize and at what level; the impact and potential extended duration of a supply/demand imbalance in the market for LEU; significant competition from major LEU producers, including foreign competitors, who may be less cost sensitive than we are; limitations on our ability to compete in foreign markets; pricing trends and demand in the uranium and enrichment markets, especially in light of the potential of limited supply and our dependence on others for deliveries of LEU; and our ability to successfully implement our planned expansion projects in Piketon, Ohio and Oak Ridge, Tennessee.
Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. Readers are urged to carefully review and consider the various disclosures made in this news release and in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, under Part II, Item 1A – "Risk Factors" in our Quarterly report on Form 10-Q for the quarter ended March 31, 2026, under Part II, Item 1A – "Risk Factors" in our Quarterly report on Form 10-Q for the quarter ended June 30, 2026, and our filings with the SEC that attempt to advise interested parties of the risks and factors that may affect our business. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
FDA přijala žádost společnosti UroGen o schválení přípravku UGN-103 k léčbě dospělých s recidivujícím nízce rizikovým až středně rizikovým neinvazivním karcinomem močového měchýře nízkého stupně malignity; rozhodnutí se očekává 14. června 2027.
PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-103 (mitomycin) for intravesical solution for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027.
“FDA acceptance of the UGN-103 NDA advances our vision for the next evolution of our portfolio and our continued commitment to transforming the treatment of recurrent LG-IR-NMIBC,” said Liz Barrett, President and CEO, UroGen. “Building on our experience with ZUSDURI (mitomycin) for intravesical solution, UGN-103 combines our proprietary RTGel® technology with a novel mitomycin formulation, which leverages a streamlined manufacturing process and simplified reconstitution. We look forward to working closely with the FDA during its review and remain focused on delivering innovative treatment options for people living with this highly recurrent disease.”
The NDA for UGN-103 is supported by the clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC. Treatment with UGN-103 resulted in a 77.8% complete response (CR) rate at three months, and among patients who achieved a CR at three months, the Kaplan-Meier estimated probability of remaining event-free at six months was 94.5%. The three-month CR rate, the six-month duration of response (DOR), and the safety results observed in UTOPIA were consistent with those observed in the pivotal ENVISION trial of ZUSDURI. We are pleased to advance UGN-103 into FDA review as we continue to evaluate its potential role in the treatment of adults with recurrent LG-IR-NMIBC.
About UGN-103
In January 2024, UroGen entered into a licensing and supply agreement with medac to develop UGN-103 for recurrent LG-IR-NMIBC. UGN-103 is designed to reinforce and build on the clinical and commercial foundation of ZUSDURI, the first and only FDA-approved treatment for adults with recurrent LG-IR-NMIBC. The program maintains UroGen’s innovative and proven RTGel technology, enabling sustained mitomycin exposure in the bladder, while incorporating next-generation enhancements, including a more streamlined manufacturing process and simplified reconstitution to support improved ease of use in clinical practice. UroGen holds U.S. patents covering the combination of its proprietary RTGel technology with medac’s licensed lyophilized mitomycin formulation, as well as the use of UGN-103 in LG-IR-NMIBC, with intellectual property coverage expected to extend into July 2044.
About ZUSDURI
ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means.
About Non-Muscle Invasive Bladder Cancer (NMIBC)
LG-IR-NMIBC affects around 82,000 people in the United States every year and of those, an estimated 59,000 are people experiencing recurrence. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include transurethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about NMIBC at www.BladderCancerAnswers.com.
About UTOPIA
The UTOPIA trial is a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in 99 patients across global sites. Enrolled patients received 75 mg of UGN-103 via intravesical instillation in an outpatient setting once weekly for six weeks. The primary endpoint is CR rate at three months, with responders entering a follow-up phase of up to 12 months to assess DOR. For more information on the UTOPIA study, please visit https://clinicaltrials.gov/study/NCT06331299.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer and UroGen’s second product, ZUSDURI (mitomycin) for intravesical solution, is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
About medac
At medac group, we believe that health is humanity’s most valuable resource. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in over 90 countries. With more than 2,000 employees, we are committed to improving human health.
Our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.
We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, hematology, and oncology. Part of our mission is to provide safe, high-quality, and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.
For more information, please visit www.medac-group.com.
APPROVED USE FOR ZUSDURI
ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working.
IMPORTANT SAFETY INFORMATION
You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI.
Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you:
have kidney problemsare pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI.
Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose.
Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose.
are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose. How will I receive ZUSDURI?
You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider’s instructions.If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI:
ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours.To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, blood in your urine.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.
Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the implications of the FDA’s acceptance of the NDA for URN-103; the expected PDUFA target action date of June 14, 2027; the belief that UGN-103 represents the next evolution in UroGen’s portfolio and the potential benefits of UGN-103 as compared to ZUSDURI, including its streamlined manufacturing and simplified reconstitution process; the expected duration of intellectual property coverage for UGN-103 into July 2044; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “advance,” “can,” “continue,” “estimated,” “expect,” “may,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-103 has been accepted by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-103 on the timeframe expected, or at all; the PDUFA target action date of June 14, 2027 may be delayed due to various factors outside UroGen’s control; preliminary clinical results may not be indicative of results that may be observed in the future; potential safety and other complications related to UroGen’s products and product candidates; risks related to our and our licensors’ ability to protect respective patents and other intellectual property, including the fact that UroGen’s or its licensors’ pending patent applications may not be successful, and in such event, the duration of intellectual property protection would be more limited; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and UroGen’s products and product candidates may not perform as expected; the data from the UTOPIA trial may not be sufficient to support approval of UGN-103; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. These and other risks and uncertainties are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the U.S. Securities and Exchange Commission on August 5, 2026. In light of these risks and uncertainties, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.
Eos Energy očekává ve třetím čtvrtletí tržby ve výši 82–83 milionů USD, což představuje meziroční nárůst o 169–172 %, zatímco záporná hrubá marže se zlepšila na −55 až −53 %.
PITTSBURGH, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long-duration energy storage (LDES) systems sourced and manufactured in the United States, today announced preliminary financial results for the third quarter ended September 30, 2026.
Based on preliminary financial information, Eos currently expects:
Revenue of $82 to $83 million, representing approximately 19% to 21% sequential growth and approximately 169% to 172% year-over-year growth. Shipments increased approximately 23% quarter over quarter, supported by continued production scaling at the Company's second manufacturing line at its Thorn Hill facility. During the quarter, Line 2 contributed approximately 17% of total battery production and exited the quarter with first-pass yield aligned to Line 1 performance. The line continued to operate on a partial-shift schedule at Thorn Hill as the Company progressed the hiring, onboarding, and training of additional employees to support production growth and full-shift operations.
GAAP gross margin of (55)% to (53)%, representing an improvement of approximately 16 to 18 percentage points compared to the second quarter of 2026, driven by higher production volumes and lower conversion costs per unit. Eos achieved its eighth consecutive quarter of gross margin improvement. As the Company continues staffing and training employees to support additional shifts on Line 2 at Thorn Hill, Eos expects further margin expansion from higher production volumes, higher capacity utilization, consolidation into one footprint, and ongoing material cost-reduction initiatives.
Total cash, including restricted cash, was approximately $344 million as of September 30, 2026, compared to $364 million as of June 30, 2026. Quarter-end cash was supported by approximately $114 million of operating cash inflows driven primarily by customer deposits, project milestone receipts, and tax credit collections, as well as an additional $87 million advance under the DOE loan facility. Capital expenditures totaled approximately $35 million, primarily related to completion of Line 2 automation.
Backlog of approximately $765 million as of September 30, 2026, representing approximately 3.2 GWh, after revenue recognized during the quarter and new orders booked. During the quarter, six purchase orders were received from six different customers, including a previously announced $100 million order under an existing capacity reservation agreement, which did not contribute to quarter-over-quarter backlog growth. Commercial traction continued across the defense, commercial & industrial (C&I), and data center markets. During the quarter, Eos announced key projects supporting the Golden Dome initiative for mission-critical defense applications and, alongside MN8, a project with Google, highlighting the growing demand for long-duration energy storage systems in data center applications.
The Company currently expects full-year 2026 revenue in the lower half of its $300 million to $350 million range. The current forecast reflects the addition of the final shift to bring Thorn Hill to 24-hour operation during the fourth quarter. Eos enters the fourth quarter with strong revenue visibility supported by customer commitments and projects in backlog. Following the manufacturing consolidation and achievement of full-scale operations, Thorn Hill will serve as the Company's manufacturing facility and is expected to have approximately 4 GWh of annual nameplate production capacity across its two production lines.
“We delivered our highest revenue to date and improved gross margin by roughly 17 points as volume begins to ramp at Thorn Hill,” said Alessandro Lagi, Chief Financial Officer of Eos. “Consolidating into Thorn Hill is the right decision for the Company. It gives us one modern, higher throughput site, lowers our cost per unit, and puts us on a clear path to positive margins. We’re being disciplined about the transition in the fourth quarter and customer demand for American-made long-duration storage remains strong.”
Conference Call Details
The Company will report its full third quarter 2026 financial results before the U.S. market opens on November 5, 2026. A conference call to discuss its results will take place the same morning at 8:30 a.m. Eastern Time.
The live webcast of the earnings call will be available on the “Investor Relations” page of the Company’s website at Eos Investors or may be accessed using this link (Registration Link). To avoid delays, we encourage participants to join the conference call fifteen minutes ahead of the scheduled start time.
The conference call replay will be available via webcast through Eos’ investor relations website for twelve months following the live presentation. The webcast replay will be available from approximately 11:30 a.m. Eastern Time on November 5, 2026, and can be accessed by visiting Eos Investors.
About Eos Energy Enterprises
Eos is accelerating the shift to American energy independence with positively ingenious solutions that transform how the world stores power. The Company’s BESS features the innovative Znyth™ technology, a proven chemistry with readily available non-precious earth components, that is the pre-eminent safe, non-flammable, secure, stable, and scalable alternative to conventional technology. The Company’s BESS is ideal for utility-scale, microgrid, commercial, and industrial long-duration energy storage applications (i.e., 4 to 16+ hours) and provides customers with significant operational flexibility to cost effectively address current and future increased grid demand and complexity. For more information about Eos (NASDAQ: EOSE), visit eose.com.
Forward-Looking Statements and Important Information
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding preliminary revenue, gross margin, backlog, total cash, customer collections, manufacturing capacity, Battery Line 2 performance, expected manufacturing consolidation activities, anticipated throughput and efficiency improvements, expected revenue visibility, and the Company’s ability to achieve its operational, commercial, financial, and production-capacity objectives, including the extent to which any purchase orders, capacity reservations, backlog, or project pipeline may ultimately result in executed contracts, construction activities, or revenue. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and the information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected.
Factors which may cause actual results to differ materially from current expectations include, but are not limited to: risks related to the preliminary nature of the financial information included in this release, which is based on information currently available to management and subject to completion of quarter-end closing procedures, management review, Audit Committee review, any applicable independent auditor review procedures, and finalization of the Company’s financial statements and periodic report, including the risk that final results may differ materially from the preliminary results presented herein; risks related to manufacturing ramp-up and consolidation, including start-up costs, lower initial production volumes, production interruptions, cost absorption, equipment commissioning, battery line performance, throughput, yield, scrap, labor, materials, supply chain availability, operational efficiency, employee retention and transition, required approvals, and customer delivery schedules; risks related to the development, financing, construction, and commissioning of projects, including timelines and the ability of counterparties to perform; the timing, issuance, and size of future project-level purchase orders and the conversion of framework agreements, capacity reservations, backlog, and pipeline into revenue; risks related to FPUSA, including its ability to source, acquire, finance, and execute projects, and risks related to Eos’ intended equity interest in FPUSA and any related-party considerations; risks associated with the credit agreement with Cerberus, including risks of default, dilution of outstanding Common Stock, and contractual lockup of shares; our customers’ and project counterparties’ ability to secure project financing; changes adversely affecting the business in which we are engaged; our ability to generate cash, service indebtedness, and raise financing in the future; our ability to satisfy the conditions applicable to future advances under the Department of Energy Loan Facility and the timing and availability of future funding thereunder; the amount of final tax credits available pursuant to the Inflation Reduction Act; competition from existing or new competitors; risks related to legal proceedings or claims; risks associated with evolving energy policies in the United States and the potential costs of regulatory compliance; changes in applicable laws or regulations; our ability to maintain the listing of our shares of common stock on NASDAQ; our ability to grow our business and manage growth profitably and to retain management and key employees; risks related to adverse changes in general economic conditions, including inflationary pressures and increased interest rates; risk from supply chain disruptions and other impacts of geopolitical conflict; and other risks and uncertainties.
The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those more fully described in the Company’s most recent filings with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Further information on potential risks that could affect actual results will be included in the subsequent periodic and current reports and other filings that the Company makes with the Securities and Exchange Commission from time to time. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks and uncertainties may emerge that could have an impact on the forward-looking statements contained in this press release.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Key Metrics
Backlog. Our backlog represents the amount of revenue that we expect to realize from existing agreements with our customers for the sale of our battery energy storage systems and performance of services. The backlog is calculated by adding new orders in the current fiscal period to the backlog as of the end of the prior fiscal period and then subtracting the shipments in the current fiscal period. If the amount of an order is modified or cancelled, we adjust orders in the current period and our backlog accordingly, but do not retroactively adjust previously published backlogs. There is no comparable U.S. GAAP financial measure to backlog. We believe that the backlog is a useful indicator regarding the future revenue of our Company.
Like the head-turning Roadster it reintroduced last week with some snazzy new performance features, Tesla (TSLA -2.13%) shares come with a big price tag. The stock enters this week at $354.72.
Despite the triple-digit price of admission, now could be a good time to buy at least a single share. Even if your broker is open to selling you fractional shares, going with a round share is more than just a cleaner transaction. It provides you with full voting power and the ability to transfer to a brokerage account, which may not allow fractional purchases.
Image source: Getty Images.
It can fly There's a lot going for Tesla stock these days. A surge in gas prices is boosting the value proposition of electric vehicles, reversing the bearish narrative that began for U.S. drivers in the fall of last year after federal tax credits of up to $7,500 for new purchases or leases expired.
The high-end Roadster is just one of the many new offerings coming from the world's most valuable automaker by market cap. Tesla's Optimus humanoid robots, improvements in its autonomous driving platform, and a push into commercial vehicles leave analysts expecting annual revenue to nearly double in the next three years.
TSLA Tesla$354.72-$7.72 (-2.13%)
NASDAQ · As of 4:00 PM ET 10/16/26
Sticking the landing A lot can also go wrong. Profitability was cut in half in its previous quarter. Analysts see a much smaller decline on the bottom line when it reports third-quarter results later this week, but it still needs to turn that around.
The top line has recovered quickly from last year's fourth-quarter decline, bringing us to today's opportunity. The shares are down 21% this year. The fundamentals are holding up better. Even as we head into Wednesday afternoon's financial update, analysts are bracing for flat sales. This is actually a good thing, since last year's third quarter was when sales spiked as U.S. buyers scrambled to get their orders in before the federal tax credit expired.
Tesla is out of favor with investors this year. Volatility has always been part of this story, but historically, as with its new Roadster Rocket, it's just a matter of time before it lifts off the ground.
Rick Munarriz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy.
Akcie společnosti Tesla se obchodují za zhruba 203násobek očekávaného zisku v letošním roce a 13násobek tržeb; autor očekává, že jejich výkonnost by do roku 2030 mohla kopírovat výkonnost indexu S&P 500 nebo za ní zaostat.
Whether you're a bull or a bear on Tesla (TSLA -2.13%), it's probably one of the most interesting and hotly debated stocks on the market. The electric vehicle (EV) leader is fresh off the unveiling of its long-awaited Roadster -- with the added twist that the car has rocket thrusters that allow it to fly and hover for short periods of time.
The Roadster's debut has generated plenty of excitement and once again highlighted the company's impressive penchant for innovation. On the other hand, some big questions remain about Tesla stock's performance outlook in the coming years. With that in mind, how likely is it that the stock outperforms the S&P 500 through 2030?
Image source: Getty Images.
Tesla is an undeniable innovator
While CEO Elon Musk is undeniably a controversial figure, there's also no denying that he's been at the forefront of some of the most significant trends and technology breakthroughs over the last couple of decades. That's not an accident, even if the CEO may have a penchant for overpromising or exaggeration on project details and timelines. I think that Tesla deserves some level of valuation premium due to his visionary approach to leadership and commendable track record of execution given the difficulty inherent in many of the projects he and his teams have taken on.
Is Tesla's flying Roadster likely to be a meaningful sales and net income contributor anytime between now and 2030? Probably not. While Tesla has said that the vehicle is set for production in 2028, it wouldn't be surprising to see the company miss that release window.
Given early reservation details for the Roadster that suggest a massive sticker price and regulatory issues that could prevent the car from being street (and air) legal, the vehicle's prospects in the consumer market are probably pretty limited. If the vehicle does wind up being available for consumer purchase by the end of the decade, Tesla could take a sizable loss on each unit sold.
TSLA Tesla$354.72-$7.72 (-2.13%)
NASDAQ · As of 4:00 PM ET 10/16/26
While the Roadster's unveiling and potential commercial viability have inevitably attracted criticism and skepticism, the event foregrounded the characteristics that make Tesla so interesting and "cool" as a company.
With the Roadster's flying capabilities being enabled by Space Exploration Technologies' thruster technology and the vehicle at the unveiling featuring one of Tesla's Optimus humanoid robots in the driver's seat, the event highlighted the tech ecosystem that Musk's companies are building and pointed to growth opportunities that help explain why Tesla deserves a substantial valuation premium compared to other automakers. That doesn't necessarily mean that Tesla stock will beat the S&P 500 through 2030.
Tesla is richly valued, but there's a big SpaceX question
Trading at roughly 203 times this year's expected earnings and 13 times this year's expected sales, Tesla stock looks very expensive in the context of recent business performance. Despite encouraging momentum in vehicle deliveries, the company's gross margins have been under pressure -- and the core EV business is unlikely to be a strong earnings growth driver over the next few years.
Meanwhile, the rollout for the company's robotaxi business is proceeding at a much slower-than-expected pace and continues to face meaningful regulatory hurdles. Betting on Optimus to emerge as a major driver of sales and earnings over the next few years is risky, and Tesla could see massive capital expenditures and surging operating expenses connected to its Terafab semiconductor manufacturing plant. With that in mind, I think a rough outlook on spending, earnings, and highly growth-dependent valuation could set the stage for stock moves that roughly track or underperform the S&P 500 through 2030.
On the other hand, I think there's another factor that will play an even bigger role in shaping how an investment in Tesla fares through the end of that period. Given the synergies between Tesla and SpaceX, Musk's focus on building a comprehensive tech ecosystem, and potential compensation incentives for the CEO, I think it's more likely than not that the two companies will merge by the end of the decade.
Given that SpaceX is currently the larger of the two companies and the underlying financial profiles of each business, a potential merger would likely see Tesla being acquired by SpaceX in an all-stock deal. That would set up the valuation premium for Tesla, the market's reaction to stock dilution from SpaceX needed to facilitate the acquisition, and subsequent business performance of the combined entity as the key factors likely to shape how Tesla stock performs through 2030.
Coca-Cola vyplácí roční dividendu 2,12 USD na akcii; k dosažení ročního dividendového příjmu 1 000 USD je potřeba 472 akcií v hodnotě přibližně 43 424 USD.
It's common for equity income investors to say they want to generate a specific amount in yearly income from a specific dividend stock. Accruing the capital to hit that goal, particularly if it's of the four-figure or higher variety, right off the bat is another matter.
Take the case of Coca-Cola (KO +2.06%), one of the largest consumer staples companies by market cap. On Thursday, Oct. 15, the beloved soft drink stock hit an all-time high before settling at $92. The stock is up nearly 34% year to date, outperforming all "Magnificent Seven" stocks.
It's expensive to grab $1,000 a year in dividends from Coca-Cola stock, but it is worth it. Image source: Getty Images.
Still, it's not cheap to extract $1,000 in yearly income from this stock. My back-of-the-envelope math tells me that, based on Coke's annual dividend of $2.12 per share and an Oct. 15 closing price of $92, the 472 shares required to get to $1,000 in annual dividends from Coke will cost a cool $43,424. That's not small potatoes, but that capital outlay is worth it for investors who can afford it.
Don't trip on Treasury comparisons Coca-Cola is a Dividend King, or one of the companies with a dividend increase streak of at least 50 years. For the beverage giant, the streak of payout increases spans 65 consecutive years. However, the stock yields just 2.31%.
Sure, that's more than double the dividend yield on the S&P 500, but it's not a knock-your-socks-off yield. It arguably seems paltry at a time when 10- and 30-year Treasuries are yielding north of 5%. Conventional wisdom often dictates that when U.S. government bond yields are unusually high, that's bad news for dividend stocks because investors may be apt to ditch those stocks for the perceived lower-risk attributes of Treasuries.
As noted above, Coca-Cola stock is up nearly 34% this year, so it's defying that wisdom. Plus, the last 10 years of history confirm that shares of Coke have been an infinitely better bet than intermediate-term and long-dated Treasuries from a performance perspective.
KO Total Return Level data by YCharts
The point is that the real risks may well be leaving potentially significant amounts of capital appreciation on the table in the name of safety and high yields. An interesting, related footnote: While researching this article, I came across a 2019 piece about "Coca-Cola millionaires," or folks who bought small amounts of the stock during the Great Depression and went on to become millionaires decades later (or their heirs did). One of the author's points was to embrace dividend growth and not be tricked by yield.
Coke is stackin' dubs As in "W's" for "wins." Not only is Coke performing like a technology stock this year, but more importantly, it's scoring victories, including over rival PepsiCo. On Thursday, KFC announced it's moving to Coca-Cola beverages away from Pepsi.
That sign that the beverage wars rage on is noteworthy because KFC's parent, Yum! Brands was spun out of Pepsi in 1997, and since then, Yum's KFC, Pizza Hut, and Taco Bell have served Pepsi drinks. That news comes on the heels of Marriott International announcing in July that it will switch from Pepsi to Coke; Costco made the same announcement last year.
Those are wins that support the case for Coca-Cola stock, confirming that long-term investors, regardless of starting capital, ought to consider the shares.
Tržby Google Cloud ve 2. čtvrtletí fiskálního roku 2026 meziročně vzrostly o 82 % na 24,77 mld. USD, k čemuž přispěla vertikálně integrovaná strategie Alphabet v oblasti AI.
One investing strategy separates Alphabet from every other AI giant, and it shows up most clearly when you stack the balance sheets side by side against Microsoft and Amazon.
My Alphabet (NASDAQ:GOOGL | GOOGL Price Prediction) position has grown repeatedly this year, and every earnings report adds to my conviction. It comes down to one strategy. Vertical integration gives Alphabet ownership of the entire artificial intelligence (AI) stack. It makes the Gemini models, designs its own TPU chips, rents that compute through Google Cloud, and sells AI to billions of people through Search and YouTube. Every layer it owns is a layer it never pays someone else for. For a retirement portfolio I plan to hold for decades, that kind of control is what I want to own.
Three Numbers That Keep Pulling Me Back
First, cloud growth keeps speeding up. Google Cloud revenue reached $24.77B in Q2 FY2026, up 82% YoY. Two quarters earlier it grew 48%, and a year earlier it grew 34%. Backlog rose from $155 billion in Q3 2025 to over $460 billion by Q1 2026. That backlog is signed demand.
Second, AI is expanding Search. Revenue from Search and related lines rose 17% to $63.27B, while the Gemini App reached 950 million monthly active users and nearly 90% of Fortune 100 companies use Gemini Enterprise.
Third, profits are growing faster than sales. Operating income rose 30.4% to $40.77B on revenue growth of 24.2%, and Q2 marked the 12th straight quarter of double-digit revenue growth. Return on invested capital stands at 29.60%.
How Alphabet Stacks Up Against Microsoft and Amazon
The obvious alternative is Microsoft (NASDAQ:MSFT). Azure grew 43% in its latest quarter, trailing Google Cloud’s pace, and the stock trades at a P/E of 29 against Alphabet’s 15. Alphabet’s trailing multiple gets help from equity gains, so I also check its forward P/E of 23.
Amazon (NASDAQ:AMZN) gave AWS 37% growth, yet the stock has a P/E of 35, debt-to-equity of 0.37, and interest coverage of 35.2x. Alphabet’s debt-to-equity is 0.143, and its interest coverage is 175.5x.
Risk That Keeps Me Disciplined
Alphabet guided for $175B-$185B in 2026 CapEx, Q2 free cash flow came in at -$5.86B, borrowings rose from $46.5B to $98.2B, and buybacks were suspended in Q2 2026. A $49.6B equity raise dilutes me. Reported net income also includes a $99.03B unrealized equity securities gain, so I look past headline EPS.
Operating cash flow still grew 40.8% to $39.069 billion and net debt stands at just 0.19 times EBITDA. Alphabet is borrowing against a backlog it has already signed.
Why Alphabet Stays at the Core of My Portfolio
Alphabet raised its dividend 5% to $0.22 a quarter even while spending heavily, and the stock has returned 737.14% over ten years. Chief executive Sundar Pichai called its “differentiated, full stack approach to AI” the engine behind the results, and the numbers back him up. I stay invested because Alphabet owns more of the AI stack than any other company I follow.
Contact [email protected] for any questions or corrections.
Google plánuje v Minnesotě datové centrum s příkonem 780 MW a zaplatí rozšíření kapacity sítě společnosti Xcel o 1 400 MW větrné energie, 200 MW solární energie a 300 MW bateriových úložišť.
If there's one thing most Americans can agree on, it's that they don't want a data center in their backyard.
A Gallup survey conducted in March found that 71% of Americans opposed the construction of a data center in their local area. Chief among their concerns: energy usage. Half of Americans surveyed by Pew Research Center in July and August said data centers would be mostly bad for the environment and for household energy costs.
Now Google is betting that a massive AI data center can help finance a cleaner, more reliable power grid. Its proposed deal with Xcel Energy would add more wind, solar and battery capacity than the data center is expected to use.
Under the agreement, Google would help pay for the added capacity and continue paying, even if it doesn't use all of the power.
Google's bet that AI can finance a cleaner grid Pine Island, Minnesota, is a small town of about 4,000 residents an hour southeast of Minneapolis. Google hopes that its new 780-megawatt data center plan will build goodwill with the Pine Island community and keep the company on track to meet its goal of operating on carbon-free energy, 24 hours a day, seven days a week by 2030.
Google — whose cloud business powers its own Gemini AI and brought in nearly $25 billion in second-quarter revenue, an 82% increase from a year earlier — says it has found a model for doing this the right way. The company plans to finance the addition of 1,400 megawatts of wind, 200 megawatts of solar and 300 megawatts of battery storage to Xcel's grid.
Those additions amount to more than the capacity of the data center itself, which Google said is because wind and solar do not generate energy at all times. Xcel Energy said the new power will serve all customers in the local area, not just Google. Xcel also said the upgrades will help advance the local grid's carbon-free energy supply.
The proposed agreement between Google and Xcel includes minimum demand charges and exit fees, which Google says will keep the company on the hook for the infrastructure being built on its behalf, even if the AI boom cools. Google will pay for at least 75% of its contracted capacity, even if it uses less, and would owe up to eight years' worth of those minimum demand charges if it terminates the agreement early.
"Nobody wants to have a big buildout and then have nowhere for that power to go and nobody to pay for that power," said Amanda Rome, executive vice president and chief customer officer at Xcel Energy. "That's where these protections come in."
The agreement between Google and Xcel Energy is pending approval by the Minnesota Public Utilities Commission.
Data centers are driving a historic power buildout New data centers will account for "most" of the projected increase in electricity demand over the next decade, according to the North American Electric Reliability Corporation, a nonprofit regulator.
The Department of Energy under President Joe Biden reported that more than 70% of U.S. transmission lines and power transformers were at least 25 years old and found that the cheapest ways of meeting future demand would require the nation's transmission system to more than double in size by 2050.
But hyperscalers argue that they can finance badly needed grid upgrades while also making the grid cleaner and more reliable.
"The timing of this industrial revolution couldn't be more perfect," said Amanda Peterson Corio, Google's global head of energy and power. "It's right at the time when we needed capital to fix aging infrastructure in the United States."
Could data centers use the grid as is? Jigar Shah, a partner at Multiplier, a consulting firm that helps clean energy startups go public, said data center operators could be constructing smaller facilities in places where the grid already has unused capacity. That would minimize the need to build — and pay for — new generation or transmission equipment.
"If you fit the load growth that the data centers want into the existing grid, everybody's rates go down by a lot," said Shah.
That's because the existing grid has enormous fixed costs from the infrastructure already in place: power plants, transmission lines, substations. If one new customer comes onto the grid and pays a large slice of that, everyone else's bills go down.
"And so the question really is, why are people not doing these 25-megawatt data centers? Why are they doing 1,000-megawatt data centers? And it turns out people are just lazy," Shah said. "They're like, well, it's easier for me to contract one data center that's one gigawatt in size than figuring out how to do something on the order of 40 data centers that are 25 megawatts each."
Industry watchdogs also warn of another reason that utilities often prefer to build new infrastructure, rather than make more use out of their existing grid.
"When [utilities] build something new, they fund part of that investment with dollars from their investors on Wall Street, and they enjoy incredibly high, exorbitant returns on those investments, typically around 10%," said David Pomerantz, executive director at the Energy and Policy Institute, a utility watchdog agency.
Building a data center that fits neatly into an existing grid provides little opportunity for a utility to make new money.
What if a hyperscaler offers to pay for those grid investments?
"One way to leverage data centers to lower people's bills is for data centers to provide that capital at much cheaper rates than the utility," said Pomerantz. "But that's a big problem for the utility. And this fight is actually already emerging."
Still, Shah said, the Google/Xcel project in Minnesota is a good example of a data center project acting as a catalyst for newer, greener technology.
"Google came in and said, well, here's a new way of doing things, using new technologies. How about we do it that way? And then that helps ratepayers. And the utility was like, yeah, that makes a lot of sense."
Watch the video above for the full story, including an interview with Google's global head of energy and power.
— CNBC's Jeniece Pettitt and Lora Kolodny contributed to this report.
Microsoft nasadí čipy Maia ve vícekigawattovém měřítku od roku 2027; Maia 300 má nabídnout o 40 % více tokenů na megawatt než přední systémy s grafickými procesory.
Microsoft Corp. NASDAQ: MSFT wants to stop renting its AI future from NVIDIA Corp. NASDAQ: NVDA. Its new Maia 300 chip is a clear sign and a potential catalyst ahead of earnings.
Microsoft plans to deploy Maia chips at a multi-gigawatt scale starting in 2027. It expects Maia 300 to deliver 40% more tokens per megawatt than leading GPU-based systems.
Get Microsoft alerts:
Microsoft Today
$529.05 0.00 (0.00%)
As of 10/16/2026 04:00 PM Eastern
$349.20▼
$553.720.69%
29.46
$589.76
More importantly, Microsoft says Maia will become the primary inference hardware for Microsoft’s own products. That speaks to the question hanging over every AI stock: Is this a bubble?
The bear case is simple. Generative AI is becoming a commodity. Chatbots are interchangeable, and token prices keep falling. Agentic AI may follow the same path. If the product is a commodity, why spend hundreds of billions on data centers?
Falling token prices don't necessarily mean weaker demand. Cheaper tokens can encourage more AI use, especially as agents take on increasingly complex tasks. Commodity markets don’t punish everyone equally, though. They reward the low-cost producer. Maia 300 is Microsoft’s attempt to become that producer.
Investors will get a fresh read on the strategy soon. Microsoft is estimated to report first-quarter fiscal year 2027 (FY2027) results after the close on Wednesday, Oct. 28.
Maia 300 Targets the Real Constraint: PowerElectricity availability is becoming a major constraint on data center growth, even as demand increases. That makes tokens per megawatt an important measure of efficiency.
Maia 300's compute chiplets are built on Taiwan Semiconductor Manufacturing Company’s NYSE: TSM N2P process, and the chip includes eight stacks of HBM4 memory. A full rack holds 96 chips. Microsoft says that a full rack delivers up to seven times the token throughput of a Maia 200 rack.
The chip targets long-context reasoning and multi-step agentic tasks. In other words, it was built for the workloads driving demand today.
Greater efficiency could allow Microsoft to process more AI workloads without a proportional increase in power consumption, potentially improving margins as usage grows.
The scale is meaningful, too. Reuters, citing The Information, reported that Microsoft ultimately aimed to secure manufacturing capacity for more than one million Maia 300 chips, although the company has not confirmed production targets. Microsoft plans to discuss its broader AI strategy at its Ignite conference in November.
Beyond Maia: Physical AI Is a Future CatalystPhysical AI, especially humanoid robots, is a later catalyst. Counterpoint expects global humanoid shipments to top 50,000 units in 2026. That’s small next to agentic demand. But as adoption grows, robotics could create another source of demand for cloud-based AI services.
Microsoft won’t build robots. Instead, it’s positioning itself as the platform that trains, hosts and manages them. In January, Microsoft Research unveiled Rho-alpha, a robotics model that translates natural-language commands into robotic movements and incorporates tactile sensing. Microsoft plans to offer it through its Foundry platform.
The company also partnered with Hexagon Robotics in January to develop industrial humanoid applications, targeting automotive, aerospace, manufacturing, and logistics customers. Azure supports the cloud infrastructure behind that effort.
Here’s the link to Maia. Robot training and simulation already use cloud computing, while some inference happens on the robot itself. However, Microsoft is also exploring ways to shift inference workloads to edge and cloud infrastructure. If that approach gains traction, Maia's efficiency improvements could eventually help Microsoft serve those workloads at a lower cost.
Microsoft has not announced plans to use Maia for robotics, so the connection remains a possibility rather than an established use case. None of this will show up in the upcoming results. It’s optionality. But it gives Microsoft a potential second demand curve after AI agents.
Microsoft Stock Nears Highs as Analysts See More UpsideMicrosoft’s chart shows MSFT in recovery mode. Shares rebounded from a midyear low and moved higher following the company's fiscal fourth-quarter earnings beat. After a strong rally in recent months, MSFT is trading near its 52-week high.
Momentum is constructive but not stretched. The Relative Strength Index (RSI) remains below overbought territory, while the MACD line remains above its signal line. Volume on the recent climb is lighter than during the August breakout. That’s worth watching into earnings.
Analysts remain supportive. MarketBeat-tracked analysts give MSFT a Moderate Buy consensus rating and an average price target of approximately $590, suggesting additional upside from recent levels.
What Investors Should Watch in Microsoft's Upcoming EarningsAnalysts expect earnings per share (EPS) of about $4.72 on revenue of $90.6 billion. Last quarter, Microsoft posted adjusted EPS of $4.74, beating the $4.24 estimate.
Azure growth will get most of the attention. Listen closely to the capital expenditure commentary, too. While Maia 300 won't begin deployment until 2027, it could eventually help Microsoft manage the costs of its expanding AI infrastructure. For now, investors will be looking for signs that Azure growth and profitability can justify the company's substantial spending.
Should You Invest $1,000 in Microsoft Right Now?Before you consider Microsoft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microsoft wasn't on the list.
While Microsoft currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Šéf společnosti Nvidia Jensen Huang uvedl, že laboratoře jako OpenAI a Anthropic představují jen 25–33 % poptávky po jejích čipech, takže růst AI nestojí pouze na nich.
Artificial intelligence (AI) stocks have taken a tremendous hit in October, as a toxic combination of higher interest rates and skepticism over the returns on AI spending has led to a steep sell-off.
Higher interest rates make it more costly to build AI data centers, all else being equal. Meanwhile, while leading AI labs Anthropic and OpenAI are still private, recent media leaks about their third-quarter revenue figures have suggested a potential slowdown.
If these two labs' revenues don't grow as much as some people anticipate, investors may cast doubt on the entire AI build-out, since Anthropic and OpenAI wouldn't be able to fund their commitments.
Are the fears real, or overblown? This week, Nvidia (NVDA -1.43%) CEO Jensen Huang weighed in on this very issue on a popular tech podcast.
NVDA Nvidia$214.13-$3.10 (-1.43%)
NASDAQ · As of 4:00 PM ET 10/16/26
The controversy
On Oct. 8, The Financial Times reported that in an investor presentation, OpenAI revealed it had reached $50 billion in annualized recurring revenue (ARR). That is well short of the $70 billion revenue figure leaked in September. While the difference was later addressed as a discrepancy in accounting methods, the headline still caused anxiety.
Then last week, Anthropic held its own investor presentations, revealing that it had made roughly $16.8 billion in revenue in Q3. Considering Anthropic generated only $4.6 billion in revenue in all of 2025, that's a remarkable achievement. Yet investors may still have been disappointed. In August, it was leaked that Anthropic was already at a $65 billion ARR at the end of July. So, the $67.2 billion Q3 annualized revenue figure would indicate a pretty sharp slowdown from July through September.
The back-to-back "leaks," along with rising inflation, were enough to send AI-related stocks, especially in the semiconductor sector, into a tailspin. After all, if Anthropic and OpenAI are slowing down, or not making as much as they thought, who is going to buy all of these chips and build all these expensive data centers?
Image source: Getty Images.
Jensen: AI is bigger than Anthropic and OpenAI
Last Thursday, Nvidia (NVDA -1.43%) CEO Jensen Huang appeared on a podcast with venture capitalist Brad Gerstner. In that interview, Gerstner put the big question to Huang: Would Anthropic and OpenAI generate enough revenue to continue growing the AI build-out?
Huang remained confident for the following reasons.
1. There's more than just two frontier labs
The first point Huang made was that Anthropic and OpenAI aren't the only two frontier labs. During the interview, Huang pointed not only to OpenAI and Anthropic but also Grok, the chatbot and agent from xAI, which is owned by Space Exploration Technologies (SPCX -1.74%), Meta Platforms' (META -3.72%) new Muse agent, and Alphabet's (GOOG -2.32%) (GOOGL -2.47%) Gemini, as all "doing great" and growing.
Of note, Grok Bot, xAI's new personal and business agent, launched in August. Meta Platform's much-lauded Muse personal agent debuted in September. An impressive open-weight model from China's Moonshot AI, called Kimi, debuted in July. Not to be outdone, OpenAI released its latest Codex model in July as well, meant to compete more strongly with Anthropic's leading coding capabilities.
That's a deluge of competitive agents substantively entering the fray during Q3. As such, it's perhaps inevitable that Anthropic's slowdown was due to competition and market-share loss rather than an overall slowdown in AI usage or spending.
While we don't have exact figures, Axios reported that OpenAI's revenue run rate grew by roughly 70% in Q3, well above Anthropic's 46% quarter-over-quarter growth. That seems to price in the share-loss story, not a general AI slowdown story. We also don't know how much SpaceX, Alphabet, or Meta's AI-related revenue grew, as they haven't reported earnings yet. None of these companies breaks down AI agent revenue specifically, either. So, it may be difficult to even understand how fast AI agentic revenue is growing inside these companies when they do report.
2. Frontier Labs are only 25% to 33% of Nvidia revenue right now
Another point Huang made was that frontier labs account for only a quarter to one-third of Nvidia's chip demand. Another third, according to Huang, is general computing, while the final third involves new and emerging AI-related companies. These companies, for instance, may use an open-weights model and then add proprietary data and industry knowledge to create new AI products.
On general computing growth, one point Huang has stressed over the past couple of years is that Moore's Law is "over." Moore's Law says that the amount of computing power roughly doubles every year at the same price, as chips pack more and more transistors onto a piece of silicon. However, Huang claims that semiconductor manufacturing is running up against the laws of physics and that, as a result, compute efficiency gains are slowing. Therefore, if someone wants to double their compute next year, the cost will increase rather than remain the same.
Given that there are more than just two labs, and that frontier labs account for only 25% to 35% of demand, Huang thinks people are putting way too much emphasis on OpenAI and Anthropic. Meanwhile, those labs still appear to be doing quite well even as they face more competition.
There should still be a shortage
Almost all commentary from leading AI chip companies says there is still a huge shortage of compute relative to demand. So even if leading frontier labs are under competitive pressure, semiconductors seem likely to find a buyer somewhere.
It appears from early Q3 earnings reports, especially from Taiwan Semiconductor Manufacturing, that chip demand remains strong. However, AI investors would do well to listen to other companies downstream from the chip giants to see whether they are generating AI-related revenue growth and efficiency gains.
Ultimately, AI will have to generate revenue and/or cost efficiencies for the end customer to justify this spending. So, commentary from AI users -- not necessarily the chipmakers themselves -- may be more important to chip stock performance than the chip companies' earnings during this upcoming earnings season.
Johnson & Johnson ve třetím čtvrtletí zvýšila tržby o 6 % na 25,4 miliardy USD, ale pomalejší růst segmentu MedTech, který činil 2,5 %, vedl k poklesu akcií.
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this…
Our 24/7 Wall St. price target for Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is $291.60 over the next 12 months. That means 15.57% upside from the model’s reference price of $252.32. Our rating is a buy, and our confidence is high.
Metric
Value
Current Price
$252.32
Price Target from 24/7 Wall St.
$291.60
Upside/Downside
15.57%
Recommendation
BUY
Confidence Level
90%
J&J has a beta of 0.206, a dividend yield of 1.99%, and 64 consecutive years of dividend increases (the kind of multi-decade run we screened for in our free Dividend Kings guide, which you can grab here).
Its oncology business is also growing at a double-digit pace. Shares traded at $257.62 noon Thursday, up 1.46% on the session.
MedTech Miss Cools a Strong 2026 Run
The stock is up 26.49% year to date and 38.02% over the past year. It has slipped 3.27% over the past month and now sits between a 52-week low of $180.59 and a 52-week high of $281.07.
J&J reported third-quarter results on October 13. Sales rose 6% to $25.4 billion, and adjusted EPS came in at $2.59. Innovative Medicine grew 7.9%. MedTech grew only 2.5%, and shares fell after the device miss.
Management also reset adjusted EPS guidance to $11.05 to $11.15 to account for the Firefly Bio and SAIL Biomedicines deals. It announced a $5.5 billion resolution of the ovarian talc litigation as well.
Why Bulls See $304 and Beyond
The bull case is $304.22. TREMFYA grew 68.2%, and management believes it can become a “$10 billion plus franchise.” Oncology grew about 17%, and J&J wants to be the top oncology company by 2030 with sales above $50 billion.
Management sees “a clear path to double digit growth by the end of the decade” without any further acquisitions. More catalysts are on the calendar: the OTTAVA robot, a DePuy Synthes spin targeted for mid-2027 and a December 8 Enterprise Business Review.
On the ratings side, 16 analysts rate the stock a Buy or Strong Buy.
What Could Go Wrong for J&J
The bear case sits at $252.88, essentially flat. STELARA sales fell 54%, and Abiomed declined 1.5%. The deal dilution is $1.36 per share next year, which puts our forward EPS input at risk.
As a counterpoint, management said EPS growth would approach 9% without those transactions, and the talc agreement could remove a long-running drag.
How J&J Compares to Merck and AbbVie
Merck (NYSE:MRK) is a direct oncology rival. It trades at 15x forward earnings, but KEYTRUDA’s patent expiration explains part of that discount.
AbbVie (NYSE:ABBV) competes with TREMFYA in immunology. It trades at 16x forward earnings while growing revenue 10.2%.
Company
Forward P/E
Dividend Yield
Revenue Growth (YoY)
J&J
21
1.99%
6.6%
Merck
15
2.34%
5.1%
AbbVie
16
2.43%
10.2%
J&J accounts for a premium multiple, so our target looks somewhat aggressive next to these peers. That premium gets diversification and a lower risk of losing exclusivity on a single key drug.
Why J&J’s Defensive Profile Supports Our Target
A 24/7 Wall St. price target of $291.60 supports a buy with 90% confidence. Durable pharma growth is the deciding factor.
The thesis strengthens if TREMFYA and oncology keep growing faster than STELARA declines. It weakens if MedTech weakness spreads beyond Abiomed and international markets.
Our model projects these values if current trends hold.
Year
Price Target from 24/7 Wall St.
2026
$255.36
2027
$291.60
2028
$323.87
2029
$351.98
2030
$380.13
J&J would need to keep executing on its current strategy for these projections to hold. The DePuy Synthes spin or new pipeline results could move the path significantly in either direction.
Contact [email protected] for any questions or corrections.
Johnson & Johnson: Ve studii fáze 3 dosáhl přípravek TREMFYA ve 48. týdnu kombinované remise perianálních píštělí u 35 % pacientů při dávce 100 mg každých 8 týdnů.
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized, placebo-controlled trial in patients with this debilitating and challenging manifestation of Crohn's disease , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease (CD).1 The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2. The late-breaking findings are being presented at the 2026 United European Gastroenterology Week (UEG Week).
Key findings from the Phase 3 study in Crohn's disease with perianal fistula
Combined fistula remissiona, which incorporates both clinical and radiologic assessment, was maintained or improved in both TREMFYA maintenance regimens through Week 48. Among patients receiving TREMFYA 100 mg every 8 weeks (q8w), combined fistula remission further increased from 28% at Week 24 to 35% at Week 48. Similar findings were observed for rates of clinically assessed fistula remission.b
Results among patients receiving TREMFYA 200 mg every 4 weeks (q4w) remained consistent through Week 48. More than 90% of all randomized patients, which included both bio-naïve and bio-experienced patients, completed treatment through Week 48.
"Perianal fistula remain one of the most debilitating complications of Crohn's disease, where achieving durable disease control beyond symptom improvement is a challenge," said Laurent Peyrin-Biroulet, MD, PhD, study investigator.c "The latest findings from the FUZION study, which is the first of its kind in 20 years, shows that patients treated with TREMFYA maintained or improved upon the clinical benefits observed at Week 24, providing encouraging evidence for its use in this patient population."
Safety findings through Week 48 were consistent with the well-established safety profile of TREMFYA in Crohn's disease.
The 48-week findings reinforce the previously shared Week 24 results from FUZION, which showed that in the overall study population at Week 24, 28% of patients receiving TREMFYA 100 mg q8w and 27% receiving TREMFYA 200 mg q4w achieved combined fistula remission compared with 10% receiving placebo, making TREMFYA the only IL-23 inhibitor to demonstrate efficacy in a dedicated, randomized, placebo-controlled trial in patients with Crohn's disease with perianal fistula.2
"These one-year findings expand the evidence for TREMFYA in perianal fistulizing Crohn's disease where long-term treatment options remain limited," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "Building on our longstanding expertise in immune-mediated diseases, we are committed to studying TREMFYA across the full spectrum of moderately to severely active Crohn's disease and generating evidence that may transform outcomes for patients, including those facing some of its most challenging complications."
For a full list of all Johnson & Johnson data being presented at UEG Week visit: https://www.jnj.com/innovativemedicine/immunology/gastroenterology.
Editor's Notes:
a. Combined fistula remission was defined as complete closure of all external fistula openings with no drainage, without development of new fistulas and no evidence of underlying fluid collections on MRI.
b. Clinically assessed fistula remission was defined as: 100% closure of all treated external openings without development of new fistulas or abscesses and without any drainage by external openings, occurring spontaneously or after gentle finger compression.
c. Dr. Laurent Peyrin-Biroulet is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
About the FUZION study (NCT05347095)
FUZION is a randomized, placebo-controlled, double-blind, multicenter, Phase 3 study designed to evaluate the efficacy and safety of TREMFYA in adults with Crohn's disease with perianal fistula. Patients enrolled in the study had one or more active draining perianal fistulas confirmed by blinded central MRI review, CD Activity Index [CDAI] <350, and inadequate response to oral corticosteroids, azathioprine, 6-mercaptopurine, methotrexate, or up to 2 advanced therapy classes. Patients were randomized 2:2:1 to receive TREMFYA 200 mg intravenous (IV) induction at Weeks 0, 4, 8 weeks followed by TREMFYA 100 mg subcutaneous (SC) induction every 8 weeks (q8w); or TREMFYA 200 mg IV infusion in at Weeks 0, 4, 8 weeks followed by TREMFYA 200 mg SC every 4 weeks (q4w); or placebo.3
About Crohn's disease
Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million Americans and an estimated four million people across Europe.4 5 Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.6 Symptoms of Crohn's disease can vary, but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss, and fever. Some patients may also develop fistulas, abnormal connections between the intestine and other organs or tissues, which can be associated with pain, drainage, infection, and substantial impairment in quality of life. Currently no cure is available for Crohn's disease.7
About TREMFYA (guselkumab)
Developed by Johnson & Johnson, TREMFYA is the first fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the cellular source by blocking IL-23 and binding to CD64 (a receptor on cells that produce IL-23). Findings for the dual-acting mechanism are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model. The clinical significance of this finding is not known.
TREMFYA is a prescription medicine approved in the U.S. to treat:
adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). adults and children 6 years and older who also weigh at least 88 pounds (40 kg) with active psoriatic arthritis. adults with moderately to severely active ulcerative colitis. adults with moderately to severely active Crohn's disease. TREMFYA is approved in Europe, Canada, Japan, and a number of other countries for the treatment of adults with moderate-to-severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate-to-severe Crohn's disease and adults with moderate-to-severe ulcerative colitis.
The legal manufacturer for TREMFYA is Janssen Biotech, Inc.
Johnson & Johnson maintains exclusive worldwide marketing rights to TREMFYA. For more information, visit: www.tremfya.com.
TREMFYA IMPORTANT SAFETY INFORMATION
What is the most important information I should know about TREMFYA?
TREMFYA is a prescription medicine that may cause serious side effects, including:
Serious Allergic Reactions. Stop using TREMFYA and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:
o fainting, dizziness, feeling lightheaded (low blood pressure)
o swelling of your face, eyelids, lips, mouth, tongue or throat
o trouble breathing or throat tightness
o chest tightness
o skin rash, hives
o itching
Infections. TREMFYA may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA and may treat you for TB before you begin treatment with TREMFYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA. Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
o fever, sweats, or chills
o muscle aches
o weight loss
o cough
o warm, red, or painful skin or sores on your body
different from your psoriasis
o diarrhea or stomach pain
o shortness of breath
o blood in your phlegm (mucus)
o burning when you urinate or urinating more often
than normal
Liver problems. With the treatment of Crohn's disease or ulcerative colitis, your healthcare provider will do blood tests to check your liver before and during treatment with TREMFYA. Your healthcare provider may stop treatment with TREMFYA if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms:
o unexplained rash
o vomiting
o tiredness (fatigue)
o yellowing of the skin or the whites of your eyes
o nausea
o stomach pain (abdominal)
o loss of appetite
o dark urine
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
have any of the conditions or symptoms listed in the section "What is the most important information I should know about TREMFYA?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA. are pregnant or plan to become pregnant. It is not known if TREMFYA can harm your unborn baby.
Pregnancy Registry: If you become pregnant during treatment with TREMFYA, talk to your healthcare provider about registering in the pregnancy exposure registry for TREMFYA. You can enroll by visiting www.mothertobaby.org/ongoing-study/tremfya-guselkumab, by calling 1-877-311-8972, or emailing [email protected]. The purpose of this registry is to collect information about the safety of TREMFYA during pregnancy. are breastfeeding or plan to breastfeed. It is not known if TREMFYA passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects. See "What is the most important information I should know about TREMFYA?"
The most common side effects of TREMFYA include: respiratory tract infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, herpes simplex infections, stomach pain, and bronchitis.
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects.
Use TREMFYA exactly as your healthcare provider tells you to use it.
Please read the full Prescribing Information, including Medication Guide, for TREMFYA and discuss any questions that you have with your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Dosage Forms and Strengths: TREMFYA is available as 100 mg/mL and 200 mg/2mL for subcutaneous injection and as a 200 mg/20 mL (10 mg/mL) single dose vial for intravenous infusion.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com
Follow us at @JNJInnovMed.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to TREMFYA. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
REFERENCES
1 Ailsa Hart,1 Axel Dignass, et al. Efficacy and Safety of Guselkumab in Perianal Fistulizing Crohn's Disease: Week 48 Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled FUZION Trial. LB09 at UEG Week 2026. October 19 2026.
2 Laurent Peyrin-Biroulet, et al. Guselkumab for Perianal Fistulizing Crohn's Disease: Week 24 Results from the Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter FUZION Study. (Abstract 1058b) Presented at Digestive Disease Week (DDW) May 2-5, 2026
3 Maria T. Abreu, et al. Efficacy And Safety Of The First Co-Antibody Therapy, Jnj-78934804, In Patients With Moderately To Severely Active Ulcerative Colitis Refractory To Systemic Therapies. (Abstract 1058d) Presented at Digestive Disease Week (DDW) May 2-5, 2026.
4 Crohn's & Colitis Foundation. Overview of Crohn's disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed August 2026.
5 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390:2769-78.
6 Crohn's & Colitis Foundation. What is Crohn's disease? Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/causes. Accessed August 2026.
7 Crohn's & Colitis Foundation. Signs and symptoms of Crohn's disease. Available at https://www.crohnscolitisfoundation.org/patientsandcaregivers/what-is-crohns-disease/symptoms. Accessed August 2026.
Adobe is down nearly 28% this year yet still beating earnings estimates and raising guidance, which raises an uncomfortable question about whether the market has gotten the AI disruption story completely wrong.
The 24/7 Wall St. price target for Adobe (NASDAQ:ADBE | ADBE Price Prediction) is $294.54 over the next 12 months. With shares trading at $252.88, that works out to 16.5% upside. The stock gets a buy rating with high confidence.
Metric
Value
Current Price
$252.88
Price Target from 24/7 Wall St.
$294.54
Upside/Downside
16.5%
Recommendation
BUY
Confidence Level
90%
Adobe’s growth is holding up and guidance keeps rising, yet the stock is priced as if its business is shrinking. That gap drives the call. At a forward P/E of about 9x, the market has already priced in a lot of fear about AI disruption.
The open question is whether Adobe can turn rapid AI adoption into a clear acceleration in annual recurring revenue (ARR). We think the current price leaves enough room for that to work.
Rebound Week Follows a Bruising 2026
Shares gained 5.07% today and 8.64% over the past week. Shares remain down 4.79% over the past month and 27.75% year to date. The stock sits 30.5% below its 52-week high of $363.70 and 33% above its low of $190.12. The bounce came right after a widely read Barron’s report on a downgrade to Sell over growth concerns.
The latest results were solid. Fiscal Q3 revenue rose 12.9% to $6.76 billion, ahead of the $6.70 billion consensus. Non-GAAP EPS of $6.13 beat the $6.09 estimate. Management also raised full-year non-GAAP EPS guidance to $24.45 to $24.50. Leadership is changing too: Anil Chakravarthy becomes CEO on December 1, and Shantanu Narayen stays on as executive chair.
Why Bulls See $326 Within Reach
Adobe’s AI-first ARR now exceeds $650 million and is growing more than 150% a year. Firefly ARR rose 40% quarter over quarter. Creative freemium users passed 100 million, up more than 70%. Adobe has also held off on pricing actions to build its user base first, which gives it room to raise prices later.
Capital returns add support: Adobe bought back 9.5 million shares last quarter and has $24.55 billion left under its authorization. Of the analysts covering the stock, 11 rate it Buy or Strong Buy, and the consensus target is $272.31. The bull case is $326.20.
Cracks Bears Say Are Already Showing
Remaining performance obligations grew just 8%, and analysts pressed management on net new ARR. Five analysts rate the stock Sell or Strong Sell. Net income rose only 3.1%.
On the other side of the ledger, free cash flow grew 14.68%, and much of the profit lag reflects planned investment in freemium growth. The bear case is at $254.03.
Adobe Trades at a Steep Discount to Microsoft and Salesforce
The benchmark for AI monetization at scale is Microsoft (NASDAQ:MSFT). It has more than 30 million paid Copilot seats and grew quarterly revenue 17.75% while trading at about 30x trailing earnings.
Adobe Experience Cloud faces direct competition from Salesforce (NYSE:CRM). It grew revenue a slower 10.83% yet trades at 26x trailing earnings.
Company
P/E
Latest Quarterly Revenue Growth
Adobe (forward)
9x
12.9%
Microsoft (trailing)
30x
17.75%
Salesforce (trailing)
26x
10.83%
Adobe is growing faster than Salesforce at a far lower multiple. Next to that peer group, our 24/7 Wall St. price target looks conservative.
What Could Make or Break Adobe From Here
The 24/7 Wall St. price target remains at $294.54, with a buy rating and 90% confidence. Valuation is the deciding factor.
Shares could outperform if AI-first ARR keeps growing at triple digits and the new CEO starts turning freemium users into paying ones. The bear case gains weight if net new ARR keeps slowing into fiscal 2027.
Year
Price Target from 24/7 Wall St.
2026
$261.36
2027
$294.54
2028
$335.35
2029
$360.13
2030
$396.73
Adobe would need to keep executing on its current strategy for these projections to hold. Generative AI competitors could drive results well below this path, while faster monetization of its user base could drive them well above it.
Contact [email protected] for any questions or corrections.
Shares of International Business Machines (IBM -0.85%) trade around $234 as I write, two days before the company posts third-quarter results on Wednesday, Oct. 21. The stock has shed about 21% of its value so far in 2026, and it is 29% below the all-time high of $329.23 it closed at on June 2.
The hardest hit was on July 14, when IBM said second-quarter revenue had come in below its own expectations. Shares sank 25% that day.
What bothers me most about that quarter is software. IBM's software revenue grew 5% year over year. But without acquisitions, it was flat, according to CFO James Kavanaugh.
With the stock this far below its high and a dividend yielding almost 3%, is IBM worth buying before Wednesday's report?
Image source: The Motley Fool.
Software growth slowed sharplySoftware is IBM's biggest segment by both revenue and profit. It pulled in $7.8 billion in second-quarter sales, and its segment profit climbed 9% year over year to $2.5 billion. But its revenue growth has slowed for two straight quarters. The segment's revenue grew 14% year over year in the fourth quarter of 2025. Growth then eased to 11% in the first quarter of 2026, and the second quarter brought just 5%. And acquisitions, such as data-streaming firm Confluent, which IBM bought in March, provided all of that latest 5%.
Management blamed timing. In the last weeks of June, many customers moved budgets to hardware to lock in supply before expected price rises. And "tens of large deals failed to close on the timelines we expected," Kavanaugh said on IBM's July 22 call with analysts.
This hurt transaction processing, the software linked mainly to IBM's mainframes, which slid 8%.
Of course, there were bright spots. Red Hat, IBM's hybrid cloud business, grew 11%, and data software grew 19%. And CEO Arvind Krishna said around a third of the delayed deals closed in the first three weeks of the third quarter.
But a quarter with no organic software growth is hard to shrug off. Software is arguably the part of IBM that its growth story relies on most.
The report needs software to pick back upIBM now expects software revenue growth of 6% to 8% this year in constant currency. Kavanaugh called the low end an anchor that assumes recent spending patterns hold through the second half. The high end, he said, means "a second half that's approaching double digits."
Around 80% of IBM's software sales are recurring subscription and consumption-based revenue, like Red Hat. Kavanaugh said that recurring revenue rose 7% in the first quarter and accelerated to 8% in the second, and IBM's high-end case has it hitting about 10% in the second half.
For IBM overall, management expects third-quarter revenue growth, in constant currency, in line with its full-year range of 4% to 5%. That would be a clear step up from 1% growth in the second quarter.
So the number I'll watch on Wednesday is software growth. A climb from 5% toward the high single digits might signal the delayed deals are coming back. It'd also come against a tough comparison -- software rose 9% on a constant-currency basis in the year-ago quarter. Another quarter around 5%, driven by acquisitions, might point to the low end instead.
IBM International Business Machines$232.14-$1.98 (-0.85%)
NYSE · As of 4:00 PM ET 10/16/26
Is the dividend reason enough to buy now?The stock already prices in plenty of disappointment. At around $234, it trades at about 18 times IBM's expected 2027 earnings. At June's high, it fetched about 25 times those same earnings estimates.
Meanwhile, IBM pays $1.69 a share a quarter ($6.76 a year). At the stock's current price, the dividend yields around 2.9%. April's hike was IBM's 31st yearly raise in a row, though only by a cent.
The payout looks well covered, too. IBM produced $14.7 billion in free cash flow in 2025 and still expects the number to climb by around $1 billion this year, while its dividends cost about $1.6 billion a quarter.
But a yield just below 3% is modest pay for waiting on a software recovery that hasn't turned up in the results yet. Until organic growth returns, 18 times earnings might simply be a fair price for a slower business.
If Wednesday's report shows software growth climbing toward the high single digits, with recurring revenue rising toward 10%, I think IBM stock could be worth considering at this price, with the dividend paying around 3% a year as the rest of the recovery plays out. If the quarter looks like the second, I'd keep waiting.
Michael Lou byl s okamžitou účinností jmenován prezidentem a generálním ředitelem společnosti Chord Energy (CHRD), kde nahradil odstupujícího Dannyho Browna.
Michael Lou Appointed President & Chief Executive Officer
, /PRNewswire/ -- Chord Energy Corporation (NASDAQ: CHRD) ("Chord," "Chord Energy," or the "Company") today announced that Michael Lou has been appointed President & Chief Executive Officer, effective today. Additionally, Mr. Lou has been appointed and elected to the Chord Energy Board of Directors. Mr. Lou succeeds Danny Brown, who is stepping down immediately as President and Chief Executive Officer and from the Chord Energy Board of Directors to pursue another professional opportunity.
Mr. Lou has more than 25 years of experience in the oil and gas industry, including 17 years in various positions of leadership at Chord and its predecessor companies. In his roles as Chief Strategy Officer and Chief Commercial Officer as well as Chief Financial Officer, Mr. Lou has been instrumental in shaping and driving the Company's strategic and financial outcomes, including growing the organization to the largest operator in the Williston Basin while maintaining a pristine balance sheet.
"Michael has been an instrumental member of the Chord leadership team and a key driver of our success," said Susan Cunningham, Chair of the Chord Energy Board of Directors. "He has helped profitably scale the business, and has led strategic and commercial initiatives while demonstrating strong business acumen and the ability to lead across the organization. His deep knowledge of Chord and his proven leadership make him well-suited to lead the Company. The Board has full confidence in Michael's ability to build upon Chord's momentum."
"On behalf of the entire Board, I thank Danny for his leadership and contributions to Chord Energy," said Ms. Cunningham. "Chord Energy is implementing this leadership change from a position of strength, as the organization delivers continually improving execution, while lowering costs and driving resilient adjusted free cash flow generation. Our succession planning and the depth of our executive team position Chord well for continued success."
"I am honored to be named Chord Energy's President & CEO," said Mr. Lou. "We have built a top-tier organization with talented leaders and employees who are passionate about executing on our strategy and driving long-term value for shareholders. Chord has made tremendous progress and is well positioned as a stronger, more efficient, and more resilient company. I look forward to working with the Chord team as well as our communities and other stakeholders to build upon our strong operational and financial performance, while safely producing the affordable and reliable energy the world needs."
Mr. Brown said, "It has been a privilege to serve as Chord's CEO. It is difficult to leave such a great company and all of the talented people I've had the pleasure to work with, but I depart knowing the business is in great shape and the future holds continued success. I am proud of what the team has accomplished, building a multi-year track record of disciplined capital allocation and portfolio optimization, advancing continuous improvement initiatives and delivering strong returns for shareholders, while building strong relationships in the communities we serve. I am confident that Michael and the rest of the management team will build on this progress and lead Chord to continued success."
About Michael Lou
Prior to his appointment as President & Chief Executive Officer, Michael Lou served as Chord Energy's Executive Vice President, Chief Strategy Officer and Chief Commercial Officer from March 2024 through October 2026. Formerly, he was Executive Vice President and Chief Financial Officer from July 2022 to March 2024. Prior to the merger of Whiting Petroleum and Oasis Petroleum, he served in roles including Chief Financial Officer and Executive Vice President for Oasis Petroleum and its subsidiaries and President and Director of the general partner of Oasis Midstream Partners.
Mr. Lou began his career in investment banking, where he spent 10 years holding positions of increasing responsibility at several global investment banks focused in the energy sector.
Mr. Lou holds a Bachelor of Science in Electrical Engineering from Southern Methodist University.
Contact:
Chord Energy Corporation
Bob Bakanauskas, VP, Finance
(281) 404-9600
[email protected]
About Chord Energy
Chord Energy Corporation is an independent exploration and production company with quality and sustainable long-lived assets primarily in the Williston Basin. The Company is uniquely positioned with a best-in-class balance sheet and is focused on rigorous capital discipline and generating free cash flow by operating efficiently, safely and responsibly to develop its unconventional onshore oil-rich resources in the continental United States. For more information, please visit the Company's website at www.chordenergy.com.
Forward-Looking Statements
This press release may include certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the management transition, Company operations and results after the management transition. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that are difficult to predict and many of which are beyond management's control. These risks and assumptions are described in the Company's annual reports on Form 10-K and other reports that are available from the United States Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management's view only as of the date made.
Any forward-looking statement speaks only as of the date on which such statement is made and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Společnost Chord Energy ve 3. čtvrtletí 2026 překonala horní hranici výhledu celkové těžby, když dosáhla 290,5–290,9 tis. barelů ropného ekvivalentu denně oproti očekávaným 277,7–284,0 tis. barelů ropného ekvivalentu denně.
, /PRNewswire/ -- Chord Energy Corporation (NASDAQ: CHRD) ("Chord," "Chord Energy," or the "Company") today provided an update on operational and financial performance in 3Q26.
Highlights:
Operational Strength: Volumes exceeded the high-end of guidance across oil, natural gas and NGLs, and CapEx was in line with guidance; Shareholder Returns: $205MM of share repurchases at an average price of $135.74/share during 3Q26 and another $44.3MM QTD in 4Q26 at an average price of $142.32/share; Announced divestiture of non-operated Marcellus assets for total gross consideration of $550MM, including $55MM deposit paid during 3Q26; and Cash and cash equivalents of $804.7MM and total debt of $1,482.2MM on 9/30/26. "The entire organization delivered another strong quarter of operational and financial performance," said Michael Lou, Chord Energy's President & Chief Executive Officer. "Strong performance across new and existing wells and better than expected downtime performance drove volumes above the top-end of guidance. Strong volumes, in line capital and favorable price realizations drove adjusted free cash flow above expectations. Chord continues to be focused on disciplined capital allocation, operational efficiency, and attractive return of capital, and our balance sheet continues to strengthen with robust adjusted free cash flow generation and strategic actions."
3Q26 Operational and Financial Update:
The following table presents select preliminary operational and financial data compared to guidance released in August 2026:
Previous 3Q26 Guidance
Preliminary 3Q26 Results
Oil volumes (MBopd)
161.5 – 164.5
165.4 – 165.6
NGL volumes (MBblpd)
50.0 – 52.0
55.0 – 55.2
Natural gas volumes (MMcfpd)
397.0 – 405.0
420.4 – 420.8
Total volumes (MBoepd)
277.7 – 284.0
290.5 – 290.9
CapEx ($MM)
$360 - $390
$379 - $385
Oil Premium/(Discount) to WTI ($/Bbl)
$(0.70) - $0.30
$0.06 - $0.16
NGL realization (% of WTI)
4% - 10%
13% - 15%
Natural gas realization (% of Henry Hub)
20% - 30%
35% - 37%
LOE ($/Boe)
$10.00 - $11.00
$10.51 - $10.61
Production taxes (% of oil, NGL and gas sales)
8.0% - 8.4%
8.1% - 8.3%
Cash taxes paid ($MM)
$32.0
Preliminary 3Q26 CapEx includes approximately $4.5MM of reimbursable non-op CapEx. Additionally, Marcellus-related preliminary CapEx exceeded expectations by approximately $6MM during 3Q26. These two items together would adjust Preliminary 3Q26 CapEx downward by approximately $10.5MM. NYMEX WTI averaged $85.69/Bbl and NYMEX Henry Hub averaged $2.96/MMBtu during 3Q26. Lastly, during 3Q26, Chord had a loss on realized hedges of $48.7MM and received distributions from its investment in equities securities of $2.3MM-$2.5MM.
Preliminary Financial Data
The Company's condensed consolidated financial statements for the three-month period ended September 30, 2026 are not yet available. The Company has prepared the preliminary financial data presented in this press release based on the most current information available to management. Accordingly, the operational and financial results presented in this press release are subject to the completion of the Company's normal financial reporting processes and any adjustments that may result from the completion of the quarterly review and finalization of our consolidated financial statements. As a result, the Company's actual financial results could be different from this preliminary financial data, and any differences could be material. The preliminary financial information has been prepared by and is the responsibility of the Company's management. Our independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to these preliminary results (including any financial data). Accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect to these preliminary results.
Non-GAAP Financial Measures
Non-GAAP financial measures, including adjusted free cash flow referenced in this press release, are not prepared in accordance with GAAP and are used by management and external users of the Company's financial statements, such as industry analysts, investors, lenders and rating agencies. The Company believes that these measures are useful supplemental measures that provide an indication of the results generated by the Company's principal business activities. However, these measures are not recognized by GAAP and do not have a standardized meaning prescribed by GAAP. Therefore, these measures may not be comparable to similar measures provided by other issuers.
Adjusted Free Cash Flow
The Company defines adjusted free cash flow as Adjusted EBITDA less Cash Interest and CapEx (excluding capitalized interest and acquisition capital).
Adjusted free cash flow is not a measure of cash flows from operating activities as determined by GAAP. Management believes that the presentation of adjusted free cash flow provides useful additional information to investors and analysts for assessing the Company's results of operations, financial performance, and its ability to generate cash from its business operations without regard to its financing methods or capital structure.
Contact:
Chord Energy Corporation
Bob Bakanauskas, VP, Finance
(281) 404-9600
[email protected]
Forward-Looking Statements and Cautionary Statements
Certain statements in this press release, other than statements of historical facts, that address activities, events or developments that Chord expects, believes or anticipates will or may occur in the future, including any statements regarding future opportunities for Chord, future financial performance and condition, guidance and statements regarding Chord's expectations, beliefs, plans, financial condition, objectives, assumptions or future events or performance are forward-looking statements based on assumptions currently believed to be valid. Forward-looking statements are all statements other than statements of historical facts. The words "anticipate," "believe," "ensure," "expect," "if," "intend," "estimate," "probable," "project," "forecasts," "predict," "outlook," "aim," "will," "could," "should," "would," "potential," "may," "might," "likely," "plan," "positioned," "strategy" and similar expressions or other words of similar meaning, and the negatives thereof, are intended to identify forward-looking statements. Specific forward-looking statements include statements regarding Chord's preliminary unaudited third quarter financial results, Chord's plans and expectations with respect to the return of capital plan, production levels, anticipated financial and operating results, other guidance, and the effects and anticipated benefits of the Marcellus divestiture. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on certain assumptions made by Chord based on management's experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Chord, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. These include, but are not limited to, the ability to complete or realize the anticipated benefits from the Marcellus divestiture, changes in crude oil, NGL and natural gas realized prices, uncertainty regarding the future actions of foreign oil producers and the related impacts such actions have on the balance between the supply of and demand for crude oil, NGLs, and natural gas, the actions taken by OPEC+ with respect to oil production levels and announcements of potential changes in such levels, including the ability of the OPEC+ countries to agree on and comply with production levels, changes in trade policies and regulations, including increases or change in duties, current and potentially new tariffs or quotas and other similar measures, as well as the potential impact of retaliatory tariffs and other actions, war between Russia and Ukraine, military conflicts in the Red Sea Region, Iran, and the wider Middle East and their effect on commodity prices, changes or uncertainty in general economic and geopolitical conditions, inflation rates and the impact of associated monetary policy responses, including fluctuating interest rates, logistical challenges and supply chain disruptions, including as a result of conflicts, our business strategy, including the continued implementation of our 4-mile well program, the geographic concentration of our operations, uncertainties in estimating proved reserves and forecasting production results, drilling and completion of wells, operational factors affecting the commencement or maintenance of producing wells, the availability of infrastructure and midstream service providers, our ability to realize the anticipated benefits from acquisitions, the condition of the capital markets generally, as well as Chord's ability to access them, the proximity to and capacity of transportation facilities, uncertainties regarding environmental regulations or litigation and other legal or regulatory developments affecting Chord's business and other important factors that could cause actual results to differ materially from those projected as described in Chord's reports filed with the U.S. Securities and Exchange Commission (the "SEC").
Any forward-looking statement speaks only as of the date on which such statement is made and Chord undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Additional information concerning other risk factors is also contained in Chord's most recently filed Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other SEC filings.
About Chord Energy
Chord Energy Corporation is an independent exploration and production company with quality and sustainable long-lived assets primarily in the Williston Basin. The Company is uniquely positioned with a best-in-class balance sheet and is focused on rigorous capital discipline and generating free cash flow by operating efficiently, safely and responsibly to develop its unconventional onshore oil-rich resources in the continental United States. For more information, please visit the Company's website at www.chordenergy.com.
Ocenění společnosti Linde (LIN) metodou DCF stanovuje vnitřní hodnotu na základě zisku na 245,08 USD a na základě volného peněžního toku na 180,79 USD, oproti aktuální ceně 498,43 USD.
On October 19, 2026, we delve into the DCF analysis for Linde PLC LIN, a company that has seen a notable price performance with an 18.1% increase year-to-date and a 13.7% rise over the past year. However, the valuation models present a stark contrast:
DCF Earnings-based intrinsic value suggests a significant overvaluation compared to the current price, indicating a margin of safety of -103.4%. DCF Free Cash Flow (FCF)-based intrinsic value also points to overvaluation, with a margin of safety of -175.7%. The GF Score™ of 91/100 indicates strong financial health but raises questions about the reliability of the DCF inputs due to its low predictability rank of 2/5 stars. What Is LIN Worth? DCF Earnings-Based Model The DCF earnings-based model for Linde PLC employs a two-stage approach to estimate intrinsic value. The first stage anticipates a robust growth in earnings per share (EPS) over the next ten years, followed by a terminal growth phase. Below are the assumptions used in this model:
Parameter Value Current EPS (TTM, excl. non-recurring) $15.67 10-Year Growth Rate 10.9% 10-Year Treasury Rate 5.08% Discount Rate (ceil(Treasury) + 6%) 12% Terminal Growth Rate 4% In the first stage, the EPS is projected to grow at 10.9% annually for ten years, discounted at a rate of 12%. The calculation summary is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 10.9%, discounted at 12% $148.48 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 12% $96.60 Intrinsic Value Growth + Terminal $245.08 With the current price at $498.43, the intrinsic value of $245.08 indicates that Linde PLC is significantly overvalued, resulting in a margin of safety of -103.4%. Notably, GuruFocus employs EPS excluding non-recurring items because research indicates that stock prices correlate more closely with earnings than with free cash flow. For further analysis, you can visit the LIN DCF Calculator.
What Does the Free Cash Flow DCF Say? The Free Cash Flow (FCF)-based intrinsic value for Linde PLC stands at $180.79. This figure further corroborates the earnings-based DCF analysis, as both models indicate significant overvaluation. The margin of safety for the FCF-based valuation is -175.7%, reinforcing the notion that Linde PLC is trading at a premium compared to its intrinsic value.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Linde PLC is calculated at $513.00, suggesting a slight undervaluation of 2.8%. This proprietary measure from GuruFocus is derived from historical trading multiples, past business growth, and future performance estimates. While the DCF models indicate significant overvaluation, the GF Value™ presents a more favorable perspective, highlighting the discrepancy among the three valuation methods. For more insights, check the GF Value™.
What Does LIN's GF Score™ Tell Us? The GF Score™ evaluates a company's financial health and growth potential based on various metrics. Linde PLC boasts a strong GF Score™ of 91/100, indicating solid fundamentals. However, the predictability rank of 2/5 stars suggests that the DCF models may be less reliable for this stock. Below is a summary of LIN's GF Score™ metrics:
Metric Rating GF Score™ 91/100 Financial Strength 6/10 Profitability 9/10 Growth 9/10 Valuation 9/10 Momentum 5/10 For a comprehensive overview of LIN, visit the LIN stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as Linde PLC, tend to yield less reliable DCF estimates. The terminal growth rate of 4% used in this analysis serves as a simplifying assumption that may not fully capture future market dynamics.
What This Means for Investors In synthesizing the three valuation perspectives—DCF earnings, DCF FCF, and GF Value™—a clear tension emerges. The DCF models indicate significant overvaluation, while the GF Value™ suggests a slight undervaluation. Given the low predictability rank and the mixed signals from the valuation models, investors should exercise caution. Additionally, the Guru 13F activity shows that 20 gurus currently hold Linde PLC, with 8 adding and 8 trimming their positions, while insiders have been net selling over the past 12 months. This insider activity could serve as a warning signal. For further insights into Linde PLC's valuation, explore the LIN DCF Calculator.
Frequently Asked Questions What is LIN's intrinsic value based on DCF?
earnings-based $245.08, FCF-based $180.79
Is LIN overvalued or undervalued?
Based on the DCF and GF Value™ consensus, LIN is significantly overvalued.
How reliable is the DCF model for LIN?
The DCF model's reliability is diminished due to its predictability rank of 2/5.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Pilulka emvistegrast společnosti Gilead Sciences ve 12týdenní studii ulcerózní kolitidy zlepšila příznaky u 66 % pacientů oproti 37 % pacientů ve skupině s placebem.
Gilead Sciences (GILD.O) said on Monday its experimental once-daily pill reduced symptoms of a chronic bowel illness in more patients than placebo in a mid-stage trial.
The drug, emvistegrast, was being tested in adults with moderate to severe ulcerative colitis, a chronic condition that causes inflammation and ulcers in the digestive tract
The pill is designed to block the α4β7 integrin pathway, a target already validated in inflammatory bowel disease
After 12 weeks, 66% of patients taking a 200 mg dose of the drug saw their disease symptoms improve, compared to 37% on placebo, meeting the trial's main goal
Also, 31% of patients receiving the treatment achieved clinical remission, compared to 8% of those in the placebo group
BMO Capital Markets analysts said they view the data as "an incremental positive for Gilead's inflammatory strategy that establishes emvistegrast as a credible oral α4β7 option"
The drug was generally well tolerated, with overall side-effect rates comparable between the treatment and placebo groups, and no serious side effects were linked to the study medication
Gilead said it plans to initiate a late-stage monotherapy study of the pill in 2027
The Pound-New Zealand Dollar could strengthen if UK inflation reinforces BoE hike bets, while softer New Zealand inflation may weigh on the Kiwi.
Trade in the Pound to New Zealand Dollar (GBP/NZD) exchange rate was uneven last week amid a fluctuating market mood.
At the time of writing, GBP/NZD was trading at around NZ$2.358. Almost unchanged from start of last week’s session.
Latest — Exchange Rates:
Pound to New Zealand Dollar (GBP/NZD): 2.358121 (-0.14%)
Euro to New Zealand Dollar (EUR/NZD): 1.988273 (-0.34%)
New Zealand Dollar to Dollar (NZD/USD): 0.565285 (+0.58%)
DAILY RECAP:
The New Zealand dollar (NZD) tracked shifting risk appetite throughout the week, experiencing notable swings as investors reacted to geopolitical uncertainty, rising energy prices and changing expectations for US interest rates
After initially struggling amid concerns over renewed tensions in the Middle East, the ‘Kiwi’ was catapulted higher as a sharp correction in the US Dollar (USD) triggered a notable risk rally in the latter half of the session.
The New Zealand Dollar also benefited from comments by Reserve Bank of New Zealand (RBNZ) Chief Economist Paul Conway, who signalled that further interest rate increases could be necessary to bring inflation under control.
The Pound (GBP) traded without strong conviction through the first half of last week’s session, as conflicting economic signals left investors hesitant.
Although the International Monetary Fund (IMF) raised its outlook for UK economic growth, gains were constrained by remarks from Bank of England (BoE) Chief Economist Huw Pill.
Pill, typically regarded as one of the more hawkish members of the Monetary Policy Committee, sought to rein in expectations for an aggressive tightening cycle, questioning market bets that the BoE would raise interest rates four times over the coming year.
The Pound found firmer footing later in the week, however, after the latest UK GDP figures revealed an unexpected expansion in August, overturning forecasts that the economy would contract.
Near-Term GBP/NZD Forecast: UK Inflation in the Spotlight
Looking ahead, the Pound to US Dollar exchange rate could gain ground this week as investors reacted to the latest UK consumer price index.
Forecasts point to inflation climbing to 3.4% in September. Such a reading could lend support to Sterling by reinforcing expectations that the BoE will start raising interest rates next month.
However, the latest UK labour market figures may limit the Pound’s advance. Unemployment is expected to have increased in August, potentially tempering optimism over the strength of the domestic economy.
Meanwhile, New Zealand’s own inflation figures will likely act as the primary catalyst for the ‘kiwi’ with NZD exchange rates likely to soften if an easing of price pressures in the third quarter dampens RBNZ rate hike expectations.
Exchange Rates UK Research
Our currency coverage draws on live market data, official economic releases and published bank research.
Společnost Micron 21. října 2026 v 8:00 horského času uspořádá technologický webinář o inovacích v oblasti pamětí DRAM, HBM a NAND, který povede její prezident a ředitel pro technologie a produkty Scott DeBoer.
President and Chief Technology and Products Officer Scott DeBoer to discuss innovations across DRAM, HBM and NAND that extend Micron’s technology leadership | Source: Micron Technology, Inc.
BOISE, Idaho, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (Nasdaq: MU) announced today that it will host a technology webinar on Wednesday, Oct. 21, 2026, at 8 a.m. Mountain Time. Scott DeBoer, Micron president and chief technology and products officer, will lead the discussion.
The path to accelerating Super Intelligence demands a fundamental leap in memory and storage capabilities. The next generation of AI infrastructure will require significantly higher bandwidth, capacity and efficiency in how data is moved, stored and accessed. The webinar will detail how Micron's technology foundation, multigenerational roadmap, close customer co-design and long-term research position the company to extend its technology leadership over the next decade and beyond.
DeBoer’s presentation will be followed by a question-and-answer session.
The webinar will be webcast live at http://investors.micron.com/. Webcast replay of the presentation can be accessed from Micron’s Investor Relations website for approximately one year after the event.
About Micron Technology, Inc.
Micron Technology, Inc. is a global leader in semiconductor memory and storage, powering AI and compute-intensive applications from cloud to edge. With a relentless focus on our customers, technology and product leadership, and manufacturing and operational excellence, Micron’s comprehensive portfolio of high-performance DRAM, NAND and NOR solutions deliver the speed, efficiency, and scale today’s workloads demand, accelerating intelligence to enrich life for all. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.
Metis TechBio uzavřela s Eli Lilly spolupráci na vývoji cíleného doručování léčiv, která může přinést přibližně 1,1 miliardy USD v milníkových platbách a licenční poplatky.
Hong Kong-listed Metis TechBio (7666.HK) said on Monday it has entered into a collaboration agreement with Eli Lilly (LLY.N) worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.
The Chinese biotech will use its proprietary AI-driven drug-delivery platform to develop next-generation technologies aimed at improving how LNP-based drugs reach target tissues.
Metis will be eligible to receive an upfront payment in the low double-digit millions US dollars and up to about $1.1 billion in development, regulatory and commercial milestone payments.
It will also be eligible for tiered royalties at a single-digit percentage of annual net sales of products that are developed due to the collaboration.
The Chinese biotech will use its proprietary AI-driven ionizable lipid discovery and optimisation platform to develop delivery technologies aimed at improving the targeting and biodistribution of LNP-based therapies.
Metis and Lilly aim to discover and optimise novel LNP architectures that could improve tissue specificity and therapeutic performance, with potential applications across multiple disease areas.
Danaher má ve 3. čtvrtletí vykázat zisk 1,92 USD na akcii a tržby ve výši 6,56 miliardy USD, oproti 1,89 USD na akcii a tržbám 6,05 miliardy USD ve stejném období loňského roku.
Danaher Corporation (NYSE:DHR) will release earnings for its third quarter before the opening bell on Wednesday, Oct. 21.
Analysts expect the company to report quarterly earnings of $1.92 per share, up from $1.89 per share in the year-ago period. The consensus estimate for DHR’s quarterly revenue is $6.56 billion. It reported $6.05 billion last year, according to Benzinga Pro.
On Oct. 14, Danaher announced an AI collaboration with NVIDIA Corp (NASDAQ:NVDA) focused on autonomous science.
Danaher shares fell 1.1% to close at $229.04 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
TD Cowen analyst Dan Brennan maintained a Buy rating and raised the price target from $236 to $255 on Oct. 13, 2026. This analyst has an accuracy rate of 73%. Barclays analyst Luke Sergott maintained an Overweight rating and boosted the price target from $230 to $255 on Oct. 7, 2026. This analyst has an accuracy rate of 69%. RBC Capital analyst Dan Leonard maintained an Outperform rating and raised the price target from $215 to $250 on Oct. 5, 2026. This analyst has an accuracy rate of 70%. Guggenheim analyst Subbu Nambi maintained the stock with a Buy rating and increased the price target from $200 to $250 on Oct. 1, 2026. This analyst has an accuracy rate of 78%. Wells Fargo analyst Brandon Couillard maintained an Equal-Weight rating and cut the price target from $212 to $195 on July 22, 2026. This analyst has an accuracy rate of 74%. Considering buying DHR stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
BFA Law prověřuje fúzi, v jejímž rámci Ithaca Holdco získá akcie společnosti Bumble držené veřejností za 6,05 USD za akcii, včetně přiměřenosti nabízené ceny a podmínek pro menšinové akcionáře.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the merger between Ithaca Holdings (Ithaca Holdco, Inc.) and Bumble Inc. (NASDAQ:BMBL). Bumble is incorporated in Delaware.
If you are a current shareholder of Bumble, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/bumble-investigation.
Key Details of the Bumble ($BMBL) Investigation:
Investigation Overview: Breaches of Fiduciary Duty in connection with the merger under which Ithaca Holdco, Inc. will acquire the public stock of Bumble for $6.05 per shareAction: Contact BFA Law to discuss your rights Why is the Bumble Transaction being Investigated?
Bumble, Inc. is a company that is controlled by two majority stockholders—Blackstone Inc. and Bumble’s founder, Whitney Wolfe Herd. Those two stockholders alone control 83.7% of the company’s voting power. Bumble secured stockholder approval for the merger with Ithaca with the written consent of Blackstone and Whitney Wolfe Herd, with no further stockholder vote planned. Bumble’s board of directors reportedly approved the merger on the recommendation of the special committee it formed to evaluate the merger.
As a part of the merger agreement with Ithaca Holdco, Inc., Whitney Wolfe Herd’s stock in Bumble is being allowed to rollover into the post-merger company—meaning she will continue to own stock in the company after the merger closes. The opportunity to rollover shares is not being extended to any other stockholders.
BFA is investigating whether the terms of the merger, including the rollover, comply with Delaware law, including whether the $6.05 per share price is a fair price for the public stockholders’ shares of Bumble stock.
Click here for more information:
https://www.bfalaw.com/cases/bumble-investigation
What Can You Do?
If you are a current holder of Bumble stock, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/bumble-investigation
Attorney advertising. Past results do not guarantee future outcomes.
The largest Bitcoin miner just moved 1,000 BTC onto exchanges while its holdings have quietly shrunk by thousands of coins, and now Michael Saylor is hinting at a buy. Whether that signals a sale, a loan, or something else changes…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
MARA Holdings (NASDAQ:MARA | MARA Price Prediction), the largest publicly traded Bitcoin miner, transferred 1,000 Bitcoin (CRYPTO:BTC), valued at around $82.8 million, to the Binance and Gate exchanges over five days, according to the on-chain tracker Lookonchain. MARA hasn’t explained these transfers. So, is MARA selling Bitcoin?
In contrast, Michael Saylor, executive chairman of Strategy Inc. (NASDAQ:MSTR), signaled more Bitcoin purchases. He tweeted, “We found room for more orange,” his usual hint at another purchase. Strategy Inc. holds 848,250 BTC and last reported buying 250 BTC, though it has not made a new announcement yet.
Bitcoin trades at approximately $82,720. MARA shares were at $7.70 premarket, up 2.3% from the previous close of $7.53, even though they remain down 20.2% for the week and 30.3% for the month.
Meanwhile, Strategy Inc. was trading at around $140 premarket, down 9.6% for the week, as investors worry that a stock index could drop the company.
MARA’s Mining Revenue Falls as Its Costs Climb
MARA primarily earns revenue through Bitcoin mining, where specialized computers compete to add new blocks to the network and earn newly mined coins. Its revenue decreased to $174.9 million in the second quarter, down from $238.5 million the previous year. A 28% drop in Bitcoin’s average price cut revenue by $65.9 million.
MARA’s hashrate, the total computing power its machines contribute to the network, rose to 70.3 exahashes per second. However, the cost of energy needed to mine each Bitcoin has increased to $38,690 from $33,735 a year ago. Management attributed this rise to increased mining difficulty, which occurs when more machines come online.
About $343 million of MARA’s $611.3 million net loss came from a mark-to-market loss, which is a paper loss from valuing its Bitcoin at lower prices without selling any coins. Management noted that every $10,000 change in Bitcoin’s price affects that line by approximately $350 million. MARA ended the quarter with $421.3 million in cash.
MARA Is Spending Heavily on Power and AI
MARA is also moving into energy and is acquiring Long Ridge Energy, a gas-fired power plant, in a $1.5 billion deal, including debt. MARA plans to assume about $900 million of Long Ridge’s debt, and the deal is pending approval from the Federal Energy Regulatory Commission (FERC).
MARA has also secured rights to a 2 GW-powered site in Matagorda County, Texas, with plans to convert most of its capacity for AI and high-performance computing through a joint venture with Starwood. Its Exaion unit already operates an AI cloud in Europe, ensuring customer data complies with European regulations. We also cover seven suppliers benefiting from similar shifts in a free AI infrastructure report.
To finance these ventures, MARA borrowed $600 million using Bitcoin-backed credit facilities with Coinbase (NASDAQ:COIN) and Two Prime at an average interest rate of 7.6%. Lenders can claim the pledged Bitcoin if MARA fails to repay, and the new loans left 54% of MARA’s Bitcoin pledged as collateral.
Management has indicated that MARA will continue to sell Bitcoin selectively to fund operations. Its filings support this, showing MARA held 35,577 BTC at the end of June, down from 49,951 BTC a year earlier, with no updated figures released since its August 6 earnings call.
Saylor’s Buy Hint Cannot Offset MARA’s Exchange Deposits
Companies that send coins to an exchange are often preparing to sell, as exchanges facilitate trades between buyers and sellers. However, companies also move coins for other reasons, like lending them out, using them as collateral, or hedging against price fluctuations. MARA does engage in lending; in the second quarter, it had 4,742 BTC out on loan, generating about $4.3 million in interest.
While the deposits may imply a sale, they don’t prove one. MARA reported Coinbase and Two Prime as lenders for the new credit lines, yet the coins were sent to Binance and Gate. MARA has not disclosed any specific buyers, sale prices, or proceeds, and it hasn’t confirmed the wallet labels Lookonchain assigned.
Saylor’s tweet also warrants close examination. As the head of the largest corporate holder of Bitcoin, he promotes the asset central to his company’s balance sheet, but his post mentions no specific amounts, dates, or funding sources. Strategy Inc. has also sold Bitcoin this year, with $218.4 million sold to date under its Bitcoin monetization program as of its second-quarter report.
During the same period as Strategy Inc.’s last 250 BTC purchase, the company also spent $192.4 million buying back preferred shares instead of buying more Bitcoin. MARA’s deposit of 1,000 BTC is four times that 250 BTC buy.
Is MARA Selling Bitcoin? What Does It Mean for Prices? Signs suggest MARA may be selling, or preparing to sell, some of its Bitcoin. The coins went to trading platforms, and MARA has said it sells Bitcoin selectively. It also has a power plant deal, AI expansion plans, and rising mining costs to fund. Selling Bitcoin can generate cash without diluting shareholders, but it may weigh slightly on Bitcoin prices since the proceeds go into infrastructure.
MARA’s next update should settle it. If the report shows fewer than 35,577 BTC and mentions any sales, the coins were sold; steady holdings, with more coins lent or pledged, would suggest a collateral move. An 8-K filing showing Strategy Inc. buying more than 1,000 BTC would mean one buyer absorbed the miner’s coins. MARA’s shares could still rise on FERC approval or new leases, even if Bitcoin prices stall.
Contact [email protected] for any questions or corrections.
Plug Power jmenovala bývalého provozního ředitele společnosti Ballard Power Systems Leeho Sweetlanda globálním vedoucím inženýrské industrializace, aby zlepšila výrobu, spolehlivost a nákladovou konkurenceschopnost technologií PEM.
Former Ballard Power Systems COO brings extensive experience to advance PEM technology, manufacturing efficiency, and cost competitiveness | Source: Plug Power, Inc.
SLINGERLANDS, N.Y., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced the appointment of Dr. Lee Sweetland as Global Engineering Industrialization Lead. Sweetland will lead the industrialization of the company's proton exchange membrane (PEM) stack technology, advancing manufacturing performance, product reliability, and cost competitiveness across Plug's hydrogen portfolio.
"Electrolyzers are a major driver of Plug's growth, and our ability to execute at scale is just as important as winning new business," said Jose Luis Crespo, Chief Executive Officer of Plug. "Lee brings deep experience in industrializing fuel cell technology and improving manufacturing performance. His leadership will help us maximize our investments, strengthen product competitiveness, and advance our path to profitability."
Plug's electrolyzer business continues to gain traction, with major projects advancing across global markets. In Europe, key projects include Iberdrola's 25 MW facility in Spain, Galp's 100 MW project in Portugal, Carlton Power's 30 MW project in the UK, and the recently announced 280 MW Arcadia eFuels e-SAF project in Denmark. In North America, Plug is supporting the development of Hy2gen's 275 MW Courant project in Québec, while momentum in the Asia-Pacific region includes Orica's 50 MW Hunter Valley project in Australia and a recently announced 1 MW electrolyzer project for HWR Hydrogen in New Zealand.
The Rochester, New York Gigafactory is central to supporting this growth, providing critical PEM stack manufacturing capabilities. Sweetland will focus on maximizing the facility's performance and accelerating next-generation stack production.
Sweetland brings extensive experience in fuel cell technology, advanced manufacturing, and operational transformation. He spent eight years at Ballard Power Systems, most recently serving as Chief Operating Officer, following leadership roles as Chief Transformation Officer and Vice President and Director of Advanced Manufacturing. Previously, he held senior manufacturing and operations positions at Johnson Matthey's fuel cell business.
"Plug has established a strong foundation in PEM technology, with significant manufacturing capabilities and a growing global customer base," said Sweetland. "I'm excited to build on that foundation by strengthening how we design, manufacture, and deliver reliable, cost-competitive technology at scale."
His appointment reinforces Plug's focus on operational discipline, margin improvement, and sustainable, profitable growth.
About Plug Power
Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to customers worldwide across material handling, industrial applications, and energy production, advancing energy independence and decarbonization at scale.
Plug has deployed electrolyzers on five continents, along with more than 76,000 fuel cell systems and 280 fueling stations, and is the world's largest user of liquid hydrogen. Its expanding generation network produces 40 tons of hydrogen per day, supplying large-scale projects that redefine industrial power for customers globally.
Headquartered in New York, with employees and state-of-the-art manufacturing facilities around the world, Plug powers global leaders like BMW, BP, Walmart, Amazon, and Home Depot.
For more information, visit www.plugpower.com.
Foward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which Plug intends to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected impact of Dr. Sweetland’s appointment; improvements in manufacturing performance, product reliability, cost competitiveness, and margins; Plug’s path to profitability; the Rochester, New York Gigafactory and the production of next-generation PEM stacks; and the development, timing, and completion of the electrolyzer projects described in this press release and their conversion into revenue. The words “will”, “expect”, “believe”, “target”, “estimate”, “could”, “should”, “anticipates” and similar expressions identify forward-looking statements. Actual results may differ materially from those expressed or implied due to risks and uncertainties, including: Plug’s ability to integrate Dr. Sweetland and realize the anticipated benefits of his appointment; Plug’s ability to scale PEM stack manufacturing, achieve anticipated cost and margin improvements, and bring next-generation stacks to market on schedule; Plug’s history of operating losses and negative cash flows and its need for additional capital; the risk that customers do not reach final investment decisions, secure financing or permits, or complete projects on schedule, and that projects are delayed, reduced, canceled, or do not convert into revenue; changes in government incentives, tariffs, and trade policy; and the other risks described in Plug’s filings with the Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its other subsequent filings with the SEC. You should not place undue reliance on these statements, which speak only as of the date of this release. Except as required by applicable law, Plug undertakes no obligation to update them.
The EUR/USD pair is held in a tight range ahead of the upcoming statement by Christine Lagarde ahead of the ECB decision.
EUR/USD is stuck in a tight range today, with investors focusing on last week’s macro events, the ongoing performance of the energy markets, and the ongoing protests in France. It is also wavering ahead of a relatively muted week in the economic calendar. It was trading at 1.2225, a few points above this week’s low of 1.1110.
France Protests and Christine Lagarde Statement
EUR/USD pair is attempting to rebound, even as fears of a debt crisis in Europe continue. These fears escalated during the weekend when protests in France turned deadly. The core issue among the protesters is the slashing of the education budget.
The government slashed spending because of the ongoing surge in public debt that has pushed the ten-year yield to 4.88%. This is a high level since the figure bottomed out at 3.216% in March this year. Bond yields in other European countries like Germany and Italy have continued rising.
The EUR/USD pair is also wavering as crude oil prices retreat. Brent, the global benchmark, dropped to $108 from last week’s high of $110. Still, there is a risk that the ongoing oil price retreat is temporary, as fundamentals favor more gains. Iran has continued shooting tankers attempting to cross the strait, while oil inventories have continued falling.
There will be no major macro numbers from the United States this week. The only macro catalyst to watch this week will be a statement from Christine Lagarde, the head of the European Central Bank (ECB). Her statement will come ahead of next week’s interest rate decision, in which officials are expected to leave interest rates unchanged.
The key macro data to watch this week will be the German PPI and European consumer confidence report.
EUR/USD Technical Analysis
EUR/USD chart | Source: TradingView
The four-hour chart shows that the EUR/USD pair has rebounded in the past few days. It has risen from 1.1112 on October 14 to the current 1.1223. A closer look at has formed an inverted head-and-shoulders pattern, a popular bullish reversal sign.
The pair has jumped above the 50-period Exponential Moving Average (EMA) and the Strong, Pivot, Reverse level of the Murrey Math Lines tool. Therefore, the pair will likely have a bullish breakout, potentially to the psychological level of 1.3000. A move above that level will point to more gains towards the Ultimate Resistance level of 1.1352.
Biogen představí 76týdenní data z klinické studie fáze 3, podle nichž přípravek EMPAVELI u pacientů s C3G a primární IC-MPGN trvale snížil proteinurii a stabilizoval eGFR.
Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.
Key presentations include new EMPAVELI data showing sustained proteinuria reduction and continued estimated glomerular filtration rate (eGFR) stabilization in patients with C3G and primary IC-MPGN over 76 weeks. This data follows the recent U.S. Food and Drug Administration update to expand EMPAVELI’s indication to include reducing the loss of kidney function, making it the first and only therapy approved to reduce both proteinuria and the loss of kidney function in adults and adolescents aged 12 years and older with C3G and primary IC-MPGN. Additional presentations on pegcetacoplan and felzartamab will provide insights into the management and understanding of multiple immune-mediated kidney diseases.
“Data shared this week further reinforce EMPAVELI’s long-term efficacy and safety profile, while new scientific insights highlight the significant unmet needs and lack of proven therapies in AMR, supporting the potential of felzartamab to address critical gaps in transplant care and other kidney diseases,” said Daniel Quirk, MD, Chief Medical Officer at Biogen. “Biogen’s current research now spans seven different kidney diseases, and we’re proud to share updates on our portfolio’s progress with the nephrology community at this premier scientific congress.”
Biogen will also be hosting two exhibitor spotlights and 9 poster presentations related to both EMPAVELI and felzartamab. Felzartamab is currently being studied in three Phase 3 trials, TRANSCEND (NCT06685757) for AMR in adult kidney transplant recipients, PREVAIL (NCT06935357) in IgA nephropathy, and PROMINENT (NCT06962800) in primary membranous nephropathy, and a Phase 2 trial in microvascular inflammation (NCT07219043). Data from the TRANSCEND study is expected in H1 2027.
American Society of Nephrology Congress presentations include:
Oral Presentation: “Pegcetacoplan for 76 weeks maintains proteinuria reduction and eGFR stabilization for pediatric patients: VALIANT+VALE subgroup analysis,” on Thursday, October 22 at 4:30 PM MDT.Exhibitor Spotlight: “Beyond B Cells: Pioneering Plasmablast and Plasma Cell Targeting in Immunoglobulin A Nephropathy and Primary Membranous Nephropathy,” on Friday, October 23 at 12:00 PM MDT.Exhibitor Spotlight: A Treatment for Two Glomerular Diseases: C3G and Primary IC-MPGN on Friday, October 23 at 1:00 PM MDT.Oral Presentation: “Pegcetacoplan for 76 weeks maintained proteinuria reduction and stabilized kidney function in C3G or primary IC-MPGN,” on Saturday, October 24 at 4:30 PM MDT.Poster Presentations: “TRANSTELLAR: An Open-Label, Long-Term Extension Study of Felzartamab in Participants With Antibody-Mediated Rejection or Microvascular Inflammation,” on Thursday, October 22 at 10:00 AM MDT.“Epidemiology of Focal Segmental Glomerulosclerosis: A Systematic Review of Studies Published From 2020 to 2025,” on Friday, October 23 at 10:00 AM MDT.“Humanistic Burden of Focal Segmental Glomerulosclerosis: Findings From a Systematic Review,” on Friday, October 23 at 10:00 AM MDT.“Nephrologist Perceptions of Unmet Needs in the Treatment of Antibody-Mediated Rejection: Results From a Real-World Survey in Germany and the United States,” on Friday, October 23 at 10:00 AM MDT.“Effect of Current Antibody-Mediated Rejection (AMR) Treatments on Microvascular Inflammation (MVI) in Kidney Transplant Recipients: A Rapid Literature Review (RLR) and Meta-Analysis," on Friday, October 23 at 10:00 AM MDT.“Evaluation of Pegcetacoplan in Adults and Adolescents With Focal Segmental Glomerulosclerosis: Rationale and Design of a Sequential Phase 2/3 Study,” on Saturday, October 24 at 10:00 AM MDT.“User Experience With Pegcetacoplan On-Body Injector in Patients With C3G or Primary IC-MPGN,” on Saturday, October 24 at 10:00 AM MDT.“A Phase 2, Open-Label Trial to Examine Kidney Tissue–Specific Effects of Felzartamab in Adults With IgAN,” on Saturday, October 24 at 10:00 AM MDT.“Pharmacokinetic (PK), Pharmacodynamic (PD) and Exposure–Response (E–R) Analysis of Pegcetacoplan in C3 Glomerulopathy (C3G) & Primary Immune-Complex Membranoproliferative Glomerulonephritis (pIC-MPGN),” on Saturday, October 24 at 10:00 AM MDT. About EMPAVELI® (pegcetacoplan)
EMPAVELI® (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can contribute to the onset and progression of serious diseases.
EMPAVELI is indicated in the United States for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), to reduce proteinuria and the loss of kidney function. EMPAVELI is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
About C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G and primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis therapy.1-3 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence.4
About Felzartamab
Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on plasma cells, plasmablasts, and natural killer, or NK, cells. Felzartamab is a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases. Felzartamab has been shown in clinical studies to selectively deplete CD38+ plasma cells, which may allow applications that ultimately improve clinical outcomes in a broad range of diseases driven by pathogenic antibodies. Felzartamab was originally developed by MorphoSys AG (now MorphoSys GmbH, a Novartis company). Biogen owns exclusive worldwide rights to felzartamab.
Felzartamab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.
U.S. Important Safety Information for EMPAVELI
BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.
Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, unless the risks of delaying therapy with EMPAVELI outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.Patients receiving EMPAVELI are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.
Because of the risk of serious infections caused by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.
CONTRAINDICATIONS
Hypersensitivity to pegcetacoplan or to any of the excipientsFor initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B WARNINGS AND PRECAUTIONS
Serious Infections Caused by Encapsulated Bacteria
EMPAVELI, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria.
Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, according to the most current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.
Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing treatment for serious infections.
EMPAVELI is available only through a restricted program under a REMS.
EMPAVELI REMS
EMPAVELI is available only through a restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria. Notable requirements of the EMPAVELI REMS include the following:
Under the EMPAVELI REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, prescribe antibacterial drug prophylaxis if patients’ vaccine status is not up to date and treatment must be started urgently, and provide instructions to always carry the Patient Safety Card both during treatment, as well as for 2 months following last dose of EMPAVELI. Pharmacies that dispense EMPAVELI must be certified in the EMPAVELI REMS and must verify prescribers are certified.
Further information is available at www.empavelirems.com or 1-888-343-7073.
Infusion-Related Reactions
Systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria, pyrexia) have occurred in patients treated with EMPAVELI, which may resolve after treatment with antihistamines. Cases of anaphylaxis leading to treatment discontinuation have been reported. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.
Interference with Laboratory Tests
There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.
ADVERSE REACTIONS
Most common adverse reactions in adult and pediatric patients 12 years of age and older with C3G or primary IC-MPGN (incidence ≥10%) were infusion-site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea.
USE IN SPECIFIC POPULATIONS
Females of Reproductive Potential
EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.
Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.
About the Sobi® and Apellis (now part of Biogen) Collaboration
Apellis (now part of Biogen) and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan. Apellis (now part of Biogen) has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, relating to, among others, the potential clinical effects of EMPAVELI and felzartamab; the potential benefits, safety and efficacy of EMPAVELI in patients with C3G or Primary IC-MPGN and of felzartamab in late antibody-mediated rejection in adult kidney transplant recipients, and in patients with IgAN, primary membranous nephropathy, and microvascular inflammation; the clinical development programs for EMPAVELI and felzartamab; advancing our anti-CD38 platform and our nephrology research and development programs; the potential of our commercial business and pipeline programs, including EMPAVELI and felzartamab; potential of, and expectations for the design, timing and results of our clinical trial programs, including the long-term EMPAVELI Phase 3 results, as well as the TRANSCEND, PREVAIL and PROMINENT studies; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.
These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.
These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.
References:
Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation. Clinical Journal of the American Society of Nephrology. August 2024; 19(8)1005-1015.
Akcie společnosti Applied Materials od začátku července klesly o 37,05 %, přesto tržby ve třetím fiskálním čtvrtletí meziročně vzrostly o 24,8 % na 9,12 miliardy USD.
Applied Materials just suffered one of its steepest drops in years, yet analysts keep raising their earnings estimates and some price targets sit nearly double the current share price. Here is what the disconnect reveals about where semiconductor equipment spending…
Applied Materials (NASDAQ:AMAT | AMAT Price Prediction) is now priced at $409.29. The average analyst price target stands at $627.83, meaning 53.4% upside.
Applied makes the deposition, etch and inspection tools used to build virtually every new chip. AI infrastructure demand drove fiscal third-quarter revenue to $9.12 billion, up 24.8% year over year. Management guided the current quarter to about $10.25 billion.
The most bullish firms, including H.C. Wainwright and Susquehanna, have $900 targets. Those sit about 119.9% above the current price. Consensus upside stands above 40%.
Investor Day Silence Turned a Pullback Into a 37% Rout
The biggest hit came at Applied’s investor day, when the company declined to provide an industry spending forecast. Shares fell as much as 9% intraday, and the stock lost 19.28% over the past week. Since the start of July, Applied has dropped 37.05%. That leaves it 44.6% below its 52-week high of $738.88.
The first signs showed after the August earnings report. Shares fell about 4% even though guidance beat consensus. Morgan Stanley summed it up: “AMAT’s earnings were good, but not great.” Peers fell about 4% on investor day, so sector weakness made a company-specific hit worse.
33 of 40 Analysts Rate It a Buy as Estimates Climb
Of the 40 analysts who cover Applied, 4 rate it Strong Buy, 29 rate it Buy and 7 rate it Hold. None rate it Sell. Estimates rose while the stock fell. The fiscal 2027 EPS consensus is $18.4672, up from $16.7456 90 days ago. Over the past 30 days, analysts made three upward revisions and no cuts. The stock trades at about 22 times that figure.
Management guided fourth-quarter EPS to about $4.02. DRAM revenue, including HBM packaging, grew 52% year over year. Packaging revenue should grow more than 70% in calendar 2026. Leading-edge logic, DRAM and advanced packaging should account for about 80% of equipment growth.
The $900 camp argues that Applied is well placed in tools for Gate-All-Around transistors, backside power and HBM packaging. CEO Gary Dickerson set the timeline on the earnings call: “Based on the unprecedented visibility we’re receiving from our customers, we expect another strong record year in 2027.”
Lam, KLA and Teradyne Sold Off Too, but Applied Fell Hardest
The whole group fell over the past week, but Applied fell the most.
Lam Research (NASDAQ:LRCX) lost 14.74% to $263.94. Its average target is $375.81, meaning 42.4% upside. Twenty-nine of 35 analysts rate it Buy or Strong Buy.
KLA (NASDAQ:KLAC) dropped 12.82% to $165.74. Its target of $232.77 meaning 40.4% upside. Analysts are more cautious here, with 10 of 29 at Hold.
Teradyne (NASDAQ:TER) slid 15.33% to $325. Its target of $446.47 meaning 37.4% upside, and 12 of 17 analysts are bullish.
Applied has the largest consensus upside in the group. All of these targets are estimates, and they could fall if spending expectations drop.
A 59.83% Gain This Year Survives the Drawdown
Applied trades at $409.29. The average target from 40 analysts is $627.83, meaning 53.4% upside. Targets often lag sharp price moves, so treat that number as one input among several.
Even after the drop, the stock is up 59.83% year to date. The S&P 500 is up 11.93%. Over one year, Applied shares are up 80.75%.
Applied Materials Looks Like an Overcorrection Worth Researching
Applied Materials’ upside case strengthens if DRAM and leading-edge logic deliver the second-half surge management promised and fiscal 2027 earnings land near the $18.4672 consensus. At a forward P/E of about 23, that growth looks undervalued.
The upside story weakens if the investor day silence means equipment spending is peaking. Management claims multi-year visibility yet held back an industry forecast. China fell to 28% of revenue from 35%, and the Other segment’s loss widened to $118 million. A slowdown in AI capex would pull targets down toward the share price.
The data leans positive. Estimates are rising while the share price falls. Applied’s upside is also the largest of any peer. The next earnings report and its 2027 outlook will test that view. (We reverse-engineered what the biggest semiconductor winners looked like early on in a free guide you can download here.)
Contact [email protected] for any questions or corrections.
Čtyři analytici během 30 dnů snížili odhad celoročního zisku společnosti Camping World (CWH) z 0,36 USD na 0,20 USD na akcii; Zacks jí udělil hodnocení č. 5 („silně prodávat“).
The stock market can be a cruel place sometimes. Just when you think things can't get any worse, the selling continues. That's especially true for companies that are struggling to find their footing in an economy where consumers are becoming increasingly selective about how they spend their money. Big-ticket discretionary purchases are particularly vulnerable. When financing costs are high and consumers are feeling the pinch, buying a new recreational vehicle isn't exactly at the top of everyone's priority list.
That's creating some serious headaches for today's Bear of the Day, Zacks Rank #5 (Strong Sell) Camping World ((CWH - Free Report) ). Camping World Holdings is one of the nation's largest retailers of recreational vehicles. The company operates a network of RV dealerships, offering new and used motorhomes, travel trailers, and fifth wheels. It also provides financing, insurance, service, maintenance, and accessories through its Camping World and Good Sam brands.
It's a business that benefited tremendously from the pandemic-era boom in outdoor recreation. Consumers had money to spend, financing was cheap, and RV sales were booming. Unfortunately, that environment has changed considerably. Higher borrowing costs, affordability pressures, and a more cautious consumer have created a much more challenging backdrop for the RV industry.
That weakness is showing up where it matters most to us here at Zacks. I'm talking about earnings estimates. Over the last thirty days, four analysts have lowered their earnings estimates for the current year. Not a single analyst has increased estimates during that period. The bearish sentiment has pushed the Zacks Consensus Estimate for the current year down from 36 cents to just 20 cents per share. That's a decline of nearly 44% in only two months.
Next year's numbers aren't looking much better. Four analysts have also cut their estimates for the following year, pushing the consensus down from 87 cents to 56 cents per share. That's a reduction of more than 35%. Those downward revisions are the primary reason Camping World currently carries a Zacks Rank #5 (Strong Sell).
The industry backdrop isn't doing the company any favors either. Camping World is part of the Automotive – Original Equipment industry, which ranks in the Bottom 13% of our Zacks Industry Rank. That's not exactly the sort of neighborhood I want to be shopping in when the broader market is already dealing with uncertainty.
There are a few stocks in this industry that are in the good graces of our Zacks Rank. These include Zacks Rank #2 (Buy) stocks Adient ((ADNT - Free Report) ) and ChargePoint ((CHPT - Free Report) )
BioNTech na kongresu ESMO 2026 představí první data ze studie fáze II kombinace pumitamigu a docetaxelu u metastatického nemalobuněčného karcinomu plic po předchozí chemoimunoterapii.
Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic non-small cell lung cancer following prior immunotherapy plus chemotherapy Global Phase 2 data for pumitamig plus elfetabart drozuntecan, a B7-H3-targeting antibody-drug conjugate, expand the body of evidence for this novel-novel combination in multiple advanced solid tumors Updates from across the pumitamig clinical development program underscore its pan-tumor potential, including in lung and breast cancer patients with brain metastases and patients with neuroendocrine neoplasms MAINZ, Germany, October 19, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data from its late-stage oncology pipeline with 16 abstracts spanning the Company’s tumor focus areas, including lung and breast cancer, at the European Society for Medical Oncology (“ESMO”) 2026 Congress held in Madrid, Spain, from October 23–27, 2026.
Key oral presentations will focus on clinical data for pumitamig (BNT327/BMS986545), a PD-L1×VEGF-A bispecific immunomodulator being jointly developed with Bristol Myers Squibb (“BMS”), plus docetaxel in second-line metastatic non-small cell lung cancer (“NSCLC”) as well as pumitamig in combination with elfetabart drozuntecan (elfe-D or BNT324/DB-1311), a B7-H3-targeting antibody-drug conjugate (“ADC”) being jointly developed with Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), across several advanced solid tumors – complementing the data in lung cancer presented earlier this year. This new clinical data advances BioNTech’s differentiated novel-novel combination approach. Additional presentations for pumitamig and ADCs reflect BioNTech’s tumor-focused strategy aimed at addressing significant unmet medical needs across various stages of disease.
“Sixteen abstracts spanning ten tumor types – this is our significant data presence at this year’s ESMO. It demonstrates momentum for our late-stage oncology pipeline across strategic key assets and tumor areas such as lung and breast cancer,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “For our PD-L1xVEGF immunomodulator pumitamig, we will be sharing new data that highlights its pan-tumor potential, including in challenging treatment settings where patients still show limited benefit from current standard of care therapies. Our goal is to establish pumitamig as a potential backbone for future combination regimens across multiple tumor types, including novel-novel treatment combinations. At this year's conference, we will showcase the potential of this approach in two presentations featuring ADC combinations, aimed to further enhance outcomes for patients.”
Highlights from BioNTech’s presentations at ESMO 2026:
Pumitamig – an investigational PD-L1×VEGF-A bispecific immunomodulator:
NSCLC: First data from the global ROSETTA Lung-107 Phase 2 clinical trial (NCT06841055) evaluating pumitamig plus docetaxel in patients with metastatic NSCLC whose disease progressed after immunotherapy plus chemotherapy will be presented in a late-breaking oral presentation. This clinical trial extends evidence for pumitamig’s non-small cell lung cancer development program into the second-line setting where there remains high unmet medical need, representing the third global Phase 2 dataset in lung cancer.SCLC and TNBC with brain metastases: Results from a subgroup analysis of two Phase 2 clinical trials (NCT06449209; NCT06449222) evaluating pumitamig plus chemotherapy in patients with small cell lung cancer (“SCLC”) or triple-negative breast cancer (“TNBC”) showed systemic efficacy generally consistent in patients with and without brain metastases. These early data suggest intracranial efficacy and add to the clinical evidence for pumitamig plus chemotherapy in tumor types where brain metastases often occur and remain challenging to treat as many systemic therapies have limited ability to cross the blood-brain barrier.2L neuroendocrine neoplasms: First results from a Phase 2 clinical trial conducted in China (NCT05879055) evaluating pumitamig plus FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy in patients with unresectable neuroendocrine neoplasms after first-line platinum-based chemotherapy showed encouraging preliminary antitumor activity and a manageable safety profile. These data broaden the clinical evidence for pumitamig across diverse tumor types. Novel-novel combination of pumitamig and elfetabart drozuntecan, an investigational B7-H3-targeted ADC:
Advanced solid tumors: First results from the global Phase 2 clinical trial (NCT06953089) evaluating pumitamig in combination with elfetabart drozuntecan in patients with advanced solid tumors showed encouraging preliminary antitumor activity across multiple tumor types and a manageable safety profile, with minimal overlapping toxicities observed. These data support the potential of pumitamig as a backbone in novel treatment combinations, furthering BioNTech’s combination strategy across multiple tumor types with high unmet medical need. BioNTech is advancing a diversified oncology pipeline spanning next-generation immunomodulators, ADCs, and mRNA cancer immunotherapies, both as monotherapies and novel-novel combination approaches. With 13 ongoing Phase 3 trials as well as multiple novel-novel combination trials, BioNTech is focused on developing innovative approaches to address the challenges of cancer treatment among the Company’s tumor focus areas from early- to late-stage conditions.
All abstracts are available through the ESMO website. Further information on BioNTech’s oncology pipeline can be accessed here.
Full presentation details:
CandidateAbstract TitleAbstract Number/Presentation DetailsPumitamig A global phase 2, open-label trial of pumitamig (PD-L1 × VEGF-A bsAb) + docetaxel post-chemoimmunotherapy in mNSCLC: First data from ROSETTA Lung-107Abstract #LBA76
Rapid Oral Presentation
NSCLC, Metastatic
Oct 25, 2026: 8:30 - 10:00am CETEfficacy of pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in patients with SCLC or TNBC with brain metastases: A subgroup analysis of two phase 2 trialsAbstract #1951RO
Rapid Oral Presentation
Investigational Immunotherapy
Oct 24, 2026: 8:30 - 10:00am CESTFirst results from a phase 2 trial of second-line pumitamig (PD-L1 × VEGF-A bsAb) plus chemotherapy in unresectable neuroendocrine neoplasmsAbstract #2393O
Proffered Paper Presentation
NETs and Endocrine Tumours
Oct 26, 2026: 10:15 - 11:45am CETROSETTA RCC-208: A phase 1/2, open-label, randomized study of pumitamig alone or in combination with ipilimumab or cabozantinib in advanced renal cell carcinoma (RCC)Abstract #3639TiP
Poster Presentation
Renal Cancer
Oct 23, 2026: 3:15 - 4:00pm CESTROSETTA Gastric-204: A randomized, phase 2/3 study of first-line (1L) pumitamig + chemotherapy versus nivolumab (NIVO) + chemotherapy in advanced or metastatic gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJC), or esophageal adenocarcinoma (EAC)Abstract #3081eTiP
ePoster Presentation
Oesophagogastric Cancer
Oct 23 - 27, 2026A phase 1/2 trial of first-line pumitamig monotherapy or pumitamig plus ipilimumab in advanced or unresectable hepatocellular carcinoma (ROSETTA HCC-206)Abstract #1762eTiP
ePoster Presentation
Hepatocellular Carcinoma
Oct 23 - 27, 2026Pumitamig + elfetabart drozuntecanElfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) + pumitamig (PD-L1 x VEGF-A bsAb) in patients with advanced solid tumors: First results from a global phase 2 trialAbstract #999O
Proffered Paper Presentation
Developmental Therapeutics
Oct 24, 2026: 2:45 - 4:15pm CESTPumitamig + trastuzumab pamirtecanPumitamig + trastuzumab pamirtecan (T-Pam) in patients (pts) with HR+, HER2-low advanced/metastatic breast cancer (a/mBC): Phase 1 results of a phase 1/2, open-label trial (BNT323-03)Abstract #1777P
Poster Presentation
HER2+ Breast Cancer
Oct 24, 2026: 12:00 - 12:45pm CESTElfetabart drozuntecanElfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) in patients with platinum-resistant ovarian cancer (PROC): Efficacy and safety data from a Phase 2 dose optimization cohortAbstract #1255P
Poster Presentation
Gynaecological Cancers
Oct 26, 2026: 12:00 - 12:45pm CETBNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate (ADC), with docetaxel as treatment of patients (pts) with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC)Abstract #2300TiP
Poster Presentation
Metastatic Prostate Cancer
Oct 23, 2026: 3:15 - 4:00pm CESTGotistobartGotistobart plus pembrolizumab demonstrates durable antitumor activity in advanced melanoma refractory or resistant to both prior anti-CTLA-4 and anti-PD-(L)1 therapiesAbstract #2106P
Poster Presentation
Melanoma
Oct 24, 2026: 12:00 - 12:45 pm CESTBNT317BNT317: An anti–PD-1 × CD39 bispecific antibody demonstrating preclinical antitumor activityAbstract #420P
Poster Presentation
Basic Science
Oct 23, 2026: 3:15 - 4pm CESTBeruzatatug pelitecan (YL202/BNT326)Clinical outcomes of YL202/BNT326 (HER3 ADC) in advanced/metastatic HR+/HER2-null/low breast cancer (BC) in chemotherapy (chemo)-naïve and exposed patients (pts)Abstract #1881P
Poster Presentation
HR+ Breast Cancer
Oct 24, 2026: 12:00 - 12:45pm CESTBNT329A first-in-human phase 1/2 dose-escalation and expansion trial of BNT329 (an anti-carbohydrate antigen 19-9 antibody-drug conjugate [CA19-9 ADC]) in patients (pts) with advanced solid tumors that express CA19-9Abstract #1076TiP
Poster Presentation
Developmental Therapeutics
Oct 23, 2026: 3:15 - 4:00 pm CESTHealth Economics and Outcomes Research (HEOR)Real-world progression-free survival (rwPFS) from chemotherapy initiation in patients with HR+/HER2– metastatic breast cancer (mBC) in the USAbstract #1880P
Poster Presentation
HR+ Breast Cancer
Oct 24, 2026: 12:00 - 12:45pm CESTReal-world outcomes with first-line pembrolizumab-based chemoimmunotherapy in patients with advanced/metastatic non-small cell lung cancer in the USAAbstract #2705P
Poster Presentation
NSCLC, Metastatic
Oct 26, 2026: 12:00 - 12:45pm CET About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.
For more information, please visit www.BioNTech.com.
BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the initiation, timing, progress and results of BioNTech’s research and development programs in oncology, including the targeted timing and number of additional potentially registrational trials; BioNTech’s and its collaborators’ current and future preclinical and clinical trials in oncology, including the investigational bispecific immunomodulator pumitamig (BNT327/BMS986545), the investigational anti-CTLA-4 antibody gotistobart (BNT316/ONC-392), the investigational B7H3-targeting ADC elfetabart drozuntecan (BNT324/DB-1311) alone and in combination with pumitamig, the investigational HER2-targeting ADC trastuzumab pamirtecan (BNT323/DB-1303) in combination with pumitamig, the investigational anti-PD-1×CD39 antibody BNT317, the investigational HER3-targeting ADC Beruzatatug pelitecan (Beru-Pel/YL202/BNT326), and the investigational CA19-9-targeting ADC BNT329; the nature and characterization of and timing for release of clinical data across BioNTech’s platforms, which is subject to peer review, regulatory review and market interpretation; the planned next steps in BioNTech’s pipeline programs, including, but not limited to, statements regarding timing or plans for initiation or enrollment of clinical trials, or submission for and receipt of product approvals and potential commercialization with respect to BioNTech’s product candidates; and the potential safety and efficacy of BioNTech’s product candidates. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the ability to produce comparable clinical results in future clinical trials; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; discussions with regulatory agencies regarding timing and requirements for additional clinical trials; the impact of tariffs and escalations in trade policy; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
Zasvěcená osoba Phillip Carrai prodala 6 500 akcií společnosti Kratos Defense & Security Solutions za 259 090 USD v rámci předem sjednaného obchodního plánu podle pravidla SEC 10b5-1.
Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS – Get Free Report) insider Phillip Carrai sold 6,500 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $39.86, for a total value of $259,090.00. Following the completion of the transaction, the insider directly owned 169,196 shares in the company, valued at approximately $6,744,152.56. This represents a 3.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kratos Defense & Security Solutions Price Performance Shares of NASDAQ:KTOS opened at $40.42 on Monday. The company has a market capitalization of $7.59 billion, a PE ratio of 237.76 and a beta of 1.11. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.54 and a quick ratio of 4.99. The business has a fifty day moving average price of $49.27 and a two-hundred day moving average price of $54.52. Kratos Defense & Security Solutions, Inc. has a 1 year low of $37.84 and a 1 year high of $134.00.
Kratos Defense & Security Solutions (NASDAQ:KTOS – Get Free Report) last announced its earnings results on Tuesday, August 4th. The aerospace company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.07. The firm had revenue of $458.80 million during the quarter, compared to analyst estimates of $410.36 million. Kratos Defense & Security Solutions had a return on equity of 3.07% and a net margin of 2.03%. The business’s revenue was up 30.5% compared to the same quarter last year. During the same period last year, the firm posted $0.11 EPS. Analysts forecast that Kratos Defense & Security Solutions, Inc. will post 0.58 earnings per share for the current year.
Institutional Investors Weigh In On Kratos Defense & Security Solutions Large investors have recently added to or reduced their stakes in the company. AdvisorNet Financial Inc grew its holdings in Kratos Defense & Security Solutions by 15.8% during the 1st quarter. AdvisorNet Financial Inc now owns 1,392 shares of the aerospace company’s stock valued at $98,000 after buying an additional 190 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its position in shares of Kratos Defense & Security Solutions by 3.5% during the first quarter. Fifth Third Wealth Advisors LLC now owns 6,035 shares of the aerospace company’s stock valued at $426,000 after buying an additional 205 shares during the period. Cornell Pochily Investment Advisors Inc. increased its position in shares of Kratos Defense & Security Solutions by 2.6% during the first quarter. Cornell Pochily Investment Advisors Inc. now owns 9,936 shares of the aerospace company’s stock valued at $701,000 after buying an additional 250 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Kratos Defense & Security Solutions by 61.9% in the second quarter. Versant Capital Management Inc now owns 696 shares of the aerospace company’s stock worth $35,000 after buying an additional 266 shares in the last quarter. Finally, Vision Retirement LLC lifted its holdings in shares of Kratos Defense & Security Solutions by 288.2% in the first quarter. Vision Retirement LLC now owns 427 shares of the aerospace company’s stock worth $30,000 after buying an additional 317 shares in the last quarter. Hedge funds and other institutional investors own 75.92% of the company’s stock. Analysts Set New Price Targets KTOS has been the subject of a number of research analyst reports. Wedbush assumed coverage on shares of Kratos Defense & Security Solutions in a report on Tuesday, June 30th. They set an “outperform” rating and a $85.00 price objective for the company. Stifel Nicolaus dropped their target price on shares of Kratos Defense & Security Solutions from $134.00 to $115.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Citigroup reissued a “market outperform” rating on shares of Kratos Defense & Security Solutions in a research report on Tuesday, July 28th. Barclays started coverage on shares of Kratos Defense & Security Solutions in a research report on Friday, October 9th. They set an “overweight” rating and a $90.00 target price for the company. Finally, Canaccord Genuity Group raised their price target on shares of Kratos Defense & Security Solutions from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kratos Defense & Security Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $94.16.
View Our Latest Analysis on Kratos Defense & Security Solutions
Kratos Defense & Security Solutions Company Profile (Get Free Report)
Kratos Defense & Security Solutions, Inc is a technology company that develops products and systems for national security, defense, and commercial applications. Its offerings support unmanned systems, satellite communications, space operations, missile defense, hypersonic programs, launch systems, and command, control, communications, computers, intelligence, surveillance, and reconnaissance (C5ISR) missions.
The company provides unmanned aerial, ground, and maritime systems, including target drones and other autonomous platforms used for testing, training, and operational missions.
Featured Articles Five stocks we like better than Kratos Defense & Security Solutions These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Kratos Defense & Security Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kratos Defense & Security Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
USD/JPY se drží nad 20denním EMA na úrovni 157,87; průraz ze symetrického trojúhelníku může otevřít cestu k 160,00, zatímco při poklesu hrozí návrat k 156,00.
The Japanese Yen (JPY) is down against its major currency peers at the start of the week. In the European trade, the US Dollar (USD) is up 0.17% at around 158.25 against the Asia-Pacific currency.
Japanese Yen Price Today
The table below shows the percentage change of Japanese Yen (JPY) against listed major currencies today. Japanese Yen was the weakest against the Australian Dollar.
USDEURGBPJPYCADAUDNZDCHFUSD0.16%-0.05%0.11%-0.42%-0.58%-0.27%0.12%EUR-0.16%-0.21%-0.02%-0.55%-0.74%-0.43%-0.02%GBP0.05%0.21%0.17%-0.36%-0.54%-0.24%0.18%JPY-0.11%0.02%-0.17%-0.51%-0.77%-0.36%0.05%CAD0.42%0.55%0.36%0.51%-0.14%0.16%0.56%AUD0.58%0.74%0.54%0.77%0.14%0.31%0.72%NZD0.27%0.43%0.24%0.36%-0.16%-0.31%0.41%CHF-0.12%0.02%-0.18%-0.05%-0.56%-0.72%-0.41%
The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Japanese Yen from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent JPY (base)/USD (quote).
The Japanese currency is under pressure even as Bank of Japan (BoJ) Governor Kazuo Ueda signals that the underlying inflation is close to the 2% target. However, Ueda stated that “anchoring core inflation near 2% growth more crucial.”
Ueda leans cautiously hawkish as inflation loop firms and JGB guidance stays vagueUeda scores 7/10 on FXS Speechtracker versus a 7.4/10 historic average, but the emphasis on “underlying inflation near 2%” and a positive wages–prices loop marks a mildly hawkish tilt for the YEN. The focus on demand-led inflation from robust global AI-related capex, tight domestic labor markets, and the warning that long-term rates could rise if the policy rate is not adjusted properly all support a gradual normalization bias that can underpin YEN yields.
At the same time, Ueda stresses that financial conditions remain accommodative, confirms no shift in the fundamental bond taper approach, and refuses to preannounce emergency JGB measures, which tempers the hawkish tone. For FX, the combination of firmer inflation dynamics and data-dependent rate guidance is modestly supportive for the YEN, but the lack of explicit tightening timelines and the pledge to stabilize the JGB market limit immediate upside and keep carry trades only cautiously challenged.
This week, investors will focus on National Consumer Price Index (CPI) data for September, which will be released on Friday.
Meanwhile, the US Dollar trades slightly higher as French fiscal concerns resurface. As of writing, 10-year French bond yields are up 0.56% to near 4.88% amid civil unrest in France. The US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, trades 0.12% higher to near 101.90.
USD/JPY Technical Analysis
In the daily chart, USD/JPY trades at 158.20, holding the short-term Moving Average Exponential (20, close) at 157.87. The pair is inside the Symmetrical Triangle formation, reflecting broader indecisiveness among investors.
The Relative Strength Index (14) at 53.92 sits in neutral-positive territory, hinting that upside momentum is steady rather than stretched, leaving room for the pair to consolidate gains while staying supported by the underlying trend.
On the downside, initial support is reinforced by the 20-period exponential moving average near 157.87. A major action in the pair will likely only after a decisive break of the volatility contraction pattern on either side. The pair could slide to 156.00 if the formation breaks on the downside. Looking up, the pair would aim to revisit the 160.00 hurdle if it manages to break the immediate hurdle near 159.00.
(The technical analysis of this story was written with the help of an AI tool. Know more.)
Economic Indicator
National CPI ex Fresh Food (YoY)
Japan’s National Consumer Price Index (CPI), released by the Statistics Bureau of Japan on a monthly basis, measures the price fluctuation of goods and services purchased by households nationwide excluding fresh food, whose prices often fluctuate depending on the weather. The YoY reading compares prices in the reference month to the same month a year earlier. Generally, a high reading is seen as bullish for the Japanese Yen (JPY), while a low reading is seen as bearish.
SteelPeak Wealth ve 3. čtvrtletí snížila svou pozici v American Electric Power o 16,3 % prodejem 5 022 akcií; nadále drží 25 762 akcií v hodnotě 3,056 mil. USD.
SteelPeak Wealth LLC cut its stake in American Electric Power Company, Inc. (NASDAQ:AEP – Free Report) by 16.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,762 shares of the company’s stock after selling 5,022 shares during the period. SteelPeak Wealth LLC’s holdings in American Electric Power were worth $3,056,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC grew its holdings in American Electric Power by 118.0% during the 2nd quarter. Elevation Wealth Partners LLC now owns 194 shares of the company’s stock worth $27,000 after acquiring an additional 105 shares in the last quarter. Costello Asset Management INC increased its position in shares of American Electric Power by 100.0% in the 1st quarter. Costello Asset Management INC now owns 200 shares of the company’s stock worth $26,000 after purchasing an additional 100 shares during the last quarter. Parvin Asset Management LLC acquired a new stake in shares of American Electric Power in the 2nd quarter valued at about $27,000. Caitlin John LLC acquired a new stake in shares of American Electric Power in the 2nd quarter valued at about $27,000. Finally, Premier Financial Group acquired a new stake in shares of American Electric Power in the 2nd quarter valued at about $28,000. 75.24% of the stock is currently owned by institutional investors.
American Electric Power News Roundup Here are the key news stories impacting American Electric Power this week:
Positive Sentiment: Growth opportunity from Google power agreement: AEP plans to invest approximately $4 billion in a Wyoming fuel-cell power project under a 20-year agreement with Google. The contract could provide long-term revenue visibility and position AEP to benefit from rising electricity demand from artificial-intelligence and data-center operations. AEP Plans $4 Billion Fuel Cell Power Plant for Google Positive Sentiment: Additional generation capacity: AEP also agreed to purchase up to 1.6 gigawatts of Mainspring linear generators, supporting its ability to serve large commercial loads and potentially expand regulated and contracted earnings over time. AEP in deal to buy up to 1.6 GW of Mainspring linear generators Positive Sentiment: Evercore remains bullish: Evercore ISI maintained a Buy rating on AEP, reinforcing the positive view around the company’s growth prospects and demand from large electricity customers. Evercore ISI remains a Buy on AEP Neutral Sentiment: KeyCorp’s estimates were mixed: KeyCorp kept an Overweight rating and a $133 price target while raising its FY2026 EPS estimate to $6.42 and FY2027 estimate to $6.84. However, it lowered its Q3 estimate to $2.09 and made a minor reduction to its FY2030 forecast. KeyCorp estimate changes for AEP Neutral Sentiment: Analyst views remain divided: Goldman Sachs reaffirmed a Hold rating, tempering the more optimistic signal from Evercore and KeyCorp. Goldman Sachs reaffirms Hold rating on AEP Negative Sentiment: Execution and financing risk: The $4 billion fuel-cell investment and generator purchases require significant capital. Investors may remain concerned about construction execution, returns on investment, and the effect of added spending on AEP’s balance sheet. Insider Activity In other news, CAO Kate Dixon sold 2,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $125.00, for a total transaction of $250,000.00. Following the completion of the transaction, the chief accounting officer owned 15,856 shares of the company’s stock, valued at approximately $1,982,000. The trade was a 11.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.05% of the company’s stock. Analysts Set New Price Targets Several equities analysts have recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of American Electric Power in a research report on Wednesday, September 9th. Weiss Ratings reissued a “buy (b)” rating on shares of American Electric Power in a report on Thursday, August 27th. Barclays lowered their price objective on American Electric Power from $129.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, October 12th. Citigroup cut their price objective on American Electric Power from $148.00 to $142.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Finally, UBS Group set a $139.00 target price on American Electric Power in a report on Monday, September 21st. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $138.91.
Read Our Latest Stock Analysis on AEP
American Electric Power Stock Performance Shares of NASDAQ AEP opened at $127.14 on Monday. American Electric Power Company, Inc. has a 12-month low of $112.54 and a 12-month high of $140.58. The company has a market cap of $69.22 billion, a price-to-earnings ratio of 21.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.48. The company has a current ratio of 0.50, a quick ratio of 0.38 and a debt-to-equity ratio of 1.44. The stock’s 50 day simple moving average is $122.64 and its 200 day simple moving average is $128.60.
American Electric Power (NASDAQ:AEP – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $1.36 EPS for the quarter, missing analysts’ consensus estimates of $1.48 by ($0.12). American Electric Power had a return on equity of 9.95% and a net margin of 13.78%. The company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.34 billion. During the same quarter in the previous year, the company earned $1.43 earnings per share. American Electric Power’s quarterly revenue was up 7.0% compared to the same quarter last year. American Electric Power has set its FY 2026 guidance at 6.250-6.550 EPS. Equities research analysts expect that American Electric Power Company, Inc. will post 6.39 EPS for the current year.
(Free Report)
American Electric Power (NASDAQ:AEP) is an electric utility holding company that generates, transmits and distributes electricity to residential, commercial, industrial and institutional customers. Through its operating companies, AEP provides regulated electric service and manages power generation assets using a mix of energy resources, including natural gas, coal, nuclear, hydroelectric and renewable energy.
AEP operates one of the largest electric transmission systems in the United States and supplies electricity across portions of Arkansas, Indiana, Kentucky, Louisiana, Michigan, Ohio, Oklahoma, Tennessee, Texas, Virginia and West Virginia.
Further Reading Five stocks we like better than American Electric Power These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding AEP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Electric Power Company, Inc. (NASDAQ:AEP – Free Report).
Receive News & Ratings for American Electric Power Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Electric Power and related companies with MarketBeat.com's FREE daily email newsletter.
Volkswagen podle odborového svazu IG Metall plánuje zmrazit mzdy více než 660 000 zaměstnanců na letošní úrovni až do roku 2030, aniž by je valorizoval o inflaci.
Automobilový koncern Volkswagen plánuje do roku 2030 zmrazit mzdy svých více než 660 000 zaměstnanců. V tiskové zprávě to dnes uvedl německý odborový svaz IG Metall. Volkswagen odmítl komentovat informaci, kterou dříve přinesl i deník Süddeutsche Zeitung. Součástí koncernu Volkswagen je česká Škoda Auto, která má zhruba 36 500 zaměstnanců včetně agenturních. Automobilka na dotazy ohledně možného dopadu plánu na své zaměstnance uvedla, že spekulace nebude komentovat.
"Evropská a světová koncernová závodní rada (E/WKDR) informovala dnes na intranetu zaměstnance o úmyslu vedení koncernu," uvedl v prohlášení IG Metall, který je největším odborovým svazem v Německu. Podle něj plánuje vedení Volkswagenu svým více než 660 000 zaměstnanců na světě zmrazit platy na úrovni letošního roku, a to až do roku 2030. IG Metall uvedl, že pokyn nezvyšovat mzdy koncern už vydal, a to s účinností od začátku října.
Nové opatření podle IG Metall nepočítá se zvyšováním mezd ani o inflaci. "Kvůli inflaci, která zpravidla zvyšuje rok od roku životní náklady, by to mělo za následek snížení reálných mezd zaměstnanců," uvedli odboráři. Podle nich lze počítat se značným odporem zaměstnanců, protože by to v konečném důsledku znamenalo snížení mezd o deset a více procent v příštích čtyřech letech.
"K takovým spekulacím se nevyjadřujeme," řekl agentuře DPA mluvčí Volkswagenu. Po celém světě koncern zaměstnává přes 660 000 lidí, z toho 275 000 v Německu. Škoda Auto, která je jeho součástí, patří mezi největší zaměstnavatele v České republice, kde provozuje tři výrobní závody.
Škoda Auto na dotazy ČTK, zda se případný plán zmrazení mezd vztahuje také na její zaměstnance a zda by mohl ovlivnit kolektivní vyjednávání, neodpověděla konkrétně. "Omlouváme se, ale spekulace nebudeme komentovat," sdělil mluvčí mladoboleslavské automobilky za výrobu a personalistiku Martin Vejdělek.
Odbory KOVO ve Škodě Auto minulý týden uspořádaly v Mladé Boleslavi velké zaměstnanecké shromáždění, na kterém měli vystoupit zástupci odborů i vedení automobilky. Podle odborového čtrnáctideníku Škodovácký odborář chtěly odbory se zaměstnanci hovořit také o rizicích, o kterých podle nich není možné veřejně informovat. Podle firemního časopisu Škoda Mobil jsou další podniková shromáždění naplánována na dnešek v Kvasinách na Rychnovsku a na čtvrtek ve Vrchlabí na Trutnovsku.
Volkswagen se v poslední době potýká s řadou problémů, včetně vysokých nákladů, nadbytečných kapacit, rostoucí čínské konkurence nebo amerických cel. Koncern proto plánuje rozsáhlou restrukturalizaci svých aktivit. Možností je i uzavření čtyř závodů v Německu. Škodě se na rozdíl od mateřského koncernu daří. Celosvětový odbyt automobilky Škoda Auto se v letošních prvních třech čtvrtletích meziročně zvýšil o 6,1 procenta na 812.400 vozů. Odbyt celého koncernu za tři čtvrtletí naopak klesl o devět procent zhruba na šest milionů vozů.
Dozorčí rada Volkswagenu minulý měsíc schválila největší restrukturalizační plán v historii podniku. Volkswagen mimo jiné plánuje zrušit do konce desetiletí po celém světě až 100.000 pracovních míst či omezit počet modelů. Škoda Auto opakovaně uvedla, že nový transformační plán koncernu nemá na její aktivity žádný přímý dopad.
Už na konci září Volkswagen uvedl, že přezkoumá budoucí mzdovou dohodu s odborovým svazem IG Metall a k 31. prosinci letošního roku vypoví několik stávajících kolektivních smluv, aby získal větší prostor pro plánované snižování počtu zaměstnanců. Odbory oznámený krok označily za velké zklamání a pohrozily vyhrocením sporu včetně stávek. Začaly by od 1. ledna, kdy vyprší současné příměří.
19-25 Ekim haftasında kripto para piyasasında üç altcoin için önemli token kilit açılışları gerçekleşecek. LayerZero (ZRO), Plasma (XPL) ve Humanity (H) projelerinde milyonlarca tokenın dolaşıma girmesi bekleniyor. Toplamda yüz milyonlarca tokenı kapsayan bu gelişmeler, söz konusu projelerin arz dengesi ve piyasa dinamikleri açısından dikkat çekiyor. Özellikle kilidi açılacak tokenların mevcut dolaşımdaki arza oranı ve toplam piyasa değeri, yatırımcıların yakından takip ettiği göstergeler arasında yer alıyor. Token kilit açılışları doğrudan fiyat düşüşü anlamına gelmese de artan arzın satış baskısı üzerindeki olası etkisi, önümüzdeki hafta ZRO, XPL ve H fiyatlarında yaşanabilecek hareketlilik açısından önem taşıyor.
LayerZero İçin Milyon Dolarlık Kilit Açılışı
LayerZero (ZRO) için haftanın ilk önemli token kilit açılışlarından biri 20 Ekim’de gerçekleşecek. Proje kapsamında yaklaşık 23,28 milyon ZRO tokenının dolaşıma girmesi bekleniyor. Açılacak tokenların toplam piyasa değeri yaklaşık 43,3 milyon dolar seviyesinde bulunurken bu miktar, ZRO’nun mevcut dolaşımdaki arzının yaklaşık %3,83’ünü oluşturuyor. Söz konusu gelişme, özellikle kısa vadeli fiyat hareketlerini takip eden yatırımcıların odağında yer alabilir. Dolaşıma girecek yeni tokenların satışa sunulması durumunda ZRO üzerinde olası bir satış baskısı oluşabilir. Ancak fiyatın nasıl tepki vereceği, piyasa talebi ve yatırımcıların tokenları elde tutma ya da satma tercihleri gibi faktörlere bağlı olacak.
İlginizi Çekebilir: Bu Altcoin’de Yatırımcılar 2018’den Beri Zarardalar!
Plasma (XPL) için önemli token kilit açılışlarından biri 25 Ekim’de gerçekleşecek. Planlanan takvime göre yaklaşık 227 milyon XPL tokenının dolaşıma girmesi bekleniyor. Kilidi açılacak bu miktar, projenin mevcut dolaşımdaki arzının yaklaşık %5,02’sine karşılık geliyor. Tokenların toplam tahmini piyasa değeri ise 17,9 milyon dolar seviyesinde bulunuyor. Bu gelişme, XPL yatırımcılarının önümüzdeki hafta yakından takip edeceği başlıklar arasında yer alıyor. Dolaşımdaki token miktarının artması, özellikle satış yönlü işlemlerin yoğunlaşması durumunda fiyat üzerinde baskı oluşturabilir.
Humanity İçin 266 Milyon Token Kilidi Açılıyor
Haftanın önemli token kilit açılışlarından biri de Humanity (H) projesinde gerçekleşecek. 25 Ekim’de yaklaşık 266 milyon H tokenının kilidinin açılması ve dolaşıma girmesi bekleniyor. Söz konusu tokenların toplam piyasa değeri yaklaşık 15 milyon dolar seviyesinde bulunurken bu miktar, Humanity’nin mevcut dolaşımdaki arzının yaklaşık %6,84’üne karşılık geliyor.
Oransal açıdan değerlendirildiğinde H, bu hafta token kilidi açılacak üç altcoin arasında dolaşımdaki arza kıyasla en yüksek orana sahip proje olarak öne çıkıyor.
Bu nedenle yatırımcıların H fiyatındaki olası hareketleri ve işlem hacmindeki değişimleri yakından takip etmesi önem taşıyor. Artan token arzının satış baskısı oluşturup oluşturmayacağı ise kilidi açılan tokenların nasıl kullanılacağına, yatırımcıların satış kararlarına ve piyasadaki talep koşullarına bağlı olacak.
Token Unlock Gelişmeleri Altcoin Fiyatlarını Etkiler mi?
Token kilit açılışları, piyasaya yeni tokenların girmesi nedeniyle yatırımcılar tarafından yakından izleniyor. Ancak kilidi açılan tokenların tamamının hemen satılacağı anlamına gelmiyor. Fiyat üzerindeki olası etki; piyasa talebine, token sahiplerinin davranışlarına, genel kripto para piyasasının yönüne ve beklentilerin önceden fiyatlanıp fiyatlanmadığına bağlı olarak değişebilir. 19-25 Ekim haftasında ZRO, XPL ve H yatırımcılarının token arzındaki değişimleri takip etmesi önem taşıyor. Kilit açılışları tek başına fiyat düşüşü anlamına gelmese de piyasadaki oynaklığı etkileyebilecek gelişmeler arasında bulunuyor.
Son Dakika kripto para haberleri için hemen tıkla.
Konu ile ilgili yorumlarınızı bize yazabilirsiniz. Ayrıca, bu tarz bilgilendirici içeriklerin devamının gelmesini isterseniz, bizleri Telegram, Youtube ve Twitter kanallarımızdan takip edebilirsiniz.
Ardagh Group prodá celý svůj přibližně 42% podíl v Trivium za očekávaný čistý výnos kolem 90 milionů USD. Transakce oceňuje Trivium na 3,4 miliardy USD a její dokončení se očekává v polovině roku 2027.
, /PRNewswire/ -- Following the decision of Ontario Teachers' Pension Plan to sell its majority stake in Trivium Packaging B.V. ("Trivium") to Silgan Holdings Inc. (NYSE: SLGN) ("Silgan") and funds affiliated with American Industrial Partners ("AIP"), Ardagh Group, as minority joint venture partner, has entered into the agreement to sell its entire ~42% stake in Trivium. The transaction values Trivium at approximately $3.4 billion.
Trivium is a supplier of metal packaging in the form of cans and aerosol containers, serving a broad range of end-use categories, including food, seafood, pet food and nutrition, as well as beauty and personal care. Trivium recorded revenues of $3 billion in 2025. For more information, visit www.TriviumPackaging.com.
The proposed sale is expected to close in mid-2027 and is subject to required regulatory approvals, completion of applicable works council consultation processes, and satisfaction of other customary closing conditions. The transaction is expected to result in estimated net cash proceeds to Ardagh Group of approximately $90 million, which are expected to be used towards reinvestment in the business or deleveraging.
Mark Porto, Executive Chairman of Ardagh Group, said:
"The sale agreement of Ardagh Group's minority investment stake in Trivium represents a favourable outcome for all stakeholders. Trivium's combination with Silgan creates a highly complementary business. For Ardagh Group, the disposal of a non-core investment helps to simplify our overall business and organisational structure, with the net cash proceeds expected to be used towards reinvestment in the business or towards debt reduction."
Evercore is serving as lead financial advisor to Trivium and its shareholders. J.P. Morgan and BMO Capital Markets are also serving as financial advisors in connection with the transaction.
Weil, Gotshal & Manges LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are serving as legal counsel to Trivium and its shareholders.
About Ardagh Group
Ardagh Holdings S.A. is the ultimate parent company of Ardagh Group, which is a global supplier of inherently recyclable metal beverage and glass container packaging for brand owners around the world. Ardagh Group operates 58 metal and glass production facilities in 16 countries, employing approximately 19,000 people with sales of approximately $9.6 billion.
Disclaimer
Forward-Looking Statements
This press release contains "forward-looking" statements. Any statements that express or involve discussions with respect to proposals, predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking" statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated, many of which may be beyond our control, including, but not limited to, statements regarding any potential transaction. Forward looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or by statements indicating certain actions "may," "could," "should" or "might" occur. We caution you that the forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. Under no circumstances should the inclusion of such forward-looking statements in this press release be regarded as a representation or warranty by us or any other person with respect to the achievement of results set out in such statements or that the underlying assumptions used will in fact be the case. Therefore, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking information presented herein is made only as of the date of this press release, and we do not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.
Insider Steven Chaouki prodal 1 000 akcií společnosti TransUnion za průměrnou cenu 70 USD za akcii, celkem za 70 000 USD, v rámci předem dohodnutého obchodního plánu podle pravidla 10b5-1.
TransUnion (NYSE:TRU – Get Free Report) insider Steven Chaouki sold 1,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $70.00, for a total value of $70,000.00. Following the sale, the insider directly owned 78,888 shares in the company, valued at approximately $5,522,160. This represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
TransUnion Price Performance Shares of TransUnion stock opened at $74.18 on Monday. The stock’s 50-day simple moving average is $75.11 and its 200-day simple moving average is $73.46. TransUnion has a 52 week low of $60.96 and a 52 week high of $89.12. The company has a market capitalization of $14.21 billion, a price-to-earnings ratio of 19.57, a PEG ratio of 1.26 and a beta of 1.58. The company has a quick ratio of 1.90, a current ratio of 1.90 and a debt-to-equity ratio of 1.07.
TransUnion (NYSE:TRU – Get Free Report) last released its earnings results on Tuesday, July 28th. The business services provider reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.07. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.28 billion. TransUnion had a return on equity of 16.29% and a net margin of 15.08%. The firm’s revenue was up 14.9% on a year-over-year basis. During the same quarter last year, the business posted $1.08 earnings per share. TransUnion has set its Q3 2026 guidance at 1.180-1.210 EPS and its FY 2026 guidance at 4.750-4.830 EPS. As a group, analysts expect that TransUnion will post 4.24 earnings per share for the current fiscal year.
TransUnion Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Thursday, August 20th were paid a $0.1250 dividend. This represents a $0.50 annualized dividend and a yield of 0.7%. The ex-dividend date was Thursday, August 20th. TransUnion’s dividend payout ratio is presently 13.19%. Institutional Investors Weigh In On TransUnion A number of hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of TransUnion during the 2nd quarter worth approximately $1,367,560,000. Independent Franchise Partners LLP boosted its position in shares of TransUnion by 99.7% during the 4th quarter. Independent Franchise Partners LLP now owns 9,136,903 shares of the business services provider’s stock valued at $783,489,000 after acquiring an additional 4,561,619 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of TransUnion in the second quarter valued at $280,292,000. Meritage Group LP purchased a new position in shares of TransUnion in the second quarter valued at $263,751,000. Finally, Janus Henderson Group PLC increased its position in TransUnion by 8.5% in the first quarter. Janus Henderson Group PLC now owns 3,740,326 shares of the business services provider’s stock worth $258,794,000 after purchasing an additional 293,091 shares during the last quarter.
Wall Street Analyst Weigh In TRU has been the topic of several recent analyst reports. Griffin Securities set a $98.00 price objective on shares of TransUnion in a research report on Wednesday, July 29th. Morgan Stanley dropped their target price on shares of TransUnion from $106.00 to $97.00 and set an “overweight” rating for the company in a research report on Tuesday, October 13th. UBS Group dropped their target price on shares of TransUnion from $82.00 to $80.00 and set a “neutral” rating for the company in a research report on Thursday, September 24th. Mizuho cut their target price on shares of TransUnion from $88.00 to $77.00 and set a “neutral” rating for the company in a research note on Thursday, July 2nd. Finally, Stifel Nicolaus lifted their price target on shares of TransUnion from $88.00 to $96.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.19.
View Our Latest Stock Analysis on TRU
TransUnion Company Profile (Get Free Report)
TransUnion (NYSE: TRU) is a global information and insights company that helps businesses and consumers make more informed decisions. The company collects, analyzes and delivers data related to credit, identity, fraud and consumer behavior, serving customers across financial services, insurance, healthcare, retail, telecommunications and other industries.
Its products and services include consumer credit reports and scores, credit-risk assessment, marketing and audience insights, identity verification, fraud detection, investigative tools and decisioning software.
Read More Five stocks we like better than TransUnion These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for TransUnion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransUnion and related companies with MarketBeat.com's FREE daily email newsletter.
Curaleaf zpochybňuje odmítnutí své zvýšené nabídky ze strany Aurory a tvrdí, že nabízí prémii 86 % oproti 30dennímu průměru ceny akcie, respektive 217 % po zohlednění hotovosti.
, /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s ("Aurora") Notice of Change to its directors' circular, dated October 14, 2026, in which Aurora's Board again recommended that shareholders reject Curaleaf's enhanced proposal.
"Aurora's Board has a fiduciary duty to shareholders, which requires it not to take illogical steps to keep the highest bidder out of the room. The Board has locked out Curaleaf while granting diligence access to unnamed parties and cites selective sources to support its agenda. None of that reflects a board acting in the company's or shareholders' best interests. Shareholders deserve the facts, and the facts favor engagement, not obstruction," said Boris Jordan, Chairman of the Board and Chief Executive Officer of Curaleaf.
The real facts behind Aurora's key claims:
MYTH: "Aurora's process is designed to deliver the best outcome for shareholders."
FACT: Aurora is giving others the keys while locking Curaleaf out of the building.
Curaleaf – the only bidder with a binding offer for Aurora and real money on the table – continues to be denied diligence access despite repeated outreach and requests. Meanwhile, Aurora's Notice of Change discloses that it "has entered into confidentiality and standstill agreements with a number of parties who have been examining confidential financial, operating and other relevant information relating to Aurora."
These are not the actions of a company that is serious about maximizing value for shareholders. Independent analysts agree. As Seaport Research Partners wrote on October 15: "We also question why ACB is willing to provide other potential buyers access to due diligence while refusing to engage with CURLF, particularly if its goal is to maximize shareholder value."
MYTH: "The revised Hostile Bid remains inadequate and significantly undervalues Aurora."
FACT: Curaleaf's enhanced offer represents an 86% premium to Aurora's unaffected 30-day volume-weighted average share price – and an even higher premium when you factor in Aurora's cash and equivalents, as Aurora continues to point out.
Cash is ascribed value on a dollar-for-dollar basis. Investors don't pay a premium on cash – it doesn't make economic sense, which is why the ex-cash premium is relevant. The enhanced offer represents an astonishing 217% premium on an ex-cash basis.
FACT: Aurora sold shares under its ATM program, without any price limit and sold for prices as low as $2.60 per share in July 2026.
How can Aurora argue the enhanced offer is too low, while they accelerated their ATM issuances and dilution at prices as low as $2.60?
Aurora value is appropriate for the Board to sell at $2.60, but not at $5.00, a 92% premium to that level?
The Aurora rhetoric does not match the facts. ATB Capital Markets wrote on October 6: "We believe the revised bid is favorable for Aurora shareholders and offers more than the fair value of Aurora as a standalone."
MYTH: "…Curaleaf shares [are] at an inflated valuation."
FACT: The implied Aurora transaction multiple of 14.3x 2026 Adjusted EBITDA is higher than Curaleaf's multiple of 13.7x (IFRS).
Aurora argues the enhanced offer is undervalued and Curaleaf's shares are overvalued, yet the implied multiple for Aurora is higher than Curaleaf's multiple.
Also, Aurora's own financial advisor disagrees with Aurora – they conclude in their opinion that the trading price of Curaleaf shares can be reasonably regarded as a proxy for their underlying value.
Too high for Curaleaf, but not high enough for Aurora – again, the Aurora rhetoric does not match the facts.
MYTH: "Curaleaf continues to propose to use Aurora Shareholders' own cash to acquire control of Aurora without paying fairly."
FACT: That's not how acquisitions work.
Once a transaction closes, cash on the target balance sheet belongs to the combined company. The only relevant question is whether shareholders are receiving fair value for their shares today, which includes the corresponding cash on the balance sheet.
The ex-cash premium of 217% premium is completely contrary to Aurora's assertions of "not paying fairly" – the premium represents one of the highest premiums in Canada in the last ten years.
By Aurora's own logic, any acquirer of a company holding cash on its balance sheet would be "funding" the deal with the target's own money – a standard that would apply to virtually every cash transaction ever done.
MYTH: "The Hostile Bid remains opportunistic."
FACT: Continued, erroneous focus on historical results.
Aurora continues to focus on what its business was, ignoring its two most recent quarterly results, where Adjusted EBITDA declined 63% from the previous two quarters.
Aurora attributes the decline to the "industry-wide headwind" of Canadian medical reimbursement rates, not "any lasting deterioration in Aurora's business." But that reimbursement change only affected its most recent quarter – it doesn't explain the decline across both of the last two quarters. That's exactly what it is – a permanent reduction and deterioration in the revenue and profitability of the business going forward.
FACT: Opportunism cuts both ways.
Aurora's Special Committee is actively soliciting third-party bidders under the exact same market conditions it says make Curaleaf's offer opportunistic. Shareholders should ask why interest from other parties is framed as value-creating while Curaleaf's is dismissed as opportunistic.
MYTH: "The Hostile Bid remains subject to inappropriate conditionality."
FACT: Curaleaf's bid is subject to market standard conditions. Further, if conditions are the concern, Aurora knows how to fix it: engagement.
Conditions are a function of negotiation, and Aurora has not engaged with Curaleaf on deal terms at any point in this process.
MYTH: "Curaleaf has not adequately supported its estimated synergies."
FACT: Aurora wants it both ways – deny access to diligence information, but then demand more disclosure.
Aurora argues that Curaleaf's "lack of access to Aurora's confidential information is a risk it assumed when it chose to launch its Hostile Bid" and that this "does not relieve it of its disclosure obligations in respect of a figure it has made central to the Hostile Bid."
Yet Aurora has already granted diligence access to other parties. If disclosure is truly "material" to shareholders, Aurora should extend Curaleaf the same access to substantiate, refine, or even increase its synergy estimate.
Insisting on full disclosure while keeping the only public bidder with a binding offer out of the data room isn't a credibility argument. It is a process choice Aurora's Board is making unilaterally, contrary to its stated objectives of maximizing shareholder value.
MYTH: "The Updated Fort Capital Opinion confirms the offer is inadequate."
FACT: Shareholders should know how Aurora's financial advisor is paid.
By its own disclosure, Fort Capital will receive advisory fees "which may be contingent on the Company arriving at an alternative transaction, or circumstances where no transaction is completed at all."
Shareholders should weigh that disclosure carefully when assessing the opinion's independence, especially in light of Fort Capital not providing or disclosing any supporting analysis to Aurora shareholders of its stated conclusion.
In most deals, a special committee gets a second fairness opinion from a truly independent advisor – why has Aurora not done that?
Curaleaf remains ready to engage immediately in a constructive diligence process. For more information on Curaleaf's enhanced proposal, visit grow.curaleaf.com.
IMPORTANT INFORMATION
This document does not constitute an offer to buy or the solicitation of an offer to sell any securities. The offer (the "Offer") by Curaleaf to purchase all outstanding common shares ("Common Shares") of Aurora is made solely by the Offer to Purchase and Circular dated August 18, 2026, as amended by the Notice of Variation, Change and Extension dated October 6, 2026 and as may be further amended or supplemented (as so amended, the "Offer to Purchase").
SECURITY HOLDERS ARE URGED TO READ THE OFFER TO PURCHASE AND CIRCULAR, THE REGISTRATION STATEMENT ON FORM F-80, THE TENDER OFFER STATEMENT ON SCHEDULE 14D-1F, AND ALL OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Free copies are available at www.sec.gov or by contacting the Information Agent, Carson Proxy Advisors, at 1-800-530-5189 (toll-free), 416-751-2066 (local/text), or [email protected].
NOTICE TO U.S. SHAREHOLDERS
The enforcement by investors of civil liabilities under the federal securities laws may be affected adversely by the fact that the subject company is located in a foreign country, and that some or all of its officers and directors are residents of a foreign country.
Investors should be aware that the bidder or its affiliates, directly or indirectly, may bid for or make purchases of the issuer's securities subject to the offer or of the issuer's related securities, or of the bidder's securities to be distributed or of the bidder's related securities, during the period of the tender offer, as permitted by applicable Canadian laws or provincial laws or regulations.
Curaleaf has filed with the SEC a Registration Statement on Form F-80 under the U.S. Securities Act of 1933 and a Tender Offer Statement on Schedule 14D-1F under the U.S. Securities Exchange Act of 1934. The Offer is being conducted in accordance with Section 14(e) of the Exchange Act and Regulation 14E.
THE OFFER AND THE OFFEROR SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY U.S. STATE SECURITIES COMMISSION, NOR HAS ANY SUCH AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The Offeror Shares have not been registered or otherwise qualified for offer and sale in certain U.S. states where shareholders may reside. No offer is made in those states except to qualifying Exempt Institutional Investors as described in the Offer to Purchase and Circular.
AURORA INFORMATION
Information concerning Aurora herein is based solely on Aurora's publicly available filings and other public sources. Aurora has not reviewed this document. Neither Curaleaf nor its officers or directors assumes responsibility for the accuracy or completeness of such information.
ADDITIONAL INFORMATION
The disposition of Common Shares and the acquisition of Offeror Shares may have U.S. and Canadian tax consequences; shareholders should consult their own tax advisors. Curaleaf's disclosure documents are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, Find, Dark Heart, and Anthem provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is powered by a strong presence in all stages of the supply chain. Its unique distribution network throughout Europe, Canada and Australasia brings together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Contacts
Media Contact
Kekst CNC
[email protected]
Investor Contact
Curaleaf Holdings, Inc.
[email protected]
Shareholder Contact
Carson Proxy Advisors
North American Toll Free Phone: 1-800-530-5189
Local (Collect outside North America): 416-751-2066
Email: [email protected]
USD/INR klesl pod 95,00 díky intervenci RBI a pondělnímu 2% poklesu ceny ropy Brent na 107,70 USD za barel. Rizikem však nadále zůstávají vysoké ceny ropy a odliv kapitálu.
The RBI's intervention & a 2% decline in Brent crude this Monday has pushed the USD/INR below the 95.00 price mark, but upside risks remain. Current Setup USD/INR is trading below the 95.00 mark and at 1-month highs, largely due to the RBI’s aggressive stabilization effort. As of writing, the pair is at 94.82, following last week’s 2% rupee gain. A modest decline in oil prices and increased dollar sales by foreign banks have reinforced the recovery.
The US dollar started the week on weak footing, giving the rupee a chance to resume trading vs the greenback from a position of strength. However, the unpredictable oil-price picture (which remains elevated) and foreign capital outflows mean the rupee remains at risk of returning to depreciation. The recent rupee strength is more of a relief rally at this point, not a full reversal, since the macro drivers that would reverse USD/INR’s uptrend are not yet in place. RBI intervention is not a substitute for stronger rupee-strengthening fundamentals.
USD/INR: Key Macro Drivers 1. RBI Defense A key driver of USD/INR is the introduction of a separate, dedicated dollar supply window for state-run oil refiners. Other measures introduced by the Reserve Bank of India include higher costs for certain FX transactions for banks and additional charges for importer-hedged transactions. These measures were introduced to curtail spot market dollar demand, which is putting additional pressure on the rupee. It is also meant to reduce speculation against the local currency. The measures have largely succeeded in the short term, pushing the pair down from above 97.00 to below 95.00. However, these measures are only short-term, and any sustained appreciation will require reversing the current macro drivers behind the ongoing rupee pressure.
2. Oil prices remain the principal risk Elevated oil prices remain the principal risk driver for USD/INR. Despite a 2% fall in Brent crude to $107.70 per barrel on 19 October, oil remains expensive for major importers such as India. As the world’s third-largest oil importer, India’s economy is particularly susceptible to elevated oil prices. The rupee benefits from lower oil prices, as they reduce the import bill and the need for additional dollars to cover higher import costs. However, any immediate rally in oil prices will lead to an increase in dollar demand to pay for the extra cost of the product, which is priced in U.S. dollars. This could reverse the rupee’s recent recovery and lead to a retest of recent price highs.
3. RBI policy and interest-rate expectations The RBI’s recent 25-basis-point rate hike sent the repo rate to 5.50% in September. However, inflation expectations remain elevated because of persistently high oil prices, and markets have begun to price in further tightening due to these pressures, as well as rising government bond yields. Higher interest rates will support the rupee by tightening domestic financial conditions. However, a high-interest-rate environment could also stifle growth and increase borrowing costs for businesses.
Traders are still watching for the next policy signals and the Federal Reserve’s stance, which is due to release its next monetary decision on 28 October. This will be important for the currency pair’s outlook.
Bull case for USD/INR — Consistently high crude oil prices and increased portfolio fund outflows from Indian markets put additional pressure on the rupee. In this scenario, a sustained recovery above 95.50 opens the door to the recent upside target at 96.00 or higher.
Base case — Consolidation: The pair is expected to trade between 94.00 and 95.50 if persistently elevated oil prices counteract the RBI’s rupee-strengthening measures.
Bear case for USD/INR — A confirmed break below 94.50 is possible if oil prices ease, adding to the RBI’s measures to curb excess dollar demand. In this scenario, downside targets at 94.50 or lower become available targets for the bears.
Technical outlook Bears are currently challenging the 94.91 support (7 July and 14 August lows). A breakdown of this support exposes the 94.30–94.04 support. If the breakdown move extends below this support zone, the next arrival point would be the 93.40 support formed by the neckline of the 8/17 April double bottom.
USD/INR daily chart showing key price levels and RBI intervention zone (snapshot: 19 October 2026) Conversely, a recovery above 95.24 exposes the 96.00 psychological resistance and the 12 October high. Above this level, upside targets reside at 96.50 and 96.96.
Proti společnosti Chemours byla podána hromadná žaloba kvůli údajnému zkreslování informací o poptávce po Opteonu; akcie 5. srpna 2026 klesly o 18,63 %.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE:CC) and certain of the company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.
If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
Key Details of the Chemours ($CC) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon productsStock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.
Why is Chemours Being Sued for Securities Fraud?
Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.
According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the “sustained double-digit” Opteon expansion would be “driven by the continued regulatory adoption” of the AIM Act. What’s more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by “higher . . . demand” in its Opteon segment.
As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an “oversupplied channel heading into 2026.”
Why did Chemours’s Stock Drop?
On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had “built additional inventory” of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an “oversupplied channel heading into 2026.”
On this news, Chemours’s stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.
Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.
What Can You Do?
If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Or contact:
Adam McCall
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Místní soudy vydaly během veletrhu Chillventa 2026 v Norimberku předběžná opatření proti čtyřem firmám kvůli porušování patentů společnosti Chemours na vybrané směsi chladiv HFO.
Action reflects Chemours' commitment to innovation, intellectual property protection, our customers, and fair competition in the refrigerants industry
, /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE: CC), a global chemistry company, today announces that it has taken action to protect its intellectual property relating to refrigerant technology during Chillventa 2026 in Nuremberg, Germany. Local courts issued injunctions against four companies infringing upon Chemours' intellectual property and patents of select hydrofluoroolefin (HFO) refrigerant blends.
This action showcases Chemours' unwavering commitment to protecting its innovation and intellectual property investments in advanced refrigerant technologies and across applications. Enforcing intellectual property rights supports industry-wide innovation, fair competition, our customers, and continued technology development.
"Innovation does not happen by accident; it is built on years of research, development, and investment," said Joseph Martinko, President, Thermal & Specialized Solutions at Chemours. "Protecting intellectual property is essential to preserving incentives for innovation, advancing refrigerant technology, and supporting fair competition. Chemours will continue to take appropriate action to defend its intellectual property rights and protect the innovations that help our customers meet evolving industry needs."
Chemours is actively working with enforcement authorities around the globe and educating customers, vendors, and other stakeholders to raise awareness about these Patent Infringing products and the importance of buying genuine refrigerants.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 5,700 employees and 28 manufacturing sites and serves approximately 2,400 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, new product development, technologies protected by intellectual rights, governing laws and rule regarding the enforcement of intellectual property rights and patent protections, , plans to continue investment in research and development, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, regulatory changes, and changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
CONTACTS:
INVESTORS
Brandon Ontjes
VP, Head of Strategy & Investor Relations
+1.302.773.3300
[email protected]
NEWS MEDIA
Cassie Olszewski
Media Relations & Reputation Leader
+1.302.219.7140
[email protected]
